var title_f17_38_18016="Flow cytometry for XLP and XIAP deficiency";
var content_f17_38_18016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F58462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F58462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Flow cytometric analysis for X-linked lymphoproliferative (XLP) syndrome and X-linked inhibitor of apoptosis deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 279px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEXAhEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryr9lz/AJIT4Z/7ev8A0qlr1WvKv2XP+SE+Gf8At6/9KpaAPVaK5EWUureKdbik1PUraK28jy0trgoo3Jk8c+n86uf8Iv8A9RzXf/Av/wCtQB0VFc7/AMIv/wBRzXf/AAL/APrUf8Iv/wBRzXf/AAL/APrUAdFRXO/8Iv8A9RzXf/Av/wCtR/wi/wD1HNd/8C//AK1AHRUVzv8Awi//AFHNd/8AAv8A+tR/wi//AFHNd/8AAv8A+tQB0VFcH4Q02fWdKnurrWdZSSPUL60AjuiBshupYUPIPJWME+5OMdK2v+EX/wCo5rv/AIF//WoA6Kiud/4Rf/qOa7/4F/8A1qP+EX/6jmu/+Bf/ANagDoqK53/hF/8AqOa7/wCBf/1qP+EX/wCo5rv/AIF//WoA6Kiud/4Rf/qOa7/4F/8A1qP+EX/6jmu/+Bf/ANagDoqK53/hF/8AqOa7/wCBf/1qP+EX/wCo5rv/AIF//WoA6Kiud/4Rf/qOa7/4F/8A1qP+EX/6jmu/+Bf/ANagDoqK53/hF/8AqOa7/wCBf/1qP+EX/wCo5rv/AIF//WoA6Kiud/4Rf/qOa7/4F/8A1qP+EX/6jmu/+Bf/ANagDoqK5XSrebTvGTWX9oX91AbAzYuZi+G8wDjt0H6muqoAKKKKACiiigAooooA8q/Zc/5IT4Z/7ev/AEqlr1WvKv2XP+SE+Gf+3r/0qlrq3bWNR8R6ta2erfYoLTydq/ZkkzvTJ5PPUH86AOqornf7J1//AKGX/wAkI/8AGj+ydf8A+hl/8kI/8aAOiornf7J1/wD6GX/yQj/xo/snX/8AoZf/ACQj/wAaAOiornf7J1//AKGX/wAkI/8AGsq5Ovw+KtO0b+3t32uyubzzvscY2eS8CbdvfPn5znjb0OeADt6K53+ydf8A+hl/8kI/8aP7J1//AKGX/wAkI/8AGgDoqK53+ydf/wChl/8AJCP/ABo/snX/APoZf/JCP/GgDoqK53+ydf8A+hl/8kI/8aP7J1//AKGX/wAkI/8AGgDoqK53+ydf/wChl/8AJCP/ABo/snX/APoZf/JCP/GgDoqK53+ydf8A+hl/8kI/8aP7J1//AKGX/wAkI/8AGgDoqK53+ydf/wChl/8AJCP/ABo/snX/APoZf/JCP/GgDoqK53+ydf8A+hl/8kI/8aP7J1//AKGX/wAkI/8AGgDoqK53+ydf/wChl/8AJCP/ABo/snX/APoZf/JCP/GgDoqK53w1cah/bGsWOo3v2z7L5Ox/KWP7ykngfh+VdFQAUUUUAFFFFABRRRQAUUUUAFeVfsuf8kJ8M/8Ab1/6VS16rXlX7Ln/ACQnwz/29f8ApVLQB2eif8jf4l/7dv8A0Wa6Kud0T/kb/Ev/AG7f+izXRUAFFFFABRRUbzxRzRxPIiyyZ2ITgtjk4HfFA0m9iSiiigRx3gKSaHwfqktpB9puE1XWGjh3hPMYahc4XceBk8ZPSov+Ej8Z/wDQif8AlYh/wq58NP8AkXLz/sNat/6cbiuqrOcJS2k16W/VM6aFenSTU6UZ+vN/7bJHE/8ACR+M/wDoRP8AysQ/4Uf8JH4z/wChE/8AKxD/AIV21FR7Gf8Az8f/AJL/APInR9do/wDQND76n/yZy2i614mu9Thg1Pwn/Z9m27fc/wBpRS7MKSPlUZOSAPxzW1r8jxaFqUkTMkiW0jKynBBCnBBq/TZI0ljeOVFeNwVZWGQwPUEVpCLirN39bfokclerGrLmhBQ8lf7/AHm3+J87+CvFeuaXJ8PdK1nUNRv5Li3OsRzSTsz31vJp00jROc/OY5hxuzwYz2rpLr4l+IdP8PDULj+w7yW90F9btFtIpAtttaIeXKTId4Pm4DjZkow216wmj6ZGdOKadZqdOUpZEQKPsqldhEXHyDb8uFxxx0qpbeFfD1rHfR22g6TDHff8fax2cai45z+8AHzck9c9asxOK8U+JPGOlajf2ltP4fZrTSJtYcyWUxBCMQIQRMOcDBkx77B0qlP4/wDEGn+daao+mG/urGyvNONnYSS/vLiV08ho2nXefk4ffGOckcYPqNxp1lcyyyXNnbSySwm2keSJWLxHrGSRyp/u9KrXvh7Rr+J4r7SNOuY3hW3ZJrZHDRKcqhBHKgkkDoDQB5boniPUPEnifwdJrNvFb39jreo2MqxqqglLNznaskgU/NggSNyOtey1l6f4e0XTVgXTtI060W3dpYRBbJGI3ZdrMuBwSvykjqOK1KACiiigAooooA53/mof/cL/APa1dFXO/wDNQ/8AuF/+1q6KgAooooAKKKKACiiigDyr9lz/AJIT4Z/7ev8A0qlrs9E/5G/xL/27f+izXGfsuf8AJCfDP/b1/wClUtdnon/I3+Jf+3b/ANFmgDoqKKKACiisbxfqEumeHby4tkd7gqIogn3t7kKpHuCQcVMpKKbZpSpurONOO7dvvNmuV1L/AJKn4e/7Aup/+j7CtzQ52uNHspJH3ymJRIc87wMMD75yD71h6l/yVPw9/wBgXU//AEfYU07q5M4uEnF9CG+8cfZL64tv+EX8Uz+TI0fmw6fujfBxuU7uVOMg+lQ/8LA/6lLxf/4Lf/sq7aisXTqfz/gd0cRhUtaP/kzOJ/4WB/1KXi//AMFv/wBlR/wsD/qUvF//AILf/sq7aij2dX+f8B/WcJ/z4/8AJmFePeJ/G2uaD498R+feL/wjVrBBaqhhTNpczRM0UpbGSpdNhByMuvbNew1h6j4T0TUl1pb6wSddZiSG+Du2JlRSqjr8pAJwVwc89QK3POOIt/iTqFt4fW+fS0v7TTNOsrnWLx7oQyBpo1djFEEIfCtuILIOcDJq5ffEPU4dM1PULbw7DNbWmqnSIw+obHnm+1rbqQPLIVfmLEk5BGMEHcN25+H/AIZuZbV5dOf/AEeKGARrdTLHIkJzEsqBwsu3t5gar7eFtGaxls2s820t+NTdPNfm4Eom35zn/WANjp2xjigDkLP4iax/aTQan4btLe2t9Yi0S6nh1MylZ5QhRo1MK70xJHkkqRuOAcVj+IPidPe2XiLTba1WJW0rUZbLVLCe4Zd8EZ5DvBGm7nOY3faRg9jXo8nhbRpGnZ7PJn1CPVZP3r/NcxhAknXsI0+X7vHI5NZcXw38LRGTbp85RoJ7YRtfXDRxxTDEiRoX2xqR2UDHbFAHQaBI8uhabJKzPI9tGzMxySSoySav1HbQR21vFBAu2KJAiLnOABgDmpKACiiigAooooA53RP+Rv8AEv8A27f+izXRVzuif8jf4l/7dv8A0Wa6KgAooooAKKKKACiiigAooooAK8q/Zc/5IT4Z/wC3r/0qlr1WvKv2XP8AkhPhn/t6/wDSqWgDs9E/5G/xL/27f+izXRVzuif8jf4l/wC3b/0Wa6KgAoorG8Qa/b6KYRMhcsrSyYyPLhTG+TpzjcvA5OeKunTlUlywV2ROcaceaTsjZriry2i1ez8TXl2pLQ+ZbIqsQAIgWVvXOW57cV2QkUw+bn5Nu7PtWF4VhWfT9QmdA9rf3Us8WekkTgYJHuOxrnqR5movzPQwtT2UZVV0t+d/0NHw+SdC00k5Jto+T/uir9YXg2R5NHcOxYR3M8SZ/hVZGCgewAArdqqbvFMxxMeStOPmzjvAN1DZeENTu7p9lvBq2sSyPgnaq6hcknA5PApP+Fm+EP8AoL/+S03/AMRVj4af8i5ef9hrVv8A043FdVXVSlRSftYt+jS/OLOKrGq3+7kl6pv9Ucb/AMLN8If9Bf8A8lpv/iKP+Fm+EP8AoL/+S03/AMRXZUVrz4T/AJ9y/wDA1/8AIGXJiv54/wDgL/8AkzmdH8deHNZ1KGw03UfOu5s7E8iRc4BY8lQOgNdBeyyQWc8sEJnljjZ0iBwZGAyFz2yeKmqK7hFzazQGSWISoyb4m2uuRjKnsR2NYVXTb/dJpebv+iN6aqJfvGm/JW/VnnPgXxvf6vqMcer6toUZ+yvPdaabK4sru0ZcZX965EgXkMwVccHoRWZbfE3WT4L8WapeWVjBf2enjWdLiKPtls5A3lGQFgSwKMGwR1HAzW4PA2m69BcxXnivWNbWCKfTQz3FuWtC6hJVzHEp8zb8pL7mAJ6E5qfU/hT4VuobmLT7CPRUurGfT7gaVFFAJopdud/yHcylAVJ6ZPXNZGhL8PfFN1r+pazaSX2k6xaWSwtFqukxslvKzh90WDJICybVJKuRhxnBrK1z4gySazoCaVb31vo761LZXWpSpD9nuFiguDJGmWMnDxfe2AHyyA3Y+l157ZeAtDv75Li012/u9Ms9SuLtdNjnhe1huJBIsynCb+ssh2l/lLHGOlAHPax8bdLvvDGvyeFklk1W205721zLbShl3KnmFUlYptLqxSQIxGeCcitzSPGH9jrc2mrP4m1HVxPb2qWV5FYiZ5pVd1RDBtj+4rMSzYAXr1zdj+G9r/YNzolxr+v3OkyWRsIraWaLbbxZUjaRGCzAKAGcuQMjuavax4G0/U9Qu9Q+2X9rfzXNvdx3Fu6BreWFGRWQMpHKuwIYMCGPFAGTffEbTNKnu7zW11nTFhsYpnsL2OBFQtcyQr8wOd7MvUv5eza2Ryai074u6Nqkdsuk6dqeoXs941ktraPbTMJFi83PmLMYiu3uHOMEHGDWhc/DfTr1ZG1HU9YvLt4I4ftc06CZWjuHuElUqgAdXfjA2gKo24FX7Pwckep6dqN/rWr6ne2NxJcRSXbxYy8JiK7UjVQoUk4UDnk5oAz4fiPY3lnZS6Vo+talcXFvJdPZ20UfnW8cbmNvM3SKuQ6soVSxJU4BHNXbTxzpt1dwWcdve/bZdTk0v7MyKJEdEMjSMN3Efl7Wz1w6jGTiqSfDiytorcaVrGtaZPFHPC9xayxeZLFNM0rI26NgMM7bWUBhnrU+leDhbfEjVPFFx5RMllDZWoV2ZsAZklkzwHbEa8Z+WMZPJAAL/wDzUP8A7hf/ALWroq53/mof/cL/APa1dFQAUUUUAFFFFABRRRQB5V+y5/yQnwz/ANvX/pVLXZ6J/wAjf4l/7dv/AEWa4z9lz/khPhn/ALev/SqWuz0T/kb/ABL/ANu3/os0AdFRRRQAVzPiGK81TWLPT7KdYYrVory5DjiRfMyoHGcgxn06iumrF0b9/rGs3EnMscy2qn/pmqK4H5u3PvWdRXtHudWFl7NyqreK09bpfqHhD/kDH/r6uf8A0c9Z+pf8lT8Pf9gXU/8A0fYVc8OsYtS1qxTi2tp1Ma9xvUO3Pf5mJqnqX/JU/D3/AGBdT/8AR9hTpfCl/WhOLX76T76/fqvzNSfxLoUE0kM+taZHLGxR0e6jDKwOCCCeCKZ/wlXh7/oPaT/4GR/40+fw1oU80k0+i6ZJLIxd3e1jLMxOSSSOSaZ/wivh7/oA6T/4Bx/4V3L6rbXm/A81/Wb6cv4h/wAJV4e/6D2k/wDgZH/jR/wlXh7/AKD2k/8AgZH/AI0f8Ir4e/6AOk/+Acf+FH/CK+Hv+gDpP/gHH/hT/wBk/vfgH+1f3fxNmuJ8UeO38PaxNpdzpMst7cRodHSKXI1GQkK0edv7tkJBbOQEO7nBA7auI8U+BG8Ratcanc6rJFewRoNHeOLjTZFIZpMFv3jOwUNnGUG3uSeM6iWx8YXf/CU+I9N1bTrOzsdEsYb2a8jvWlLCQOQNhiXAAikyd3ZeDk7crT/iVPd+AdR16TQ/s2p2U8UEmmTXWCplMRjLSBDgFJkbhT3HOKNX+Hmo6xqfiSW+121Fjr1vaWt1BBYOjiKFyWVZPOON6vKp+XjcpH3TuXU/hZZzrrMFnqN1HZatBbx3UF7JLfF3hlDq++WQtgplCvTGD2wQDovCPiO51m81jT9SsYLPUdLmSKZba6+0wtvQOpVyiHODyCoI465rGufiLp0ninSdO02YPYyyXS3l5NazJCohiZiY52AjbDKQ2C2AD0612Gj6Tpui2YtNG0+z0+0DFhDaQrEgJ6naoAzXnn/CrbmeC00y/wBejm0CzhvbaC1jsfLn8q5jeMh5vMIYqr8EIuccg9QAWvFvxP0+y8PXNxoZuJNSEltFFFdaZdLxPMI1l8vYryJ94gpwxAUHLCtHTvG9ja2cz61q0dzcLcRWqw2ukXMM3mtAkvl+QS8jNtbfgD5QcNypNYOmfCcWdklv9p0K3KS2cgl07Qo7R5Rb3CTfvWDkuzeXjI2qM521rXvgK6/t661vS9YjttTfU/7RhM1n50SA2qW7xuodSwITduDKQSOuOQC9a+OdGla+ujq0ctlHFbNHBHYTidWlLhRjkyMxUgIqBl2nIORhZviL4ahjtWa7vGkuXljjt49OuXn3xbTIrQrGXUqHUkMoODnpWDrPwuk1xb6bWNYt72/uDZSh59ORoPNt/N+/CWw6MJSNuQQB94nmtDwz8P8A+xdU0q++0aZGbI3ZNvpulpZQt54iHCK5xt8rqSxOeowKANKf4geGYYbKYai08d3bpdxtbW004WFzhZJNiHy0JyNz7RkH0NXrPxXo16dPFreGRr+ea3gUQuGMkO7zVYFcptKMCWwM4HcZ5PQPh3qfhqG1Hh/xHDbzfYILC8km0/zfNWF5GR4x5g8tsSuOd46ccVc8K+EZLP4ieJvEFzDJDbSyBNPheRWVd6Rm4mUDO3zHROCc5Qkj5qANrRP+Rv8AEv8A27f+izXRVzuif8jf4l/7dv8A0Wa6KgAooooAKKKKACiiigAooooAK8q/Zc/5IT4Z/wC3r/0qlr1WvKv2XP8AkhPhn/t6/wDSqWgDs9E/5G/xL/27f+izXRVzuif8jf4l/wC3b/0Wa6KgCC+uY7OyuLqbd5UEbSNtGThRk4/KuQl0i58QaNrOoK6GTVrMJZRSHIgQrx83beNpYAcEd8Zrd8YTrB4cvFYEm4UWq47NKRGpPsCwz7Va0KzfT9E06zlZWkt7eOFivQlVAOPbiuylN0aXtY/E3+Cs/wA7HJVgq1T2ctkvxen5XMDVtTW/+Hr3ti8sauiqrZ2sMSBD0+hrprC0isLKC1tlKwwoEQE5wB05rgtF40LRNCuuGF69vfQHqOHlVSf++Dwa9FrlrwUMTUUdk7L03/FWO+nUk8FSUt3dv8F96afoYHhj/RbvVNL+8LabzvM6bvNLPjHbGce9b9YGjf8AI1+Iv+3b/wBFmt+saXw29fzNsZ/Fv3UX83FN/icr8NP+RcvP+w1q3/pxuK6quV+Gn/IuXn/Ya1b/ANONxXVVocoUUUUAFV9SedNOuntF3XKxOYlxnLYOB+eKsUUAeIhIF+Efw+Phxg3iyWOCXSZFILNcsm65aU9fLIMnm/X+9tqLQNX0HRb3wJd39/HpzD+011ObVJkikF8RF5wlZiBv3Zx/s7ccYr2PRdHsdEtpbfS4TBBLM9wYw7Mqu53NtBJCgkk7VwMk4HNaFAHhur6EPHPj3xHLoMOg3KPDpzw660+6ezHztvtiiNuJ2n/logyBnIyK7vw0PK+KnjOG1AFq9tYXEwA4FywlVj9TGkOfotdvWfpWj2OkvevYQGOS9nNzcOzs7SSEAZLMSegAA6AAAACgDQooooAKKKKACiiigDnf+ah/9wv/ANrV0Vc7/wA1D/7hf/tauioAKKKKACiiigAooooA8q/Zc/5IT4Z/7ev/AEqlrs9E/wCRv8S/9u3/AKLNcZ+y5/yQnwz/ANvX/pVLXZ6J/wAjf4l/7dv/AEWaAOipsjhEZ2OFUZNOrI8R30lrDbW1sqG5v5fs0RkzsU7WYlsc9FPTvirpwc5KKInNQjzMl0DWrLX9OF9pkjS2xYoGZSpyOvBqr4WdblNQvoTm2vLoywseCyhETOO3KmsnwDaw+Ho9S8P+YWFg4uPOYgAxyFiuT6gLz2rS8BI8XhHT0kVlYK+QwwfvtTxlONPEclP4d16aW/BmuDnKeDlUn8V0n+N/uaF0H/kY/En/AF3h/wDRK1U8Tafrn/CVaRrOg2um3f2Wyu7OWG9vHtv9c9u6srLFJnHkEEED7w5q5p4+yeK9Thf5mvUW6QjoqoFjIPvnmt6uens15v8AM3xWs0/7sf8A0lL80cr9u8cf9C94b/8AB9P/APIdH27xx/0L3hv/AMH0/wD8h11VFaHMcr9u8cf9C94b/wDB9P8A/IdH27xx/wBC94b/APB9P/8AIddVRQByv27xx/0L3hv/AMH0/wD8h0fbvHH/AEL3hv8A8H0//wAh11VFAHK/bvHH/QveG/8AwfT/APyHR9u8cf8AQveG/wDwfT//ACHXVUUAcr9u8cf9C94b/wDB9P8A/IdH27xx/wBC94b/APB9P/8AIddVRQByv27xx/0L3hv/AMH0/wD8h0fbvHH/AEL3hv8A8H0//wAh11VFAHK/bvHH/QveG/8AwfT/APyHR9u8cf8AQveG/wDwfT//ACHXVUUAcr9u8cf9C94b/wDB9P8A/IdH27xx/wBC94b/APB9P/8AIddVRQByfhCS+l8Q+IH1W3tra9P2fzIra4aeNfkbGHZEJ4wfujB45xk9ZXO6J/yN/iX/ALdv/RZroqACiiigAooooAKr6lcmz066ugquYInk2s4QHaCcFjwOnU9KsVm+JroWPhzVbtrUXi29pLKbcjImCoTsxz1xj8aAOc8CfErw54v0/S2ttV0yLVr6Lf8A2YL2OSeNsEsu0HJIAJ6dBmu1r5X+E2twv448O+VpXg8X9xfshGkadFG0cElgJso4G4bC5Rjnn5ga+qKACvKv2XP+SE+Gf+3r/wBKpa9Vryr9lz/khPhn/t6/9KpaAOz0T/kb/Ev/AG7f+izXRVzuif8AI3+Jf+3b/wBFmuioA53x7/yAY/8Ar9tP/SiOuirmvGcguBpmkR5+1XtykkRP3cQusj5P+6px710tdE9KEE+7fy0X5p/cYQ1rTa7Jfm/1R5qkksfxJaxMBbfffbvMRg21Ps/l/MB93n1x29a9Krzvw5/yWDxD/wBeo/nHXolRV1an3S/DT9Dpb5UqS2j+N/e/WxgaN/yNfiL/ALdv/RZrfrAs/wDQ/F+oJL11CNJYdvpGoVs+nLDFb9c1PZrzf5m+L1mn0cY/hFL80zmrvwD4OvLqa6vPCfh+e5ndpJZZdOhd5HY5LMxXJJJJJNRf8K48D/8AQm+G/wDwVwf/ABNdVRWhzHK/8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNdVRQByv/CuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTXVUUAcr/wrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE11VFAHK/8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNdVRQByv/CuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTXVUUAcr/wrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE11VFAHK/8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNdVRQBxuiaJpWg+OHtdD0yx022fTjI0VnAkKM5lALFVAGcADPsK7Kud/wCah/8AcL/9rV0VABRRRQAUUUUAFFFFAHlX7Ln/ACQnwz/29f8ApVLXZ6J/yN/iX/t2/wDRZrjP2XP+SE+Gf+3r/wBKpa7PRP8Akb/Ev/bt/wCizQB0Vc3qBNz4402zm+aCC1kvYx0xKGCA5/3XYY966SuaP734hRvF86Qac8UrLyI3MiMFb0JHOPSunDbyfk/yOfEbRXmvzMfX1NvqPjAzDYLzS1MGf+Wnlo4fH03rn613cX+qT6CuH+ILr/bGn22f315YXlrCP70jmEKPbnvXcRghFB6gVnXfNOMu8V+F1+SOmkuWhy/35fiov82Yr/8AI8Q/9g5//RqVuVha9+61jQ5Y/llkuTA7DqyeW7bT7ZUHHtW7XNDd+p0V9Y035fqwooorQ5gooooAKKKKACiiigAooooAKKKKACiiigAooooA53RP+Rv8S/8Abt/6LNdFXO6J/wAjf4l/7dv/AEWa6KgAooooAKKKKACqWt350vRr6/WFrhraCSZYUOGlKqTtHucYq7XIfE/wlofivw5IPEOkS6ulgr3cFrFNJEzyBDhQUIOT05z1oA8q+GDX+j+MNA1XUPBfhSytvFaOba50VXNxbbojMBIG4ClVOdmB69MV9CV8yfA3wlCPFfh7xDaeDNB0y1ljeeK4h1yae4iV4Wx+6ZyCTuwQRxk9MV9N0AFeVfsuf8kJ8M/9vX/pVLXqteVfsuf8kJ8M/wDb1/6VS0Adnon/ACN/iX/t2/8ARZroq53RP+Rv8S/9u3/os10VAHK+I/8AkePCH+9d/wDomuqrmL2M6h4709QfL/smBrliefM84PGAPTGzPvmtvWL4aZpV3etGZBbxtIUBxuwM4zXTiZKMKafSOv3t/k0YYWDnUmo9Zafcl+aOH8L/AL34o6tepza3dnvgk7OAyKcfipH4V6JXDTWJ03/hDLVnEhS+c7gMfeilb+tdzUTX7unJ9V+rNpyTr1VHVJ2XpZWMC9/5HfS/+vK4/wDQo636wL3/AJHfS/8AryuP/Qo6365Yby9f0R14j4af+H9WFFFFaHKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHO/81D/7hf8A7Wroq53/AJqH/wBwv/2tXRUAFFFFABRRRQAUUUUAeVfsuf8AJCfDP/b1/wClUtdnon/I3+Jf+3b/ANFmuM/Zc/5IT4Z/7ev/AEqlrs9E/wCRv8S/9u3/AKLNAHRVzfhz/kavFX/XeD/0StdJXN+Dx9pk1bVT8rXt0yGPsnlExDnvnZn8a6aOlOo32S+d0/yTOerrUgl3b+Vmv1RB4+xjw8w+9/bNsM+2TXV1xPxXmli0GGSy5vbWYX0YxnaIgSXx3AJX867SIlo1J6kA1M5qVGCXRtfk/wBS1TcKjk/tJNfiv0MTxJ8t9oUjcIl7lmPRR5UgyT25IrdrA8ef8ipff8A/9GLW/XJHSTXp/X4HdU1oQl6r7rP/ANuCiiitDmCiiigAooooAKKKKACiiigAooooAKKKKACiiigDndE/5G/xL/27f+izXRVzuif8jf4l/wC3b/0Wa6KgAooooAKKKKACs7xJayX3h3VLSASGWe1liQRuEYsyEDDHgHnr2rRqnrKo+j3yyxzyRmCQMluMyMNpyE/2vT3oA8A+C/gjUPD/AIi0B9T+FMemXdrEyT6//bazMH8plL+SGP3ycYHTdntX0XXzP8PNOX/hZ/hq48M+GPiBY2sDzm/l8Q70gCNCyqRliC249P8A9Y+mKACvKv2XP+SE+Gf+3r/0qlr1WvKv2XP+SE+Gf+3r/wBKpaAOz0T/AJG/xL/27f8Aos10Vc7on/I3+Jf+3b/0Wa6KgDmPDUn9peIdc1IjyzDL/Znl9ciIlt+ffzMY7Y6mrvjX/kUtX/69ZP5Vn+Avv+Jf+wzcfySrfi9i1pY2xOYLu8jt51/vxtncvtn2rbMdJyS7JfggynWUJed/xuVPEP8AyEvCH/X4f/REldVXMeKVCax4VA4Vb5h9B5EldPV1v4VP0f8A6UzCm71aj8/0Rgaj+68X6VPL8kJt5oRI3C72ZNq59Tg4HtW/WB4u/wCYL/2E4P8A2at+uKHxSR6NbWlTl5Nfc/8AghRRRWhyhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzv/NQ/+4X/AO1q6Kud/wCah/8AcL/9rV0VABRRRQAUUUUAFFFFAHlX7Ln/ACQnwz/29f8ApVLXZ6J/yN/iX/t2/wDRZrjP2XP+SE+Gf+3r/wBKpa7PRP8Akb/Ev/bt/wCizQBvyyJFE8krqkaAszMcBQOpJrC8DIyaBllKh7q5kXIxuVpnZWHqCCCD3Bq74o/5FnV/+vOb/wBANHhf/kWdI/684f8A0AV0pWw7fdr8E/8AM53rXS7J/i1/kcz43f7ZFr4A2f2dpUwPfzPOTP4Y8v3zntXbQ/6mP/dFcP4m+745/wCwWn/oEtdxD/qY/wDdFZR/3dP+9L9DqxCtiOVbKEPxu3+LZh+PP+RUvv8Atn/6MWt+sDx5/wAipff9s/8A0Ytb9c6+N+i/U6J/7tD/ABS/KIUUUVocoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc7on/I3+Jf+3b/ANFmuirndE/5G/xL/wBu3/os10VABRRRQAUUUUAFZviW4uLTw5qtxZSRxXUNpLJFJIMqjhCVJHcA4rSrm/HPjfw/4Gsbe88UX5sre4l8mNhDJLubBOMIpI4BoA8R+CPjGy1vxJ4eW7+J+taprdzEzz6LNZMsJl8lmdN+zbheSDnnaK+kq878K/GLwF4o1+10fQdY+0alc7vJi+xzR7tqlj8zIAOFJ5NeiUAFeVfsuf8AJCfDP/b1/wClUteq15V+y5/yQnwz/wBvX/pVLQB2eif8jf4l/wC3b/0Wa6F22ozegzXC2U7p8Wr+ASOEkttxQE4YqsWCR7ZP5muq8QalBo+j3V9dhzBEo3bBk8kAcfU1UISlJRS328/6egpyhCPNfbfy9flr8zL8Aw50efUd3GrXDagqf88xIq/KT3xjrxU2tgahq+m2ER5gmF5I4+bZsxhSOxbcSM/3TVrwtYTaX4c02xuShmt7dIn2HIyBg4NU9CBk8TeILlBut5DAiSD7rMisrAH1B4NPGzU6zts3+C/4Y0y6Hs6Tm9HGN/m7L9W/kRfEr/kSdR/7Z/8Aoxa6auZ+JX/Ilal/2z/9GLXTVtP/AHaH+KX5ROSP8eXpH85GB4u/5gv/AGE4P61v1h+M1C+H7m6H+uslN1Cf7sig4OO/0rYt2LwRs3UqCfyrij8bPRqa0IPs2vyf6klFFFaHMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHO/wDNQ/8AuF/+1q6Kud/5qH/3C/8A2tXRUAFFFFABRRRQAUUUUAeVfsuf8kJ8M/8Ab1/6VS12eif8jf4l/wC3b/0Wa4z9lz/khPhn/t6/9Kpa7PRP+Rv8S/8Abt/6LNAFnxhcLB4cvVcMTcKLVcdmlIjUn2ywz7Vd0a2ex0ixtZSpkggSJivQlVAOPyrJ8ef8gGP/AK/bT/0ojroWIUEkgAc5NdEtMPHzb/BL/M54615eSX4t/wCRytpp663p/iNJnKT3ks9i0oGcRqWVOOnAY/WtPwjqp1vw5Zag0QhMyn5A2cYYr1/Co/CYP2S+kA/dzXs8sbdnRmyGB7gjnNUfhb/yIelf7r/+jGqaKvhG30kvxUr/AH2R0Y12x1l2f4ctvuuze1e1hvdMuILld8TLkjJHTkdPcCovD1zLeaDp9zcNummt0d2wBklQTwKuXX/HrN/uH+VZ3hL/AJFbSf8Ar1i/9BFcv2/kdC1w7v0a/FO/5L7jWooorQ5wooooAKKKKACiiigAooooAKKKKACiiigAooooA53RP+Rv8S/9u3/os10Vc7on/I3+Jf8At2/9FmuioAKKKKACiiigArlPiLpmt6jo6HQPFKeGmt2M1xdPZR3KtGFOQQ5AUDrn2rq65zx9qmkaf4fa1195xa6s40tEgQvJK8wKhFAB5Izz7UAeOfC7xZqWo+L9Ia4+JF1rWmz3U1oLd/DsVok8ggMijzAdygghl45xjvX0NXz74V8BTeEfij4ft/FPihb1ZpHm0q3jsTGJ5YbVYFMjj5QywqPl7nn6/QVABXlX7Ln/ACQnwz/29f8ApVLXqteVfsuf8kJ8M/8Ab1/6VS0Aalt/yWW5/wCvRv8A0GGtr4gxm+0RNIjIWfU5lt43b7qEAyZb2whHHcisW2/5LLc/9ejf+gw1v+Kv+Qr4Y/7CJ/8AREtehSdp0pLdJv5pyaOGorxqRfVpfeopnRVh+D/+Qbdf9f11/wCjmq9rcjxaLfyRMUkS3kZWHBBCnBqHwwqr4e05wAGlgSVyP4nZQzMfckkn615b+Neh68VbDyfdr8E/8ybWrSC+0q5t7uMSQshJUkjOOR09wKqeDrue/wDCuk3V3IZLia2R5HIA3MRyeK073/jzn/65t/KsbwB/yJOh/wDXpH/6CK7Vrh35SX5P/JHnP+OvR/miXxr/AMilq/8A16yfyrVtP+PWH/cX+VZXjX/kUtX/AOvWT+Vatp/x6w/7i/yriXxv0X6npS/3aP8Aif5RJaKKK0OUKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOd/5qH/ANwv/wBrV0Vc7/zUP/uF/wDtauioAKKKKACiiigAooooA8q/Zc/5IT4Z/wC3r/0qlrUtSR8ZrlQTg2b5Gf8AZhrL/Zc/5IT4Z/7ev/SqWtO2/wCSz3H/AF5v/wCgw1vh/jfpL/0lmNf4V6r80b/iHnxT4XU/dM0+R2OIWIreu/8Aj1m/3G/lXP3jfbvHdlbH5BptubwN13mTfFt9sYzmrni+7msvDt5PbNslUKAcA9WAPX2JoxT5KcL9I/q3+TLwUHVrOMeskvwS/Md4P/5FTR/+vSL/ANBFUPAERsdFk0hiHk0yZrZ5B0ckCTI/CQD8K37K2isrSG1tl2QwoI0XJOFAwOTWN4W/5CXiX/sJf+0IaVC6oTg+ln81p+rDFSU8Sqi6t/c9f0RuzJvidAcblIrI8IyD+xIrbHzWRNozdmMfykj2OK2qwfCH/HtqX/YQuP8A0OuV/GvmdkNaE/Vfqb1FFFaHMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHO6J/yN/iX/t2/9FmuirndE/5G/wAS/wDbt/6LNdFQAUUUUAFFFFABXE/FrwpqHirQLL+wbuG11vSr6LU7B5wTEZY8gK/sQx7Gu2ooA8f0Pw54+8TeOND1v4gro2nWOhGSW2tNNZnM8zrt3MSThQD6/hzmvYKKKACvKv2XP+SE+Gf+3r/0qlr1WvKv2XP+SE+Gf+3r/wBKpaANS2/5LLc/9ejf+gw1s3khu/iDZWM/zW1tZG/iXoRNvMec9/lYjHSsa1/5LLc/9ebf+gw1veGxnX/E5PJF5GoJ7DyIuK9CL5aal2g/xk1+pwS1m495L8Ip/oWvFsrxaK4Q4EssUD+6PIqMPyY1qWkEdraw28IKxRII0BOcKBgVi223UvE1xN/rrWyQRRnoI58t5gx3O0p7elb9eXHVuR7Fb93CNLru/mlZfL9SG7UtazKoJJRgAPpWJ4BYDwjpluSBNbQrBMneORQNysOxHpXQ1zPgb/mYP+wvcf8AstdsNaE12af5r9Tzp6VoPumvyZvX9rDf2U9rcqWgmQo4BxkH3rP8I3c194ds7i5YNKwYEgY6MQP0ArYrA8B/8ipY/wDA/wD0Y1cT+Nej/Q9GOuGlfpJfipX/ACX3G/RRRWhzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzv/NQ/+4X/AO1q6Kud/wCah/8AcL/9rV0VABRRRQAUUUUAFFFFAHlX7Ln/ACQnwz/29f8ApVLWnbf8lnuP+vN//QYazP2XP+SE+Gf+3r/0qlrTtv8Aks9x/wBeb/8AoMNb4b436S/9JZjX+Feq/NG3D/yUq7/7BUP/AKOkqx44Bk8OXEEY3TzMiRRjlnO4HAHc4BP4Gk8Mc6p4kJ5I1DaCew8iI4/WpNe+fVNDRPmdboyMo5IXy3G4j0yQM+9Tjtfd8kvwRvlelRT7Nv7m3+huVz2l/wCi+LtXs4v9VNFFfNnr5jFoz+G2JePXNdDXPRERePLsyEIJtPgSLdxvZZJSwX1IBBIHTIq6OsZry/VHPW0lB+f6M6GsHwh/x7al/wBhC4/9DrerB0L/AEbWdYsE5iR1uQT97dKWLD6ccVxy+JM9ClrRqL0f42/VG9RRRWhzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzuif8AI3+Jf+3b/wBFmuirndE/5G/xL/27f+izXRUAFFFFABRRRQAUUUUAFFFFABXlX7Ln/JCfDP8A29f+lUteq15V+y5/yQnwz/29f+lUtAGpbf8AJZbn/r0b/wBBhrX+HEhm8JQ30xMl1cPK80rfekKuygk98Kqj6AV5/wDEDU9S0nx9NPof/IQk2QRgIHLbkj+UA9yQK77U7FdO8KWmi6WZLea6fyoCXI2OSZGy3UDhvzxXdWqKOCT6t2+67f38y+a8jnw+HlUxqi9mr/fZX+XLK/l6l3wbHnS5b7PGpTNehP8AnmHA+XPfGOtb9MijSKNY4kVI1GFVRgAewp9efCPLFI7a1T2tRz7hXM+Bv+Zg/wCwvcf+y101czoo+x+L9asIPltWjjvSp5PmyM4c599q8dK66OtKpHyT/H/gnFV0qQfqvw/4B01YHgP/AJFSx/4H/wCjGrfrA8M/JqOvQr8sUV2FjQfdQGJCQB25JP41xS0mn6/1+B6NP3qFSPaz+66/9uN+iiitDmCiiigAooooAKKKKACiiigAooooAKKKKACiiigDnf8Amof/AHC//a1dFXO/81D/AO4X/wC1q6KgAooooAKKKKACiiigDyr9lz/khPhn/t6/9Kpa07b/AJLPcf8AXm//AKDDWZ+y5/yQnwz/ANvX/pVLRrt7LpvxF1u+t9pmt9KnlTeMjcscJGfyrpwcHOryrdp/kznxUlCnzPo1+aOv8ASm+0WTV2GyTU52uXjHIQgCPA/CMH8asQf6X4wuJo+Fsrf7NIG6lnKuCPbFXfD+mQaPo9tY2hcwRKdu85PJJPP1NU/DI8+XUtR+79quCvl/3fLJj6987c/jWOLnGpWbhtfT0W36HXgYulh5OW9kvm9/1N2uV8R/8jx4Q/3rv/0TXVVz3jNFSzsrpABcw3tssco+8geZFcA9gykg+oNbYR2qpd0196a/U5MUr02+1n9zT/Q6GsLTP+Rv1z/rjbfyet2sNB9k8Xyfx/2hb7vTZ5WB+OfM9sYrinun5no4fWNSPVx/Jp/kmblFFFaHMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHO6J/yN/iX/t2/9FmuirndE/5G/wAS/wDbt/6LNdFQAUUUUAFFFFABRRRQAUUUUAFeVfsuf8kJ8M/9vX/pVLXqteVfsuf8kJ8M/wDb1/6VS0AX2s7W8+LVx9sjV1giWdNxxtdViIb8K6ayU3vi66vYyBDawfYyD/E5Kybh2xg4+tc/e6VJqXi/WzAu4kwW03zAYgkj/eEf7XyjH8q7mytYLK1jtrWJIoYxhURQAPwFZWlKVnsnf8Dt56cKSlH4mmvxb/J2RPRRRWpxBXNWH/JQtY/68Lb/ANDlrpa5i/P2Hx1pjwddTikhn3c4WJSy7fQ5c5rpw2vPHvF/hZ/kmc+I05Jdmvx0/NnT1gaJ/o3iDWref5ZriUXMa9d0exE3f99Aj1rfrA/5n3/uGf8AtWuKe6fmejh9Yzj5fk0zfooorQ5gooooAKKKKACiiigAooooAKKKKACiiigAooooA53/AJqH/wBwv/2tXRVzv/NQ/wDuF/8AtauioAKKKKACiiigAooooA8q/Zc/5IT4Z/7ev/SqWr9/4ZXXPiFcXyzmKbTLm1lCnlXQqCwPv8gx+NUP2XP+SE+Gf+3r/wBKpa7PRP8Akb/Ev/bt/wCizWlKrOjLng7P/PQzq0o1Y8k1p/TNjVLhrTTLu4jCl4YXkUN0yFJFVfDMKxaHaspJM6/aGz2aQ7yB7ZY4qv4vZhpCqhIL3MCkA/eUyoGHuMZz7VtIqoioihVUYAAwAPSufefojtfu4deb/Jf8EdWd4jtpb3w/qdrbrunmtZY41yBlihA5PTnFaNFbQk4SUl0OSUVKLi+pkeE5ll8OaeEbLQxCB/Z4/kcfgykZqHVmFt4i0m6m+WApJahuv7xym0Y99p56VDoxbS/EF5pLHFrOGvLRR0QEjzASedxdmYDnj06VJ4u/5gv/AGE4f/ZqeNjaTktnqvvv/wAOa5Y+aSg97NP7mv8AhjfoooqCAooooAKKKKACiiigAooooAKKKKACiiigAooooA53RP8Akb/Ev/bt/wCizXRVzuif8jf4l/7dv/RZroqACiiigAooooAKKKKACiiigAryr9lz/khPhn/t6/8ASqWvVa8q/Zc/5IT4Z/7ev/SqWgDs9E/5G/xL/wBu3/os10Vcrp99aWXi/wARfbLqC33/AGbb5sgTdiPnGevUVs/25pP/AEFLD/wIT/GgDRorO/tzSf8AoKWH/gQn+NH9uaT/ANBSw/8AAhP8aANGuZ8YD7Hd6PrA+drS4EAi6BvOKxk57Yzn3rV/tzSf+gpYf+BCf41n67eaPqelz239p6eJCN8LNcLhJF5RuD2YA/hW2HmoVE5bdfR6P8DGvBzptLfp6rVfidDWB4g/d61oDx/K73TRuw4LL5bnafUZGcVHoXiSxlslhvr+3S8gURzM8qASMBjepBwQcZ46Z5weKb4lvdN1PRbm0g1bT1lfaVLXC44YH19qwrwcbx6r+vxOzB1I88W9E9PS+n4HS0VhWHirSLsEG9hglUDekrhdp9A33W/4CSKuf25pP/QUsP8AwIT/ABoTvqjOUXF2kaNFZ39uaT/0FLD/AMCE/wAaP7c0n/oKWH/gQn+NMk0aKzv7c0n/AKClh/4EJ/jR/bmk/wDQUsP/AAIT/GgDRorO/tzSf+gpYf8AgQn+NH9uaT/0FLD/AMCE/wAaANGis7+3NJ/6Clh/4EJ/jR/bmk/9BSw/8CE/xoA0aKzv7c0n/oKWH/gQn+NH9uaT/wBBSw/8CE/xoA0aKzv7c0n/AKClh/4EJ/jR/bmk/wDQUsP/AAIT/GgDRorO/tzSf+gpYf8AgQn+NH9uaT/0FLD/AMCE/wAaAM7/AJqH/wBwv/2tXRVy9pd2954+MlpPFPGNM2lonDAHzemR9RXUUAFFFFABRRRQAUUUUAeVfsuf8kJ8M/8Ab1/6VS11+jTxL428QwtIomkW3ZEJ5YLHyQPbI/OuQ/Zc/wCSE+Gf+3r/ANKpa2Na0Ge48TaheTaAupwSiMRMbsRbcIA3fPUfpSle2hdNQcv3jaXlr+q/M37U/wBr63HfRkPp9opFu4/jlIIZgejLtOPqDW9XOLqmvKoC+GQAOg+3x/4Uv9ra/wD9C1/5Px/4UoxsVVqc7VlZLRHRUVzv9ra//wBC1/5Px/4Uf2tr/wD0LX/k/H/hVGRZ8U2FxeWMU2n7f7QtJRPb7z8u7BU5Hf5Wb8cVR1+9t9Q8Ky6nbE+ZZZuY1bho5kB+Vx2IJwRUv9ra/wD9C1/5Px/4ViMviq1mnbRdGgtorhzLLFcTJMu8nJZcMpGSeck9sYrb3atL2c3ZrZ/196+ZNOUqFZVoq66r+vuZ3cZLIpPUgGnVw/hyTxVpVhHaXOjQ3McShUKXCRn3zlmz+la39ra//wBC1/5Px/4VgvM0mkpe67o6Kiud/tbX/wDoWv8Ayfj/AMKP7W1//oWv/J+P/CmSdFRXO/2tr/8A0LX/AJPx/wCFH9ra/wD9C1/5Px/4UAdFRXGahqHjSScHT9IsoIdoyszrK2fXIkXjpxip9P1LxZHCw1HQre4l3ZDQ3CRKFwOMFm5685/CrcUo35l6a/5W/EhSbla3z0/zOsornf7W1/8A6Fr/AMn4/wDCj+1tf/6Fr/yfj/wqCzoqK53+1tf/AOha/wDJ+P8Awo/tbX/+ha/8n4/8KAOiornf7W1//oWv/J+P/Cj+1tf/AOha/wDJ+P8AwoA6Kiud/tbX/wDoWv8Ayfj/AMKP7W1//oWv/J+P/CgA0T/kb/Ev/bt/6LNdFXO+GrfUP7Y1i+1Gy+x/avJ2J5qyfdUg8j8PzroqACiiigAooooAKKKKACiiigAryr9lz/khPhn/ALev/SqWvVa8g0v4E2OkWEVjpXjr4gWNlFny7e21dYo0ySThVjAGSSfqTQB6lcaVp1zM0txYWk0rY3PJCrMeMckio/7D0n/oF2H/AIDp/hXnf/Cm/wDqo/xJ/wDB5/8AYUf8Kb/6qP8AEn/wef8A2FAHon9h6T/0C7D/AMB0/wAKP7D0n/oF2H/gOn+Fed/8Kb/6qP8AEn/wef8A2FH/AApv/qo/xJ/8Hn/2FAHon9h6T/0C7D/wHT/Cj+w9J/6Bdh/4Dp/hXnf/AApv/qo/xJ/8Hn/2FH/Cm/8Aqo/xJ/8AB5/9hQB6J/Yek/8AQLsP/AdP8KP7D0n/AKBdh/4Dp/hXnf8Awpv/AKqP8Sf/AAef/YUf8Kb/AOqj/En/AMHn/wBhQB6J/Yek/wDQLsP/AAHT/Cj+w9J/6Bdh/wCA6f4V53/wpv8A6qP8Sf8Awef/AGFH/Cm/+qj/ABJ/8Hn/ANhQB6J/Yek/9Auw/wDAdP8ACj+w9J/6Bdh/4Dp/hXnf/Cm/+qj/ABJ/8Hn/ANhR/wAKb/6qP8Sf/B5/9hQB6J/Yek/9Auw/8B0/wo/sPSf+gXYf+A6f4V53/wAKb/6qP8Sf/B5/9hR/wpv/AKqP8Sf/AAef/YUAeif2HpP/AEC7D/wHT/Cj+w9J/wCgXYf+A6f4V53/AMKb/wCqj/En/wAHn/2FH/Cm/wDqo/xJ/wDB5/8AYUAeif2HpP8A0C7D/wAB0/wo/sPSf+gXYf8AgOn+Fed/8Kb/AOqj/En/AMHn/wBhR/wpv/qo/wASf/B5/wDYUAeif2HpP/QLsP8AwHT/AAo/sPSf+gXYf+A6f4V53/wpv/qo/wASf/B5/wDYUf8ACm/+qj/En/wef/YUAeif2HpP/QLsP/AdP8KP7D0n/oF2H/gOn+Fed/8ACm/+qj/En/wef/YUf8Kb/wCqj/En/wAHn/2FAHon9h6T/wBAuw/8B0/wo/sPSf8AoF2H/gOn+Fed/wDCm/8Aqo/xJ/8AB5/9hR/wpv8A6qP8Sf8Awef/AGFAHpVpptjZyGS0s7aCQjaWiiVSR6ZA9hVuvKv+FN/9VH+JP/g8/wDsK1vC3w0/4R/XbXU/+E18b6n5G7/RNS1Xz7eTcpX502DOM5HPBANAHf0UUUAFFFFABRRRQB5V+y5/yQnwz/29f+lUteq15BpfwJsdIsIrHSvHXxAsbKLPl29tq6xRpkknCrGAMkk/UmrX/Cm/+qj/ABJ/8Hn/ANhQB6rRXlX/AApv/qo/xJ/8Hn/2FH/Cm/8Aqo/xJ/8AB5/9hQB6rRXlX/Cm/wDqo/xJ/wDB5/8AYUf8Kb/6qP8AEn/wef8A2FAHqtFeVf8ACm/+qj/En/wef/YUf8Kb/wCqj/En/wAHn/2FAHqtFeVf8Kb/AOqj/En/AMHn/wBhR/wpv/qo/wASf/B5/wDYUAeq0V5V/wAKb/6qP8Sf/B5/9hR/wpv/AKqP8Sf/AAef/YUAeq0V5V/wpv8A6qP8Sf8Awef/AGFH/Cm/+qj/ABJ/8Hn/ANhQB6rRXlX/AApv/qo/xJ/8Hn/2FH/Cm/8Aqo/xJ/8AB5/9hQB6rRXlX/Cm/wDqo/xJ/wDB5/8AYUf8Kb/6qP8AEn/wef8A2FAHqtFeVf8ACm/+qj/En/wef/YUf8Kb/wCqj/En/wAHn/2FAHqtFeVf8Kb/AOqj/En/AMHn/wBhR/wpv/qo/wASf/B5/wDYUAeq0V5V/wAKb/6qP8Sf/B5/9hR/wpv/AKqP8Sf/AAef/YUAeq0V5V/wpv8A6qP8Sf8Awef/AGFH/Cm/+qj/ABJ/8Hn/ANhQB6rRXAeFvhp/wj+u2up/8Jr431PyN3+ialqvn28m5SvzpsGcZyOeCAa7+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorO8RXF9aeH9TudItlu9ShtZZLa3bpLKEJRD9SAK8c+E3xGn1nXNL0vxJ4i1ez8SzCQ3OjalpMcETsA/yQMqKy7cA/OzE7cYBzgA90or548D/ABW8Q6n8V4pNRuUPgXWr270zSR5SDbJCEKvuA3fPnAySMsfTjH1X4neKYbzxt9h8UGXW9N8Qmw0nQBbWz/a4fNKldoj804XPzBu3PJoA+n6KZA0jwRtMgjlKgsgOdpxyM96fQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFUdctry80e8t9Lvm0++kiZYLpUVzE+OG2sCCM9QR09OteE/B/wCIHjHx14xh0HUNStbL/hHY5f7YltxC76nKJCi7AVwqDAyyY69ty4APoSivHPhp4m1hvEXxEfxN4jvb3SvDNw0MaSwWyDygrMXcxxKSwCdiByeOmMX4FfEjxTrni5rLxrMv2bXLJtT0VPKRPLjWV1MeVAydoz82ThQc88gHvtFfLngL4oeLdUsfCc8PiX+29dv9ZNpe6J9ntsJaA8zHy41ePAx8zHHOccGvqOgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCvqNqL6xntWmngEyFPNgkKSJkdVYdD71xV58M7LUdRhv9Z1vW9Tu7W2mtrGW4eEGyEq7WePZEuXxjDPvPAPXmu9ooA8vX4H+DotA0jTrK2lsrrTLiO5h1W2SFL53QkjfL5fzDJ6YxwPQV1Xg/wZp3hS/8QXmnTXckmt3z6hcCd1YJIxJITCjC898n3rpqKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAo65p/8Aa2j3mn/a7qyFzE0RuLUqsqAjBKlgQDjvjjtzXD6N8HvDWhat4d1LQ3vtOu9FgNsr27oPtaEksJ8od+SWORt6+wx6NRQB5ivwd0/7J4ntpPEfiKSPxJ82oktaqZH3A7lKwDacZXA4wx4zgi9D8JPCtnqvhzUtHtP7JvdEbMcthHFC10CoUichMyAgHPQ/M3PNegUUAcz8O/BmneAvDaaJo813NarK8we6ZWfLHJ5VVGPwrpqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood mononuclear cells were stained with antibodies to SAP (left) or XIAP (right).",
"    <div class=\"footnotes\">",
"     SAP: signaling lymphocyte activation molecule (SLAM)-associated protein; XIAP: X-linked inhibitor of apoptosis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18016=[""].join("\n");
var outline_f17_38_18016=null;
var title_f17_38_18017="Modified Martius fat pad graft";
var content_f17_38_18017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Modified Martius labial fat pad graft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 381px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF9AZ8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAparqVvpkMUlyT+9lWFFXqzMcDH6n8Kz/EPiBdDaOS5ty1qRmSRWOY+epGNu0dyWGKp6VI2teLL++JDWWlubG3XsZcAyyfUHCD/AHW9avay6pOW2Ky7AJFYZBB45B6jBIz+B6jDEadhe2+oWqXNpIJIW6EevcH0NWK5/wALabbaRCILWQiCVV8iNjkhVGMZ74GFz6BfSugpDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopFOVBIIPoaAFoorN8RavBoekzX1zyFwkaDrJIxwqD3JIFAFDV76W68Q2Gi2EssUikXt3LGOEiRhiMn1dsDHXaG9q6GuS8BWNzCL++vm3XN66ySZ7NzkD/ZGQAOwWutoAKKKKACiiigAooooAKKKKACo7qZLa2lnlOI4kLsfYDJqSue8e3ZtfDFyqnD3LJaqB1PmOEI/ImgCD4bGR/CVlPMgSWcGaQKRgu5LMffljz3rW1UHKNgbVU5PBPPHT+nQ9PSpdEtVstJtLdNmEjGdgwuTycD0yTUWsK2IpFIBBK/dz1/T2wevscU+oGDrlrBa2+i6207QrpVyWYlzsaKUeW4PqBuVgf8AYHvXYVz15p8et+GtW03DKt9byxHJyqllK8d/f/6+aseDdUOs+FtL1BsebNAvmgfwyDhx+DBh+FDA2aKKKQBRRRQAUUUUAFFFFABUcs0cO3zZFTc21dxxk+lSVV1K0+2QBN20g55GQfY/5/woAtUVT0yRzCYZwVnhO1gecjsQe4/wq5QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXF6s0er+JEB8uaKxk8iCFmGGn2lmf6gDaD2+eum13UYtI0e8v5ioS3jL4JxuPYficD8axfCmhtpsEf2gs0qO8zsed8jvKXbPXkuT9MU0B0VnGsVtGiMWUKACTnNTUDpRSAKbvXfs3DfjO3POPWnV5v4N0y9vfi54z8SanazQRwJDpGneauN0KgSSOvqGdgQfagD0iiiigAooooAKKKKACuP8AHkkc+reF9LkgeX7TfGbjOE8qNiGYjsGKn64rsK4cSnVPi88SNuttF0xTJx0nnc4X8ETP/AloA7jpVfUEd7OURZ344AAOfbB4OfT+XWp3ZURndgqqMkk4AFcPr3xF8MW8v2RNas5GIy8kTrLGnsxBx+oNAGvol0wvSgU7ZByB0BHcd/Uc8ggg9BnM+Fwa2tPEOlsGCafrV3HED/zzkYTL+H73H4VJot9bXlxBdWc0dxE/zCWFxIsg6Z3D73TGevGDyATd0hFtPGmuRYx9sSG6HvhQh/8AQRTYHSUUUUgCiiigAooooAKKKKACiiigCnduqXMDEupzsJA456A8dMj9R61cqOeJJo2RxwRjjiorJ22tDKSZYjtLH+Idm/H+eaALNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBy3jVlu59L0jJJuJHunUDO5IV3c/8AAzHXU1x0E5vPiRqciOzR6bZx2zIvZnzIc/UeX+VdjQAUUUUAYnjfXI/DXhDWdZmIC2NrJMAe7BTtH4nA/GqXwuXVR8PNAbxDdS3WrSWiS3EsuNxZxuwcdwCB+FZ/xG1/TINS8P8AhPUtKXVv+Elna3a3dgFSJAGeRgQcgcHHH14rt1UKoVQAAMADtQAtFFFABRRRQAUUUUAFcX8PBFcS69rAj2tqGoSyGVurRxnyo+c9NsYI9mFdNrt+ul6LfXz4xbwvJjPUgcD8TxXmCC9uPDei+BbSaVb6/gAvrtW5htECiZx/dZyQi+7k/wANMDX0y3X4kai2raiDJ4RtpGj06yb7l+6nBuZB/EmQQing43EcrjttPvNLZzY6dc2RaEbTbwSJmMDjG0dK80+KyahqU+i/DvwhK2mLcQedeTQOYvIs0IQRKwB2ljkDjoh69K4n4h/CVfCOhRaz4Puo7bX7eaN4JsCHyggYthh1BHBDZHqcUCPRNd8Px+E/FNvq+hxpa6XqcnlX9rENqLcYyk6gcKWwUbHU7D1FbmpXDw+PPC9yHxBf21zaOpA5cKJU+hwklJ4d1P8A4T/4X2d+nlpcX9oG+RvljuEOMgjPCyLx16Vl6wH1bwNp+qQI0d7pF1Fqnld0MbETxfUL5yfl60AejUUyGVJ4UlhdXjdQyspyGB5BFPpDCiiigAooooAKKKKACiiigAqhKBBerMyRlnXZ5uPnIBJ2n1HJI/H1q/UF8sRtZPtC7ogMtx0Hr+FAE49qKgs2YxlX2fKSF2HI2/w/pip6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiqWuXf2DRb+8GB9nt5JeenyqT/SgDj/h9JJeXmr6jcKGa9v52Ugc+UCEiJ/4BGv513tcr8OLOe18L2Md8FFykMaOAm0AhFIwPbIH4V1VNgFFFFIDiZPD+l638UbbxLFq0dxeaFayWD2CFW8iST5t7YOVYqSMEcjFdtXnXwW0m/tNN8QatrdnNaalrWsXN28Uy7XSMNsjUj02rkfWvRaACiiigAooooAKKKKAOA+Mut6dpXhyGHVSWtriXzJIl+9KkX7wqB3JYIuO+7FS/D7R7jSdNvvEvilhHreoxie7DNlLKFQSkCn0QElj3YsfSs+40t/GHxWF5MVk8PeHYhEqYBWe/LBz+EYCE/wC3jP3aofG7Updcaw+H2iTst9rMirqEsYz9ltOrbvQvjaB3G6gQ34c6jJ4s07xJ4oLyxS6jcRz2MTHlLW3J8ngjgsQ7Hrw4q94t8QT3cixJYTTlAiRwxP8A66R2Vcjt8pYEZ45OTipvE3h7UtCsYJvArIk9q8aCCXDRrEFO5H4LbSAo45yc9q878Sz6/wCInk/sjw3No2qXIWCa+m1COa2tYiOXgAG/eV/2VCkZ60wZpfsqa+Lix8U+HnmMo07UpJ7Zyu0PBKzcqOmNyseOPmr0u6SLw54ke4mXbo2rsElY5KwXTYALDoFkGBnoGH+2a8M8OWl18K/HemThZF8MrMmnzTyxhXWOfO0SHjO1lhbOOjGvpq+tIL+zntLyJZreZDHJG3RlIwRQCOO+EV5K3hy80i7Lm50LULjTD5n3jGjZhP0MTR4ruK8w0A3Xhf4pzaZqbSyWms2ii1vX5FxJB91Xb/nr5bFT/eEanrkD0+kMKKKKACiiigAooooAKKKKACiiigDPtGEd68S48oDYp9MdF/Dn8MVoVh6qJUuZzGF80oJItxwrspyM+/b6MPStqGRZYkkQ5R1DA+xoAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXO+P3A8K3UJYKLp4rTJ9JZVjP6Ma6KuP8AiQRJBoVuYvOEmpxSFM4H7tWkBP0ZFNCA39DuVubIMv8ACSvK7eAeOK0arWEMcNuqxH5R8vXPSrNNgFcl8WvEM3hX4ca/rFo/l3lvbEW7YDYmchI+DwfmYcV1tcn461LR0udC0DXNOOorrl35EUO0MqtGvm72yRwu0HjnpSA39EF4ui2A1OQSX4t4xcOFChpNo3HA4HOeKu0UUAFFFFABRRVPVtTstIsZLzU7qK1tk6ySNgZ7AepPYDk9qALlcpqmqXmvXM+k+GZzCkbGO91VQGW3PeOLPDy/mqd8n5SwjV/FTbXS40bQG+8GJS8ux6Y/5Yof++z/ALFN8Ua9Y+CdIsdN0izha9lUw6fp8Z2JhVyWbAO1FA5ODyQBkkUAVPEGs2ngnS7Lw74atln1eWPFpaklgi7sNPMepG4kn+J2JA5yRhaNpdx4E0cskL6x431yd5pJ5uVEpH35CPuRqAAFHXhR61veDvC39nSXHiDxFKlxrFyiy3NwwIAxkgbTwqoDgDsBnqSSaPYFtX1HxDerPI0zq0Akx8y9I409FHB7ZZmJpiOh8PxtpenWllqN0Z9Rl3PIzfekYnLNgdB+g4HpV0R2EV2EC26XMgyFwAzAHPTv61k60up6XotzqOlwx3uqIVmmibP7+NTlokP8J2529s9epNUvDGoXPjXRl1Se1bT9LuCJtPRwPtBTAKzMQSEJPIUZ469SKQF3xX4fg1e2nEkKyrNF5M0Z6OmD+ozXN/C/xFPFcTeDvEMxOs6cmbWaRhuvrQHasnu642sOvAPeuvtNRufLmSeAvNalkmKjAYhQysvsyn8DxXNeMPDkF5NbarbRobmHD210pO+JiOuR0B45/PI4LA63W9Lt9Y097S63qCyvHLGcPFIpyrqezAgEf1FZOl65NZXUWleJykF+zbLe7A2wXvoVPRZPWM8/3dw5o8H+Ixq6y2N8ph1e1VWmiZSu9D0kXPY8gj+FgQexOzq2mWWsadPYapbRXVnONskMq7lYf/r5pDLlFcnHp2u+HjjR5zrGmDpZXsuLiIekUx+8P9mTn/bFa2ia/Y6wZYrd2ivYMefZzjZNCf8AaT09GGVPYmgDWooooAKKKKACiiigAooooAoaxvSBJ0bHlOC3Gfl7/wD1/bNS6ZxaBOR5bMmCckYJxz9MVJeGMW0vnnEW35jnGB61Q0WZvNu7WU7ngKEN/eUqMH9D+INAGrRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXGeNN58UeHTHuPkrcy7F53EhIwD7fvDz64rs65TUreOf4hWUk5+WDS5lRccZeWMk/+QhTW4HUxKVQA4/CnUiDCgHqKWkAVzGq6Ba6n490LV5b9ftOj29wY7Lgk+cFXzOuRgKR07munri9D0a/j+KfinW72ErZzWdnZ2UhYHeq+Y0nA5HzOOtAHaUUUUAFFFcP4zvZdZ1iPwpYtNHC8QuNUuIW2skBJCwIezykMM9kVjwcGgB134pvtXa6TwslrFp9uSk2uXxP2ZSDhhCgIMxGCCcque5wRVzw54dtDPHq2oSXuqampIjvNQABUesUQwsQPsoYjqTWrpGjxWUMW5VzGNsUSjEVug4VI1HAAGBnGT+lapIAJJwBQBna7dSWFhLefabW1tbdGluJrhCwRFGSQAR715z8ItLuNclufGOutLPfaiQYfPQI8EAbdFFgAAADDH/aY9etVPEeqXHxK8QQ6Doksf/CJ291svrpW4v3RWZo0IP8Aq1YICRncTjoDn0bV7+y8I+GDMySNBaosUMKfNJK5IVEX1ZmIH40xCeILmSaRNNtWAllxvbOdgJ4BHuAx/Crl4I7S0h3RvItshkGBwSowAffn9Kx/AmkyWVvfXl6Fkvr+4NxNLktubGOM9FA4UDsBXQ6hC1xYzxRkB3Qhc9M44zQMpML290WVobs2V1KGaOUIr+Vz8vBGCMY/+tXJfDfUJ4PhL4Xmg8qd2s0V5F5XdgjcMdt1bcyNqug3+lJdmwnuN8bEMBNbo+d2Ae4yQD06HnpUWiaZp3hDRH0qxj/4lMcjfZkDbxDu58vk5HzEkfWgCfwmbkXF4tyVOFiCsDnON4I+vFa0SfZH+zsoa1fIj/2P9g+3p+XpWfp2lM9k4mZ1mYcSdMNxggeg2jr159a1rdxdQvHcIBIvyyp2+o9j2oA5bWbBrmCHUNMlNvcACS3nKbmjbHzKR6MBgg9frzWl4e8SQ6jO1jdhLfU0Bbyt3Eyjq8eeSPUdR34wTLcgaHC9xIWmsC+6ZSMmLJ++PUev59c5x9U8N2l/CksH7+2kkW6ilRj8jZBVlZefcEUCOzrL1rQtP1jy2vIcXMWfJuoiUmhPqjjkfToe4Ncvp/iPUtGkaDW42vbNWOLqIfvolz0dB98AEfOvPUleprtrO6gvbWK5tJo57eVdySRsGVh6gikM5z+1bzw7NHB4il+06dIdseqKgXyz2WdRwuf74wvqF4z1I56VW1G1W9spYHVW3KQN3TOK5v4f3csdvdaNctufTyBAxOSYCSFB56qVZPoFz1oA62iiigAooooAKKKKAI7hGkgkRGCuykAkZAOPTvWRo2F1CQEASmFUccE5QnqfYOB+dbZ6HFc7pZMevYYMks0TtIp9VKfrgg/jTA6KiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXIXG/wD4WeG8xhENKRSBnhjM2OPor119ctAEPxC1SR8FlsLWMAsMqC8xJ/HH6U0B1NFFFIArivhnqGranL4rn1c3IhTW7i3so502lLdAiqRwMqTuYHng12pIAJPQVynwt8UT+M/BFjr1zbR2zXTzbY4ySNqyuinJ9QoP40AdXRRRQAVw3w1I1BdR1iUAz31y9zu3ZIVjtjX8Iki/76b1rsNTuTZ6dd3SxmVoYnkEYOC5UE4/HFc/8N0I8JaYV+WH7JAEQAcHy1LHPc7iR+FAHTTM6Qu0aeZIFJVM43H0z2rxL4r3+r+Ida0zwS9y1s18Gur+305zmO1UHCSSkZJdsDACjGc5GK9e8QXH2PS7i8luzaWlrE89xIqBn2KpJ2k8Dp6GvJvgFo011cal4svEYS6w7XW2ZzI8aOxMYDHuECg5J9KaEz0PwL4bi0LTIBsCyKhVVC7QgJycDHGcDjtgVnXsj+I/HFpFBubTtFlLNhsCS4wQx9wgIX/edv7tb3jHVpNH0SSS02NqFwwtrJH6PO/CZ9h94+yms7w1p50Xw5b29mFa7nbbHK65LFvmZ39zhmPqTR5gdC0sFjCsMKM3lqAsMQ3MB0HHp7mpYZmk35glj29N+Pm+mDXg2ueOdc1zWJ9O8Orf2+kfaWgW5s48TXgDIpm848Ku4uBgc7eD2DfD/g/xtOryXOo6rZrgK0j67OSTn+HdxzxnjuQKLBc9pvb+waLzb+2220XzyTXcYjjhx3JfH5jNcDd/Ezw1ZaxcizYZJMhnhsGxJ0BPmOUByf7uc8YNZ1l8K7rVb+S61rxFe38aZFuJ55LoJhwQy7sKrDbjIBrs7X4f6RHZm1uF1C6EkeySWW6YMw5yDgjg5zx6CgDZ8J+KNG8VaYl5oOp21/Fgb/KbDI3o6dUPsa1ZoA7rIjbJV4DDuPQ+oryfxL8LbGHfqmgRw2d7HGqvJOPKfYvdJIgGDY7ndnAyO9ZHhLxN4n8HzXUWrW2qa5ocTgTO0yz3Vtxu8xBndJERnKnLLjjg4osFz21Z45JGtpdomK5aM/xL0JHqK4jw5Ivg7xd/wic80jaXqSyXejGXnyiDmW1B9FyHQH+Ekfwiug0LXdE8W2cepeHdTtr9ISQJIHztJH3XHUZ9CAarfELSW1Tw601t+71KwcXlnIBkpMnI/A9D6gkUhl3WLItMZQiGN9qsf4geRxx34FcNoHh250rx+F0vWrqy028tpZZ7CNQYzIrqNwDA7SQ/Vf7vOc13/hTWrfxJ4a03WLQYhvYFmCnqhI5U+4OQfpWJ4pSDSNc0fXrhgkMMptHbosccuFy3/AtpJ6ACmI7CuJns/wCzfH1neW0jBLqSSG4U9CZI9wx9DCv/AH0e+c9tXK6yEn1nRZEbzEm1BQh9DHDOW/Ir+tIZ1VFFFABRRRQAUUUUAFY2fK12LKYWVmCt77ckfiBmtmsWJUa5s5Im2Ks7llc8ncrcD6HI+gpgbVFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuThOPiLqu0qH/s+0yMZbBknx/Jq6yuWg8o+PdULqu42lqobv8AK0zAfqfzpoDqaKB0FFICG8kihtJ5LiTy4UjZnfONqgcn8BWL4AsNF0zwbpNr4XcyaIsO60cuW3oxLZyeTnJNaWu2kl/oeoWcDIstxbyQoz/dBZSBn25ql4G0ibQPBeg6PdPHJcWFjBayPHnazJGFJGcHGRQBt0UUUAZPi6V4fC2rPH/rBayBe3JUgVNoVsbOwFsFCRQu0cQH9wHC/oKo+OMnwzdKuNzvEgHXOZVGPxzityJkeNXiYMjcgg5BzQB5f8cNcik0qDwpEsjy63cxafM8fSFZD91j2JQOfovuK7fwdpiaT4ftbaKMRjYrbQc4+UcZ/SuE8VW1rqHxP0LSbeBRbWKy30/GfMnlYKCD/eChyT2DDFeo/u7W25O2KJOST0AFPoI4HUpX8QeNpxuH9maIDEAI9xa5KqztknAwjKg93auB+LfjLWNe8Wx+AtBuHtljiRtXnsy+/L9IVdQSoxtz3YkDgZr0D4W2kX/CMRaretuvNYuXvCRnP7yQyKpHtnn2HtXmPwk019c+JfjLW2cXFrper3qm3QKZJnaUlCOc7QM9eCenTFAM9U+HnhDTvDumQnyw93EWKgD/AFIJOFChRjg9McV1s3mTMjCOGMgjDT/MfwUdD+NV7OSC2t9sdtPGgf7kVsyAE89AMn61ce4dWIis5n75G1QfzNDBD445wcyT59AqAD+tJFFPGoBuTKc8l0HT8MUhmuCp2WjbuwZ1A/MZ/lURbUJIxhLaBiRkljJgd8DApDL1ZWraLbagpYAxXG0qroxA59QDhvxqT7HPtKvcxli24Eo3XvxuqJ7a9Scv5to6EHjDxNntyGI/SmI8T8aQTeBbu18UadCkFzp7iGf7OBFDPCXy8ciKgUFhkhmbAbpgnB93sbu11bS4Lu0kWazu4VljdTw6MMg/ka8++Imhard6BetFEt0iBmENxNFKrgjkAyR5XPQYII7dq5D9mvWLjS7zU/BN9OZIYUOoaaj798UDMA0ZLKM4Zh077/agF2Ow+H86+F/FOoeE7iVzbXc099pryEdTIxlgH+6Nrgejn0rofifafbPBeoRlC6Bdzgddn8X/AI7muX+JSJaX0+pBM3em+XqVswXlSjKJOe4ZNyYHY13/AIjEEvh6++0/NamEtJgZymMnH4UAYvw61XUb7wppE2qQPI1xbiSG5Q582P8AgaQHG1ym1iOmc4Pal8WmO0udHkjTa1reRzIwJ4Dv5UgP1WYnn0PpWf8ABCa5/wCFc6bYagxN7pe6wlywbiM4j5HXMZjP40fEGR3uHtgQY5bcHHQhkmibPuMNj2/GgDvKKKKQwooooAKKKKACuet1b7XFDsZViuywyeg2t3985roaxZXKa0gONkki7eO4Vs0wNqiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXK7nT4h3sJCmObTbaVcnkOkso6fRhXVVyt3akfEm1ut4CvpUkZT1ImQ5H0DH86aA6ocAUUDkUUgM/xF5v/AAj+qfZ2dZvssuxkJDBthwQR3zXP/CC+udS+F/hi6v5ZpruSwi86SYku7gYJYnkkkdTXXsdqk9cDNc/8P/FNv408I6fr9lDJbwXgciKQgshV2Qg446qaAOhooooAwfFwLw6XF/A+oQ7h64JYfqorU0sY0y0AHHkp/wCgisrxq4ttKgvmwI7K7guJCRnCBwHP4KxP4Vs2kH2a2jhDFljG0E+nagDzSwsXh+OOookhjs00+CYLwxeSSSUtnPTOz+eK634kXZsvAmuSru3tatCu3ruf5Bj3ywrmtCdZfjB4kkmDJKjwWycjDItssi9s9ZJa6P4gHfpen22wuLjVLKMj2E6Of0U0wOQ8YeI7f4ZfD6TUhCZ5bKJNN023J4Mm3JJ9hg59o/evP/2WJb/TdO8U2t1LCNuoiW4udr7yxQHksAij3Y55PHQ1p/tSC3/4QDTri5G8jX/LWMyBUwY5UIJxgDAzkg4Oa81/Z+1UaR4pe2u7xJLbU4JGjRmZ0F7Ey7DsPUlWwO/p0o3EfXUepB0H2WC6u/8ApoECK30LYB/CpRNfsvFpCpI/in6H3wtZcHiL7W6xwRxwSMocJcv+8K4ByEXJ7jgkHr0rRH9qAAg2UoPs8eP55/SkBdD7RGJmRZH4AB6nGcD170sjpGheRlRR1LHAFU2s/tkAj1WK2nwQygIcKfUZPX34oGk6f8ubOBtpDDcgbBHQ896BiSahYMVJljlZeRsUyEe4wDUcuo6a433BVRjO6aFlHHuwqzdXkVrw6ttAyTwqgfUkCqd7rltZgNKP3ZGQwkQ55xwAc0wK+rQafdaPdyW5ZoimJDaOAdp6nHQkDJ5GeOK+TPB93caF8UvDviyW5Ro9Q1SaznZXOJI5nwhVSWwpVg/XrXu/xT8Z6cnh2W3tYLiDVtRQW1pM+Ixlv4twcZ2g7gM9Sp4zmvC9Rmjj03RbScL5azW0RJkVim2WIIVwD8qjPORuVl9DQS2fTnj3TFvs7t6iexntWdOo3tHj+tT+HLyS5+F9jcsf3/8AZS7y+R86xYbP4g1qeI7Z57VXjIBVgCc4wC65P6VgfDUS3HgJ7GbyxdwTXVrIoOVVvNfaPptZT+NBRT+H9qbC+1Oa0Rvsks9vbSIOnmC3jZpeO+X2n6D0rovFluj2kUa7vPu7iG3Xn+HzFZ//AB1GP4Vm/COeS98EwX87K013c3MzlPu/691XHsFVR+Fa0gN94tiUOfI0yDzGUdDNLkLn3VA3/fwUCNyiiikMKKKKACiiigArnJIXOtWSCUkRXLOy9QQUkwPYjg/lXR1g3bP/AMJLp3lOvluZN6tnJwhHA/Af5NMDeooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzetAp4y8OvnCPHdQsPXIRx/wCi66SuR+IMQMnhq5J2i31eIswOMK8ckZ/9DFCA64dBiimx52LnGcc4p1ABXOfD7wtH4N8LW+iQXT3UUMksiyOoU/vJGkIwPQsa6OvOfg15tq/jTS55JHNl4huTF5hJIikCSLjPb5mH4UAejUUUUAQahaRX9hc2dyu6C4jaKRfVWBBH5GsbwFfyah4UsWuG3XVuGs7gk5PmwsYnJ+rIT+NdBXLeAYVgTxAi5H/E5unIJzgswb+uaAMW6ZdO+NUSIuBqmmeeSf78MgjOPqsyf98Vr+PpFSTw4GOMaosuPURwyyEf+OVgeNvMHxr+HhikMYe11NJCozuXbCQD7Zx/k102tj7R428NQZyIo7q7K444VIx/6ONMDw79o+ePVZdJ8KqFmurVJNTvGCjakkoZI15Ixy7Nz0Cg968Ht47200e3v43uFuIrvzVdmBUsQA+8dcYzyAcjJr0zxvcXFl8efFcN9M5s7mVXK+WshASCPnnlQEkOPXHPSuS0lL3W7+bTtH0X7Y0zmaK2/dhdmQwdiy4jTOBljg7sD0oRL3PXPDnjm11vS9+nSxWd1Cu6YfaFbHaQIGlXcMncHI2nf0IWu5tfEqtBuutW1WWWNSGiiG4MWw27MSkY6YOcBJB6GvGdC8BeGo0jm1e4W9mkjCMLG7WBIN64ADRK5bBVlO5sZxwK9R0b4TeG7yCJkt9YgeQN+8bUblXVMEYU5Ixg9CO5piRuX/ii0QxeXFOFfg/a7uW2QEkgEljkfwcAfxHONpxUPijzY4LhZ7KCKGX95EmqNK7xNgr0B5BDIefvYzWI3w/v7KXMvibVYzG37k31xb6gh65BSSNWxgnOG7morrwxrMkW0eN9IjVgU2LoySO24AMcZfqVBwO/PegZqahfmaQ7NS09d37qSRp1xHIMfOGdScMNh44xI3oaydY1fRLXShqOq6iL6G08xJYfLaUXAc4kj+dgGIY7gFzjeODirUnw2mv9NePU9c1nVojuDWxt4tPik6kc7AQOW5XHBPasHVvgxp19pVwkOi339oAgRzS3P3BySFkZiSPQnNAHnWp3ieJNZbFuthb2ZVEtoAkSpE3PmEqRkkhW6fLuVf4edHX4LW2ttKubjUXulF7CzxiP5GC3bdGOCq7WLAc5Gem2srXNOv8AwvqDWMElxFZWjJbxy3F0hKbiT5czpjKElhu428AjkGrGvf6R8OdSlIud0kbmSaRRhGWSRwgYkggFpF4wcOh7mgR9lao22xkVWVWf5FJI6ngY964r4cAs3i+wCm3Y6gZlwQSFlhT5x9WDmuqhuY7zwzb3cyBkltkmYEdioNcr8P0ij8V+JIoXcube0eQtn7xM4B574Vc+9LoWT/BiF7PwLDp8kIgeyubiExAg7B5rMo44+6y1teFXaS88QlyHZdSZd4/iAijwPwB2/hWX8N0ntv7btbp5WdbtZV8wYKo0SKAf++DWr4XUJeeIUXtqTE/UwxN/WkBvUUUUAFFFFABRRRQAE4BJ6Cuewo8QWChlKkzSrxz8yjHPbgnj6V0NZKKJNUsyVJaOJ2J7A8L249aANaiiigAooooAKKKKACiiigDxbxR8Ttb8P614u8PTQ2cmurNajw6mwgXSXLBAGGeSjZyRjODWtpvxbhuPGS+H10q7uI479tJm1CPGBcoMMxjAJEe4Ebi34V1NzoHhfxF4xg1i4sVudf0E+THOwkTySw3AY4V+GJB+bBPGDT/+EE8OjxC+tx2Dxag8wuZDDdTRxySjo7xK4jZuByVJoA88u/jDrd54Y8Oa5oXhKVLPVtUtbKJry4iPnrI7qyxhXyrZQAM4AyehHNasfxMks7jVbeSyvL/Um1xdHs7EmKMLI0KyFfMHGwDdljk/Wugh8I+D7vQx4LisXOn6O8U6W4lnQwOSzoyTZDZzuOVYkdDim3Xg7wbJcT6HcaezT38w1RgZJy3mxhUEqy5zG4GB8rA9fegDnPGPxhk8IiH+2vDjpIkCz3sEV8kstuplaMHaoOVIUMGYoCGA6ggdL8Pdf1DWdb8aW2oSrJFpmrm0tgEC7I/KRsHHXljyarXvwg8EXsBiudHldGi8mT/T7kGVd7SfvCJMyHczHLZPPWus0jQtO0e61K40638mbUrg3V029m8yXaF3YJOOFHAwKANKiqmk6la6tYR3thI0ltIWCs0bISVYqeGAPUHtVugAoorm9Q8N3099LdWPinW7AyNu8mP7PLEOnAWSJiBx2IoA6SuX+JkSP4NvJJBlbaSC6PsI5kcn8lNVrjT/ABvaRM1hr+j35GMRX2mMjN/20jlAH/fB/rWJ4iu/Hd5oGqadfeEtMvIbq2lgaS11TYcMpHCOnPB/vCgD0e2lWeBZE+63IqWvMfDPxFmPh3Tbmfwj4la2lt43W4tIYrmJgVGSCkhbrnqv9a1Y/ip4TyFu7y8sJO63unXEGP8AgTIF/Wm0I7msCw8RwXXjPV/Dxt3iubG2guvNYjEySFxx3+UoQc+tN07xt4W1Nwmn+JNGuZP7kV7GzD2K5yDUV1p+j2nj2x12a+MOrX9mdLggLrtuFVjNkDGSygMcg4wTSGdNRRRQAVz/AIaBi1jxNDgBRfrIuB2a3hJ/XNdBWD4eDf214mLAYN8m36fZof8A69AHMahIbn45aajg+XYaS2w4B+edyT9OLcc+9b+DL8TMjlbfSOeehkm/r5X6VjazF5Pxo8PT7Ti6024jJHrGwIz+Ehx+NbOlA/8ACwPERckn7HZBfZcz/wBc0wPk39oW9t7X4469cqzGZIIbcRpkZd7cYY47A7R+XNd/8OPhpBc+GItMvbOGcsvnXkwPzNIw+UOT8uFB4U7gMrlT1HFfH3REg/aRs/7Rbbp+qtaz/OuUIAEZU+o3R8/WvqbR9BtrDSYYpgrSAH5rj51H+6n3Rx6D86aJauZmkaHaW1o9nHd2USElmjsEO7rk8qcj6DA9q6ax0prUMYtQvn38nzpPMx9N2cVPFAsuY5BO0YAwzEIp/AY/UVIlnAA6fZ41jzkY78dfalcaRUbSCcM06ySfxNJAhLfXAFPksIo0kaU2scePveQo2++TkVLBbRM7ExTx7GwC0pw3uMN0+tTG0t2laVoUaQnJZhk0DM20htJYzbwyzvuIzNFH5Y45++igfrWb4ntLC4cedEWkQbdzXTxsAT/Dhh710E8SfMZ7iTZjld+0fpg02F7a3ULbwOqnvHCcH8cUCPMPEfhq0vtNuVd7t0uUaBkkvGuFIYYyEkZiCP8AZ6elfM/iy31TwlbX+j30bPatBM9tLIHCujfLnoORkqRj7209Mmvt3WVstQsZYL+C6aDvthfjHfgc/rXzX8ePB+l2ejvqGnXAuI4pFc5dVdIiw8xCABkEfwkZG0Y70CtqfQdg8kfw70wSMkUrWNujBjxkooIHv1A96z/Avmv4q8TPIECotrCNvUkK7kn8JFH4c11WoWqXFpCqoSI3V0CnGMd/wBrm/hxvlk8SXkhUi41NmjwuMIIowB79+fUmjoMTwVayWvizxf5rIWluY5dqnO0ENjPocAH8q1vCaNs1adiSJ9RnZSTnhSI//ZK5/wAMKdLvfHPiCba0VzOtyvTdtjt1AU49gPfmus8OWbWGhWNvJ/rUiBlPq55Y/ixJpDNGiiigAooooAKKKKAI7mMS28sZAbcpGD3qvZRIkkhx844JIGRklsZ/GrZGRimwrtjA37x2PtQA+iiigAooooAKKKKACiiigDxPxL4M8VaprmrgQ3babd+KNOuh5d8IybFIws5GHDKM5+UYY9QDWUnw+8S2JFs+lXep+F7TxBfTpoo1JVae0kijFuwZpANqOJDsdgctnFdTN8Rr7SNT8bm/WC7g03VLaysYHlSD/WQq5UNglznJAAZj2GKxoPi7q2s6x4el0HR5XhuLbUftemSyJG3m27IP9awyAMnsCcgEDsAZ+seCPFl3aeJIrfTNVtLK7TSRaWcOpxTFFhjkE0beZIBIoYoGBZd3UE45k0HwT49itraMRxaTN/YOo2qPb3X7uG5kkBhJXexVsZOU3KvY9q6Ow+LFteSX2p2/m/2emhW+qJbXTxQIpkkZMGQ8hsjHcccAk10vwz8eR+OINUzp02n3WnXAgmikbcDuUMrKSFOCD3AoA8pTwB4xbw/qlvYaXeaTbzjTI/sH9qK7ySxyg3NwJFkwgK+jBmxnAOBXpnwv8MXvhbV/F1sYZoNDmvkm0xJLnzhsMS7yMsWX588HFc2PjVPLLCtn4Qv50ulvfsb/AGyFRM1o2Js5OVULzk8k8AHrU3iX42WejaNpGqw6RJd2t7p0epSRrcqJ4Y3OOYwD0/vEqp6AnsAc9o3w58SahYeE7HxTaXj2ltaaqt+n9o4/eSTlrfcUky/y4I6gd8V6p8LLDVtL+HmgWPiISDVre1WK4EkokYMOMFgSDxjua5Gf4oPp3iLxLa3FleXEsF1ptlp9lmJVlkug/lkOOQG27jvzt6CrC/FoPHZwQ+HL6fWJtUuNHksIp4sx3EMe9gJGKqylSDuyOvTtQB6hRXmFx8WYrTxxZ+H7rR2CXF5Hp5uYbpZfJndNwR1UbV5yMbs8E4xXp9ABRRRQBxvw1ljt9MudFKGKfSria32nvH5jbGHsV2n8a7IgEYIyK5SzVLXx/qsasnm3MEF1t7svzRP+RSI/jXV0wMvUvDui6p/yEtI0684x/pFskn8xXnvjf4b2Onz6DrfgTQLO01fTtVguJEs0SHzLcnZMu3hfuMT68cc9fVqzvElvdXfh7VLbTp5La9ltZUgmjOGjkKEKwPqDg0gNGiuV+FetzeIvh5oOpXYcXklsqXAfO4TJlJM577lauqoAKwtPkjtvF2q2eQJLqKK9Ud2wPKb8tkf/AH1W7WF4gWO01LStWKjMMhtZH9Ipio6+m9Yj+FAGT4rVE8e+EbhwBhbqMPnlS3ldu+cY/Gr1nJ5XxG1SJutxpltIh9dkswb/ANDX86pfEOw+13vhp97RYvmhMijJUPC4H/jwQ/gKteIM2fjTw1fD5Y5/tGnSt671EiZ/4FDgfX3piPOP2ovDv9oaHo+rw+TFNZ3DW8tw8YZo4ZUOWGe4ZVIPY816L4O1E6loWnXaiOO4mgXzGmJklLYAOQOgzz16dhWP8e1j/wCFZahLcBfIhuLWWQt0VBcR7ifYDNSfDLP/AAh9pDpdg+lRJEEEt3Gu9sEjhVCggAcE9sccUdA6nZyWbSE+ZdXGCOVVgg/QZ/Wo/wCzYUwTPd5Hc3T/AONPWxUjM09xMSOS0hAP4LgU9bC0Uki2hyRgkoOlIZD9mtmcR/aZmZhwv2lskDr3qDRNWi1O41a1iieM6bdfY3LNnefKjkyPwkH5Veht7W3YeTDBET02IFz+VYPhC4tp9X8WrbWvkSRaoEnfzC/nP9mgO/B+78pVcD+7nvQB0aQxxklEVSepA5NMmuYIB++mjj7fMwFOlgilz5katkbTkdvSo4YLS23eTFDFtHO1QMfWgAa9tlBLTxgAZOT0rzP4wm31PRL3TrWRJrq8RLWEoAxDzP5aAkEEDceoJxjkV6mrKw4IPGeK8/1S0hvvFejsqRpPLfB2dARviiVn5/4EsQIPQq3rTQmdRqr/ANnaLHGWYxpGsRkPLZ4UH65OfwrJ8PzJpnw+uNQ2hFaK4veOflJZl/8AHdtM+I10bW1jmaULDbxvKU2E7pOBF24+Y4+pFX9c08x+FrTR7dN4c29pgf8APMMu8/gisaAK11YiDQNM0hyWlv7hFnLdW6yyfhtQqPQYrrKxG/0vxggABjsLQknP/LSVuPxCxn/vqtukMKKKKACiiigAooooAptcr5jjcCmQi84BbkEZ+oFWo0CIqKMKowBWTFEWvbdVI2CaeVgOh+bjPvkg9a2KACiiigAooooAKKKKACiiigDjL3wb4M12+1m2lgguL5ryC+vlhvZFmhuFjxE/yOGibZ0xtyCeuarS/CPwVJbQQHSZljhM5Ty9QuUP74gygsJASGwMgkiuD8S/D3xE3ij4k3OgWEsE2uQW8mn6il/sX5QnnwMu/crPhgG24APUdK7b4SaDqmiyeIZLywl0jSbu5jfTtJluVuGtVESrIdysygO4LbQTj8aANa7+HfhS8guYJ9GhMFxZRadJGruq+RE26NAAwC7W5DDByBzxV/wt4S0bwt9tOiWskLXrrJcPJcyztKyrtBLSMxzgV434R8CeLNN8YzXviCy1PUOb4XVxBewiHUYpFfy0YNIHBzsCgqoXGdwFYOvaH4u8L/CvxXP4nS9N5JHpq2V4upCQ28H2mIfZMggh1yd0gyHz97igD3W3+H3hi3+xeTpm37H9r8j/AEiU7PtX+v8A4ud3vnHbFUNQ+E/gvULW2trnR2MNvZrp6LHeTx7oFOVR9rjeAeRuyRXnL+BfFT2eoSw6TcwaHPrlveHwy2pKZZLZIiso83eUy8m19hfB28nPXL174e+OpvDeiQR2d3d3Fsbp4rKS9imt7dZJcxRS7pUYlEwPMRmI6AHHIB6jpnwytGvPEtx4muYtX/tprXMUcDWy26W4Ii2EOWDjOd4YHPTFbmn+BPDenjS/smmiNtNuJLu2fzpGYTSAq8jsWzIxBOS+6vJZ/AXjP/hYcGpXkV5PHHdWc1td2F6gjtokVRJCwlcP5eQ+QFbeDk8mvoCgDkJfhv4Vl8Qf202mMNQF6uo7luplj+0qMCXyw+zdjqdvPfNdfRRQAUUUUAcZ40iNn4r8K6yhVYxPJptyTnmKZcqOOv7yOMf8CrslO5QR0NYnjaxkv/C9/HbjNzEouYBjOZImEiD/AL6UCtPTruK/sbe7t23QzxrLGfVWAI/nQBZooooA5Pwv4kuL/wAY+KtA1GKCGfTJYZbbywR5ttLGCrHJ5IcODj2/HrK5Hxjq+meEb+w1u60sO9/cQaXcaggUNbxsx2Fyedm9scdC1ddQAVW1Syi1LTrqyuP9VcRtG2OoBGMj3qzRQBxeoXUl74BttQvuLixkjluDnGGhk2yn6YV63fENuLi1s5dyq0F3BMpbp98Aj8QxFVtOtoHuvEGj3MO63mfzyrHh45lIb/x5ZKNAjN94bfTb1i09qWspW77k4V/qV2P+NAEvjfRj4i8IaxpKkLJd2zxxseivj5T+DYNec/BHUY7nRPKt7Abo+fIxxayZw8Uj+WMMrA4IJypGRnJr1q0lZ7aFpl2SsPmU8fN3rxcJa+CviTrkTpcPDfS/2hHaRRSuJlkxkgI20ESh8kqeGxnJUFoTPY41uZJQZZ40Qc+XEM5+rH+gFTiCP5sgtuO47iTz+PSsm3vGu7dczeUSP9TaoSy8dCWHH1wKpeKPE8fhbw5e6ldRfubSPKxPOGmlY8KoHqWIHXvSGaXiPX9I8L6W2oa7ewWFijBDLJwAT0HHrXA/D3x1p2vaxrTDW4oba71d4tLDxpD9sRbeHIQMoZiGJ568jtisjV7+z8C3yGaS58S+LPEchlG8KAqIx25LEpFFGWwMDk5609fEGuXlt5fxL8KaNd+H5CBJdWcvmvaA4+d42G4KDjLrgjG4DA4dhHrgtbkAZv5f+/af4U+IeTlbi5ErNx8wVfwwK5fQr7WLTxnqehapB9o0swJeaXeRREKsYIRoJGOQXU4IJOWDE9q6p5vLbPkSkE8lVB6/jmkMzNQvdJW1lEqLKgXaVSFnzxwo2g5+grA8N20M3iyP7MALewsjKVAxmWdsA8cE7IeSOu7PeneP/FdjpGnNJcNckRkboY7ZmlLE4TAOO5wODkkcjrWj4A0W40jRGk1I7tVvpWu7snHys2MJkdkUKv4E96YjL8WSrd63pmmzSKktzexhYhzvjjbzD/6Bn/gNdPeGOXWLbdKFWzjaeQY6bgVUk9uN/wCVcvY28V/8Qo5WlMktjC9xjP3Q+UjOP9rMx/AVoX7NdW14iH97qt19jiIPSFRhz+QlP1IoGaHhNZZrGbUrmMxzajKbjYcErHgLGD/wBVJ9ya26RVCKFUAKBgAdhS0gCiiigAooooAKiu3MdrK65yqkjAyalpsmdpxk54wOtAEFijpG+8nmRzg+7GrNFFABRRRQAUUUUAFFFFABRRRQB4+/xN1PRvF/iiHVbB7zQbHVrSwW4iZENos0aY+X70nztz6A8Z6VsP8AFK1ksLWWGwuEe71e50WMllOySIOfMPqp2dPenSeHvh9e/Ei4R4RceKVlj1CeHz7h41kVAI5Hj3eUGCgFcjPcetWLz4e+AtO12HVruxtrTULu/MsLyXskYku3VhhELhS7Dd8oHOM44oA898O/FTxRt0S6uLUaxFJ4Tk1m7t4zHbkyJcBWkDEdkBG0dSR9R1d18ZbBTJd2ekXlxolrFYS316ZEQ24vArQ4jPL8OhbBGM963Lr4T+DLq3soJdJl8mzs/sEKJfXCD7Pu3mNtsg3qW5IbOav3/wAPfC19q1vqNzo8JuYBEqhHdI2EX+q3xqQj7P4dwOO1AGTZfESfUJtWubLQZG0DTZrm2l1Oa8ihHmQKxY7GIwhZdoYnqckAZNc/p3xvtZ9N1q7vNDuYV0k2slwYpvMQwTsVEqsVUkKRk8cjkE10Pijwh4D0hNR8Qa/ZJb28zN9rYzTeS7z/ALlmMKtsLt5m0ttz82c96v6Z8NfCmm2mqW1rpjmHU7VbO7E13NMZYVBCrl3JGAxwRgjj0FAHL6r8Z7O1toHs9IuLqW81C8srEGZUjuEtsCSYPg4Uk4AwST6DmrmifFb+29StbPTvDOqO0lhFqFw0rxxfZY2d0bersCSpQ/dBJ9K6Gf4eeF5tB0vRzpYSx0sk2Qinljktyc5KyqwcE5Ofm575q1o/gzQdHupLnT7J47iS0Fk8j3EsjNCGZgpLMcnc7Hd1OetAHB6V8a7aeCC81bw9f6dpl1pU+rWtwZ45TMkON67FPynnjJ5yOlSz/GH7Fpmoy6n4av4L+1tra9S1ilWYPBOdqSM6j5QCPm4OO2a7C18AeGLaDTYY9KjMOnWcthbRySyOqwSgCRCGYhgwH8WTVW0+GXhK00+4s7bTJY4p2jZ3W9n8393nywsu/eoUE4AYAZ6UAZHhr4q2mt3Ok262KB9Qgu51ktrxLiNRBtyNy9zu6EAjuOlYqfHKzlm0FE0WWCPVbeK4SW9ukt0+dyoRHYbXYY5GVrrbj4V+C7izsbaXREMdlJLLCwuJRJvk/wBYXkD7n3YGdxOcUR/CzwdGllGukuYLRY1iga8naEiM5TfGX2yYP98GgDtq5vwafsbapopyBp1yfIB/54SDen4DLJ/wCukrlvEbyaN4i07W12/YZgNP1DJxsVm/cyf8Bdip9pCe1AHU0UUUAZ3iLRNP8R6NdaTrNuLmwuVCyxFiu4AgjkEEcgHI9KpeD/Eun+JLO8bTRKhsLuWwnhmGJI5IzjDDOeRgj2IrerjTpegeDvFOpeJJ757KTxBLbWkkTsBDJOMqhAxkO2cE5xQB2VFFFAGLqzix13TLw5EdwTYykDoW+aMn/gQK/wDA6jvf+JV4igvAcWmolba49FmH+qf8eUPvsrU1SyTULCa1kZkDjh0+8jA5Vh7ggEfSs+3C63pF1p2rIPtCZguVXjJxxIvoDwynt9RQBLqguUuVeNgyHBiB42yjPBPowOPY/WuW+J/h658T+HrfUfDwRfEGmuZ7MShcP2kgcNkfMBjnowU9q6HRrqS4jn0fVnB1K2XDt90zx9FmX698dGBHpmxC7W8rysp3AhblVHX0lA+g5/8ArUwOI+HevWt/Y2kV1cwm6lDfaLMnypI3Hyt+6C5Y5G05Jxiuh8dx3UHhqebQrYG5gnt53jS1EhljWVDIApBy2zdjHOenNYfjXwlNaarL4q8LxO96yqb6yiAJu1Xo8YJA80DjnhhwcHBG/wCEPFuma9bQrYXBmBUDlcFCBgo/PyuCCCpAIPagSPHfjPqKeHfjB4X8XXTuuhTWUmnzTGN8RMPMYbk43BvMXjjO3qMVu+MNX/4SC0s9M0S/2anq+6GCODy5g0LfLJIMA4UADccgYz369cvhnU/CWjalbeFYIdasJ51kt9G1Gby4rVTkyLHJtYlSSCEYYHPPasjwPr+s3esS6XpPgHS9C+wTpBqshvIwsJYB8RCJP3mUZTk7Rk4PrQFjQ1PT/FFv488NT2KwXuk6dZ3EdzFBceQTv8sR7kZjuPyMQenXkd+kvfFMVgrtf6Xq0CqMlvs3mr+cZao/DmhP4fkv7iWSbUb6/kEtzfSsodscKgTgLGo4VQe5PJJNc/488VSWl3Z2ttDO9xcOY7aGNRIbh8ZClOqnvuZdq9SRQMraNqkPjfxZbW8eySw0zbqFyVZ9pnOfITBI6Dc5+UYKrkevpF/cRWllcXFy6xwRRs7sxwAoGSSa53wx4Qs9N0VYdShhvNQmka5urh0BLzOcsVPUAcKPZRWfr3h+PXL86HBc38WnRoJb1hcl1JJykW192c4JYcfLgfxDAIl8Jxz/ANjXessjR3mrsv2dGXBjh6QgjtwS5B6bsdq1tLgjl1uZo1/0fTYhZw85+YgNIfrjYPwNQ6vJqWl2xv53s72O0UsqYaBixGAONwLHOBwOtLol3caZpsMOp6deRzndJNLEomVpGO5j8hLdSe3SgDo6Kz7XWdOuX8uG8h83/nmzbX/75OD+laFIYUUUUAFFFFABR3qrdyTJc2aQlQjyESbhk7QjHj3yBVqgAooooAKKKKACiiigAooooAKKKKAPDtf8Aa3HrXxP1PR9GjuZ9XazWxE13hZ49sZuML5gwQynAfaOMfdJB5iH4Y+J28NW8V9od9dpYeKI9QgsJNQhSVrIw4kVCkgjQ7sHG4YwcHnn6YooA8i+NZm/tn4f2kdhd30U97PHLp0FyImuF+zt8hYsqkfU4OK4TX/h348uPBmh6U+mNeS29heFGhvo2ns53kLQxF5XUFFXaN6gtkEAgYNfTFFAHzb41+H3jPWYb8Xui3OsXtxY6UlldNqMQWxaLyzdIytIMszKzbgCDnr6/SVFFABRRRQAUUUUAFFFFABVXVLGDVNNurG8TfbXMTRSL6qwwatUUAYPg2+uLnS3tNSYNqmnSG0uj03soG2THo6FX/4FjtW9XA/EeDWNFWfxN4ZcCZYPLv4CoYPGp3LKB3KfNkdSjMByFrsdF1BNU0y3vIxtEqAlc5we/Pceh7jBoAu1heOfDVr4u8Kajod8SsV3HtWQDmJxyjj3VgD+FbtFAGN4bb7FYWWi32qx3+tWdnF9pYsBJJxt80r1AYg81s1xni7whc33ifRfEnh66hsNasnEFy8iEpd2bH54nA6kfeU9j9a7OgArH1izuEuY9U01d95CnlyQFsC4izkp7MDyp9cg8E1sVXQmAiNtzRAcO3JHXqfT3oAzbmGHX7G1vtOnMN1Cxe3n28xt0ZHU9uoZT6diARc0m6nubb/Trb7NeISkke7cCR/Ep7qeoJx7gGqN9ay6Zdy6npqPLHJ813aJz5uB/rEH/PQAdP4hx1ArUtpLe7iS6tmR1lT5ZVHJX6/0oAfEhiYoOYuq89Pb6V5z4v8ADGoW+sXPiDwThdWZwb2xlbC3CgY3xZIVZMdz8rd+QDXoUUzJIIbj7/8AC/Z/8D7VJPAs205ZHU5V1OCP8fpTA4bw/wCOtJ1GJItdR9M1OJQXttQHkyBgf7pOPxBIPrWBo/xI8N6X4t8YWk0tpB5d3DKkkMmXug1uhLHcx3ENlflGAABXqMlqLlBFqFvb3KA5BZAR9dp6VNbWlvaqVtoIoVPaNAv8qBHnkfiPxJ4qLRaF4euLSyZv+PzV8wR47FEH7xweo4Ucda6Hwn4OtNBu7nUpp5dQ1q6AWa9m6hM5Eca5IRAedo69SSea6iq89ztnSCJfMmbkjOAi+p9Pb1pAVtU1AwEW1oBLfyjEaHkL/tN6AdffHFP0fTo9Ms/JjZndmaWWVvvSyMcsx+p7dhgDgVNBaxxTPLgF2J5xjAPWqmtak9oIbazRZdRuiUgjPQY6u/oi9z9AOSKBlS8B1bX4bRGItNOZbi4wOHlxmNM/7PDn/gHqa3qpaRp8em2SwIzSOSXllb70rk5Zj7k/l06CrtAENzbQXUey5gimT+7IgYfrWbH4ftbZ3bTpruxLEsVhmJTJ9EbKj8AK2KKAMnydZg/1V3a3accTxGNse7Kcf+O0v9pXkH/H5pVwB3e2dZl/Lhv/AB2tWigDMi13TZH8trtIZf8AnncAxN+TAGtIEMAQQQe4pssUcyFJUWRD1VhkH8K5/VdOsbJrZbGH7Lc3UwiT7PK0IzgknapAOApPQ0Aa9qftcn2h12+W8iJ7gHGfxxVyseLTtRtIlSz1TzFVcBbuBX/VNp/nTxd6rCQLjTY5l/vWs4J+u1wv8zQBqOyorM7BVUZJJwAKZBPDcKWgljlUHBKMCB+Vcr49M2s/CvxQtlZ3hubnSbyKO2aFhMzmJ1ChOpJPTGc5GM5rwXwD4f8AGfhiw19tO0GfT/ENx4Zsxpr2Vi0VtIVUGTztwI+2DJB3YyQ3HIoA+qKK+dtNuPHo8N3wjufFMtkdRsWuA9jMl9BakOLgQtKoaRsiP7oO3J25q1pel6mnxV0nWrL/AITSSzl0e4tbWfUrd8icXG5Yrj5NyREDdl8E4XntQB7/AEV8++GIviHqdnqNql34ltbx9Cka7m1KPy1j1QSAxrbEgAoQGB2ZTaR3pZNV8e6l4Hk1rUbHxFaXWq6rFGtnbJKkmnWyRbS5iRfNKtIGYquCcqc46gH0DUC3ls169mtxCbtEEjQBxvVScBivUAkHmvmx9f8AGll4X8Ov4ru/E1nax2+pNLLBA0dy88bkQGcY3CPYQcng8bietSDU/Hl54Uk1PTf7ZlvLnw1pMkN3b2pd5Jmul84qwU7m8skkc4HOMUAfS1QS3ltDdQW0txDHc3AYwxM4DybRlto6nAIzjpmvCtdPjPQ18W6Xbv4r1Wwj1SxWzvv3jTJDJCWmdWjTdKivhSseCPbmo/ANv4svvFHw7u/Elrq8z6fNrcMl1eWkiMkRWMQmQsONwBwWOTjqcUAfQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAQCCCMg9Qa5rw7ptr4Y/4lUDGOzBkmtgx4EZbcyEn+6WOP9kj0NdLUF3brcxhW6qwYH/PYjIPsaAJwQQCOhopkOwJsjAUJ8u0cbfan0AFFFFABQRkYPSiigBn3CAo+X09PpWXNby2dzJdaWokV2LXFoCBvb+8ueA/qDwfY81rkZqExkHIyTn7w4IH9aAI4Z4L+1YoPMXo0bDDKf7pB6H61EksiyFIXMhAz5UowV5/vf4j8ajuLfzJhJGzQXfTz4hnIHZ17j6/gRSS3E6xhp7L7QR0ktmB/Q4I+gz9aYCnVGUqsls8EjcATOqjPpwTn8M1pZIXJHOOQKzLe7h1EkQ3BUBhuhljKupGDjsf51qUgKJe8uCFjT7LHjl3wz/gBkD6nP0qzbW8dshWJcFjuZjyWPqT3NY+r65dWUzRW2iX92ecSKUVDgeuc/pWbJqPiO9jYeVaaRERjzCfOkAJ6jfsUH6q340Abmq6r9klS0tIvtWoyjdHADgKv99z/AAoPXv0AJ4pdI042plnuZTc382POnIwOOiqP4UHOB+JJJJqHRNPt7aKQQKziU7pZpGLtMfVmPLfyHQVsDigAooooAKKKKACiiigArHtUh1TVjflA8dkzwWzEZ+fpI4/9Az7N60nim6uYrAWmmts1G+b7PbvtyIiQcyEeijJ+oA71oabZQ6dYW9nartggQRoO+AO/qfU0AWaKKKAMXxtrv/CM+EdY1v7NJdf2fayXHkxjl9qk49h6nsMntXnfhr4sSJYi+8Ym1sYV0NdZkhgs5lkRGnMS/eJyDgY45yG6GvSfFdlY6l4X1ew1a4+y6dd2ktvcT71Ty43Qqzbm4BAJ5PFcy3w40e5KXNvqOpIW0OHQ0lhljwbeN96v9wgsehzlSDjbzQBkXPxitBeeHorPw9rU8OrXUltvMPKbY9+5Au4SZyOAwxgntiukX4haE3l4kuPn1xvDw/dH/j7Xdkf7vyn5q520+DvhvRrKGW11LU7Gezvm1T7fHJDEyuY9jZURiJU29cIPXNWLf4V6Dc6zDrlnrGsPbSasviCK2iu0e0a4IJLqNhyrbs9foQKAM3SPjJaW/wAOdA8S+J7G5jbUoZZpDYxBoogjlTy7A5wAcDJ68V3useJ7HTfC66+I7m7sHjjlT7NHlmR8bWwxAA5BJJGK4GH4NeFNR0HTbTTtZ1RraxsbjSRcW1xDIZIZHYyKxMZUMGJGVCnsc113iHwFpeu+DtN8OXU97Ha6ebdreeJ081WhACMdylG6cgqQc9OlAHJ6j8QPAPinTtGur/QpNdluLi5t7O1fSlu545olDSqq4bBxtOVOMc544k1j4x6JD4RF94atby/u5NJuNSt7ZLU4gjh3JunGRsQSIVOCehxV/SPhv4d8L6lo+oPq199otdTuruBryeICe4u4/LdDhFzkfdUYOfXpWbafCDwxc6QtrpGu6tHFHaXWk3E9ndQs08MszySRSHyyvyvI+MAEZwc0Aei+GNQk1fw1pOpTIiS3lpDcOqfdUugYgZ7c1p1T0bT4tJ0ix063Z2gs4Et42kILFUUKCcADOB6VcoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBNo37sc4xS0UY5HtQAUUUUAFFFFAAc4OOtQRTtvEc6bJOxHKt9D/Sp6RlDDDDIoAGUN1GSOh9KjMCZZgoLE5z0P5ioLqO5VMW0nTpnkj8+o9uPrVVpTJInnho51+U+VIcEeu0/4fQmmBYkMC3FvHLM0cnVEcg7yPc9SPY1j+OtSvLC0sYtO4mubgIzZwQiqztg9s7cZ9M98VS8QXlzbahZxajeWY0e5Bt3jyBNK7DChVbkt3ypPAPHet/WNJXUZtNfzCgs5zLwTlgY3TGf+B5/CgRT0+xubv57+9upsH5lwIkb6KM8fic1rQ2FrDIHjhjDjIDBRmqn9uabFcm0a5xKmQ37ttox1y2MD86u217bXTEW88ch6/Kc0hliiiigAooooAKKKKACmyyLFGzvnaoycDJ/Kl3fMFwemc44qCNJzeSvJIBBtCxxqPzYn17Y9vfgAisonlf7XdIFmIIjXvGh7fU4BP5dqu0UUAFFFFAHL/FAX5+HXiMaPFNNqJsZfs8cMfmOz7TgKuDk57YryHxTH4+ktPFd7pt34ntptKsdKl0q0tYD5dzMyfv12bCZMEcqDwTyOlfQ1FAHh2oTeJm1jxYuqf8JcdT868XSobK2L6a9p5DeTuIUoWJ6gnfvwAKxIrjx7HrPg9RF4jng+waYk9nFBLZpC/loZ2aQIYm5zuWTaRggAcGvoyigD56EnjOLw7oovovE1tp5utUN3/ZVqy3fmeY32Xcqru8sjPIGDxuOMGm6pD8Sr/Tb57298RWeoWXhi3u449Ojwk+oBn3IcIdz4C7kU9+nSvoeigDzL4kWmqat4f+H8gsrqe7j1/S7q7WOBiYlVsyO4A+VR3JwBXKaXa+MtQ1LQtNmm8QaVYXWt6wL24tIPJZIApaBixQhVYgBWI5zwc4Ne8UUAfMdxc/E+bw/4cW+n8SWsX2G5R7mCzmecXa3UixtPHGhcjyhERuG1sknrmvo/Q3uZdE0+S/3fbHt42m3R+Wd5Ubsr/DznjtV2igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqC5t1nj2ukbgHIEi7hU9FAGVaRW8aw3U9h9nmAKruwzRjoQME4H07VW8YWLarpEVsjT+RJcwGb7O2GaPeCf8AgPTPquau65ti0mYLHE2cKqNIYgST/eHIPPbkn61lahdnRbHQLa0mSSOedYvMmPDII3fg9idoxTA0rOxnsEijglSWNPlO/KkL3xjI/DArSG4Dkc896w7XTbO6upJ3tCk5+WSYAq0vGMllwO1bUEKwrtXOPckn8z1oAcm/J37cdsU6iikAUUUUAFFFFABRR360UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTZY1ljaORQyMMEHvTqKAKGp2EdzaujzTxLlXLI2SNpzxnNYviqGOLQNNm06MSpaXNs0CLzuRmEeBnOflc10N/bvdWzQpM0IfhmUZO3uB6Ejv2qp5V65EUcFnDaxNiMPlzhcbTgYA6ZHPpQBcsUZLSJWBDbckHt7VPVHzb2H5po4p488mHKso9dpzn8/wNXI3WRA6MGVhkEUAOooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq97I4VYoGCzSnCk87R3b8P54qxVBLjfq7R+XwiFQ+Op+Unn05X9fSgC7GgjQKCT6k9T71Ct3G2oSWYDebHEsrHthiwH4/Kao+ItZi0G3hvb0KmnCQJczk4FupHDt/s5wCe2c9AaxdF1WK8+JfiS3jbKWum2HzhsqS7XDcfgV/OgDW1J5bG7SazHyA77iHtIp4JX0YHB9wefUaMaBJBLAcxS8sB0z/eH9a5yxuJb3VryYOsixSLH8mcBSMqD7lWGfTI4zW9peI4pbcOGaJuM9dp5H8/0pgXqKjgcunzAB1OGAOQDUlIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooApaqGliitlLDz5AjFTghRy3PuBj8azNYuk0iKe6uRItrArTM0UZc7QyMcKoLEgZ4AOcVszwmS4t5MnEbE4+qkVMxXIDEZPQGgDzu2+K/hOaIQ3epRSAwq0hETFcNgEPkYU53/ACnBwp4rhtP0iDwv8Wb6x8EWUeqaZ4j00TmOK6AjsXjkPO7nER3j5RzzgcV7jc3VgbWSS5mtvswIDtIw25OMA547ivJNB1TwtpvxjurvQJrE6dqOmrbl7WRPK+2iRv3YwcK7ogHbJQDrQDPWNC04aXpscBZXnJMk8gGPMlY5ZvxJ/LFSNIsWqKvyr5kJLE98MAOf+BH86qnW4WeJYYpGDuqFmG0KTng57jHT3FZmlvM8kEkytNK7kybRgjPk8n0xjOKYHRR5F7OPl2lVYc855B4/AVPVdSn29wAd/lKSe2Mn/wCvVikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQ3LFBG3YOM844PH9ao3kExmMgx8smU6kHIXGfT5lH4VpSIsiMjjKsMEVTleRrSaIbjPFg47uAcj88Y/OmBl23hqyl1a21WcSu9uG+zwM+YkJxiTZ/fAAGT05xjJrlP+EYii+OjX6W9o1lc6S800bpk+f5ioWHb7oXqO59TXoa3sbTQKoYxzoWjk/hJ67fY45/A1m39nL/wl+kX8MQZRbXFtM2QCqsY2U+4ymP8AgVAF5dI05JRJHY2ySKchljAOfwpLSNY7qSIFzsO7ngEnJz78YqW8uxBJDCgDzzNhUz2/iY+wH9B3pqzmZpGixwTHG3UE9z9AePwoAfaSGWW5f+AP5annnA5/XI/CrNMhjWGJY0+6oxT6QBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUx4wW3qAJMY3Y7elPooAzrmzcF/KXzIWO/wArO1kf+8h7euD/AI1SvDHcqkd4bhLmP/VyQxPv6c5wMD8DW9RQBg2OnSMrBPPiV1xJczNm4lH90H+Efr6Ada07O1EG07UUIvlxIgwI09PrwKt0UAFFFFABRRRQAUUUUAFFFFAAR05NFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A vertical incision is made over the labia majora.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18017=[""].join("\n");
var outline_f17_38_18017=null;
var title_f17_38_18018="Pediatric basic life support algorithm";
var content_f17_38_18018=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Pediatric BLS algorithm for healthcare providers: 2010 guidelines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 736px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AED: automated external defibrillator; BLS: basic life support; CPR: cardiopulmonary resuscitation.",
"     <br>",
"      * The boxes bordered by dotted lines are performed by health care providers and not by lay rescuers.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission. Pediatric Basic Life Support: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. &copy; 2010 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18018=[""].join("\n");
var outline_f17_38_18018=null;
var title_f17_38_18019="Lidocaine and chlorhexidine: Patient drug information";
var content_f17_38_18019=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lidocaine and chlorhexidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/46/26339?source=see_link\">",
"     see \"Lidocaine and chlorhexidine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13709174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Instillagel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13737635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691414",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area before care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2739759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to clean the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13737634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3631384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lidocaine, chlorhexidine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13737639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13737640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13737642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13737637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13737643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13737644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17139 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18019=[""].join("\n");
var outline_f17_38_18019=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13709174\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737635\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737634\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737639\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737640\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737642\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737637\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737643\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737644\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/46/26339?source=related_link\">",
"      Lidocaine and chlorhexidine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_38_18020="Heart stents and angioplasty";
var content_f17_38_18020=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Heart stents and angioplasty (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/38/18020/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/38/18020/contributors\" id=\"au6237\">",
"       Julian M Aroesty, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/38/18020/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/38/18020/contributors\" id=\"se3839\">",
"       Donald Cutlip, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/38/18020/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/38/18020/contributors\" id=\"de1101\">",
"       Gordon M Saperia, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?17/38/18020?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     There are two main types of treatment for people with angina (chest pain) caused by coronary artery disease: medications (medical therapy) and interventional treatment (treatment that opens or bypasses narrowed coronary arteries). The goals of these treatments are to improve a person's quality of life and to alleviate symptoms such as angina. In some people, these interventions may also delay or stop the progression of the disease and thereby prolong life.",
"    </p>",
"    <p>",
"     This topic review discusses percutaneous coronary intervention, also called angioplasty or stent placement. The other interventional treatment, coronary artery bypass graft surgery (CABG), is discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"      \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Medical therapy for coronary artery disease is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/1/31766?source=see_link\">",
"      \"Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)\"",
"     </a>",
"     .) A comparison of medical treatment and interventional treatment is also available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=see_link\">",
"      \"Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS ANGIOPLASTY?",
"     </span>",
"    </p>",
"    <p>",
"     Angioplasty, also known as percutaneous coronary intervention",
"     <strong>",
"      or PCI",
"     </strong>",
"     , is a procedure that uses a flexible plastic catheter with a balloon at the end to dilate narrowed arteries in the heart. The procedure usually includes placement of a metal stent to hold the artery open. In this way, angioplasty helps to restore blood flow to the heart muscle.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Why do I need angioplasty?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chest pain that is a consequence of decreased oxygen rich blood to a portion of the heart muscle is called angina pectoris. Angina is a signal that the heart muscle is not getting sufficient blood flow, specifically sufficient oxygen. Lack of oxygen is termed ischemia. Blood flow is most often reduced by coronary artery disease (CAD), which causes a narrowing of the arteries that carry blood to the heart muscle (",
"     <a class=\"graphic graphic_figure graphicRef78702 \" href=\"UTD.htm?3/9/3219\">",
"      figure 1",
"     </a>",
"     ). Narrowing in the coronary arteries occurs as a result of calcium and fatty deposits, called plaques.",
"    </p>",
"    <p>",
"     A person with narrowed arteries may develop angina during activity, exercise, or any other physical or mental stress that increases the heart's demand for blood. Angina can be \"stable\" or \"unstable\". Angina is unstable when there is a change in the usual pattern, such as a change in frequency, severity, duration, or precipitating cause. Unstable angina may be associated with damage to the heart muscle (or heart attack). The term",
"     <strong>",
"      acute coronary syndrome",
"     </strong>",
"     refers to people with unstable angina or a heart attack; these conditions require immediate evaluation in a hospital. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=see_link\">",
"      \"Patient information: Chest pain (Beyond the Basics)\"",
"     </a>",
"     .) In severe cases, heart attack can lead to heart failure or sudden cardiac death.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Angioplasty candidates",
"     </span>",
"     &nbsp;&mdash;&nbsp;Angioplasty may be recommended in addition to medical therapy for two groups of people with stable angina:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People who have persistent and intolerable symptoms despite adequate medical treatment",
"      </li>",
"      <li>",
"       People who have specific patterns of arterial narrowing and a high risk of either a heart attack or death",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The usefulness of angioplasty depends upon the severity of arterial narrowing. Angioplasty is often recommended when arterial narrowing is moderate to severe or when only one or two coronary arteries are severely narrowed. It may be less effective in patients who have diabetes. People with diabetes appear to have greater benefit from bypass surgery, especially if there are two or three vessels involved.",
"    </p>",
"    <p>",
"     People who have extensive coronary heart disease, including a large number of narrowed coronary arteries or narrowing of the left main coronary artery and poor pumping function of their left ventricle (lower heart chamber), tend to live longer when they have coronary artery bypass surgery rather than medical treatment. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"      \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Angioplasty benefits",
"     </span>",
"     &nbsp;&mdash;&nbsp;Angioplasty relieves angina and improves a person's ability to exercise. However, many individual factors influence the effectiveness of interventional treatment and its continued benefit over time. It is therefore important to discuss realistic expectations for each of these procedures with a doctor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Angioplasty risks",
"     </span>",
"     &nbsp;&mdash;&nbsp;Angioplasty is an invasive procedure and is associated with risks that should be discussed with a doctor. The extent of this risk depends upon many individual factors. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Angioplasty complications'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      THE ANGIOPLASTY PROCEDURE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Preparing for angioplasty",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood tests and an electrocardiogram (EKG) are usually performed before angioplasty. These tests help to ensure that other potential medical problems are identified and managed prior to angioplasty.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Coronary arteriography",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prior to angioplasty, testing is done to determine which coronary arteries are blocked and to evaluate the severity of the blockage. This procedure is called cardiac catheterization or coronary angiography. In patients with stable angina, it is usually performed in a hospital, often immediately before angioplasty.",
"    </p>",
"    <p>",
"     Most patients are told not to eat or drink anything for 6 to 8 hours before the catheterization procedure. People with diabetes should speak to their doctor about how much medication to take before the procedure. Anticoagulant medications such as warfarin may be decreased or even stopped temporarily before surgery, depending upon the reason the anticoagulant is used. However, aspirin and a second antiplatelet medication are usually continued. It is important to follow all of the instructions regarding medication use before surgery; the procedure may need to be canceled or delayed if instructions are not followed exactly.",
"    </p>",
"    <p>",
"     The patient is given a sedative and may be given a pain medication before the procedure. Most people do not remember the procedure as a result of these medications. A tiny catheter is inserted into an artery in the leg (the femoral artery) or in the arm (the radial artery). The catheter is guided through blood vessels to the heart. The coronary arteries are viewed by injecting a dye (contrast) through the catheter and using a type of x-ray machine (called a fluoroscope).",
"    </p>",
"    <p>",
"     Based upon the results of this test, the doctor sometimes proceeds immediately with angioplasty if it appears reasonable to do so. \"Reasonable\" is determined both by the nature of the blockage and by the patient's wishes, which are usually discussed before the catheterization.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In some cases, a procedure to treat the blocked or narrowed arteries (angioplasty) can be performed immediately following the catheterization.",
"      </li>",
"      <li>",
"       In other cases, treatment with medications is continued",
"       <strong>",
"        OR",
"       </strong>",
"       open heart surgery with bypass may be recommended. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?31/1/31766?source=see_link\">",
"        \"Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"        \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      How is angioplasty performed?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Angioplasty is usually performed in a hospital in an area called the catheterization laboratory. The procedure usually takes between one and two hours. The patient is given a sedative and pain medication before the procedure. Many people do not remember the procedure as a result of these medications.",
"    </p>",
"    <p>",
"     To open the narrowed artery, a long, thin catheter with a deflated balloon at its end is inserted into an artery in the leg (the femoral artery) or the arm (the radial artery). The catheter is guided through blood vessels to the beginning of a narrowed coronary artery in the heart. The placement of the catheter is confirmed by injecting a dye into the coronary artery and using a type of x-ray machine (called a fluoroscope) to view the catheter's position.",
"    </p>",
"    <p>",
"     The balloon is then inflated, which expands the narrowed artery. A stent (an expandable metal tube usually made of wire mesh) is usually placed after the vessel is expanded to reduce the risk of narrowing in the future (",
"     <a class=\"graphic graphic_figure graphicRef78702 \" href=\"UTD.htm?3/9/3219\">",
"      figure 1",
"     </a>",
"     ). Some stents are coated with a medication (called drug-eluting stents) to help prevent the development of excessive tissue growth. This tissue forms in an effort to \"heal\" the stented area and could potentially narrow or totally block the coronary artery over time. The drug-eluting stent releases a medication that helps to prevent excessive tissue growth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Angioplasty complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Complications of angioplasty are relatively infrequent. The most common complications include discomfort and bleeding at the puncture site where the catheter was inserted.",
"    </p>",
"    <p>",
"     Occasionally, angioplasty creates a small tear (dissection) of an internal layer in the coronary artery. Usually, the tear is small and heals by itself. In some cases the tear is corrected with a stent. If the tear is severe, causing a blockage in blood flow in the artery or loss of blood around the heart, immediate treatment is given. This usually includes a repeat angioplasty and insertion of a stent. Rarely, a person will need urgent bypass surgery, but this is necessary in less than one percent of patients.",
"    </p>",
"    <p>",
"     Many patients have evidence of a very small amount of heart damage after angioplasty, based upon blood testing. However, less than one percent of patients have a heart attack large enough to cause a substantial amount of damage.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Limitations of angioplasty",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although angioplasty restores blood flow and relieves symptoms in over 90 percent of patients, there is a risk of recurrent symptoms within six months, often due to recurrent narrowing (restenosis) of the artery. Restenosis that is severe enough to cause symptoms occurs in:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Approximately 30 percent of people who have balloon angioplasty without stent placement.",
"      </li>",
"      <li>",
"       Approximately 15 percent of people who have a bare metal stent.",
"      </li>",
"      <li>",
"       Less than 10 percent of people who have a drug coated stent.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some coronary artery sites are more prone to renarrowing than others. In addition, some conditions increase the risk of narrowing, potentially requiring a repeat catheterization and reopening or bypass of the narrowed artery:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Diabetes",
"      </li>",
"      <li>",
"       Continued cigarette smoking",
"      </li>",
"      <li>",
"       High blood pressure",
"      </li>",
"      <li>",
"       Arteries that are narrow",
"      </li>",
"      <li>",
"       High level of bad (LDL) cholesterol",
"      </li>",
"      <li>",
"       Narrowing in a major blood vessel that is at or near the beginning of a side branch",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Recurrent symptoms can develop as a result of other vessels that become narrowed. Some vessels that are very small, have longstanding total blockages, or have a very calcified (hardened) lesion, are more difficult to open.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Care after the procedure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Following the angioplasty procedure, the catheter is removed from the artery and pressure is applied to the area. In some cases, a pressure device is used to limit bleeding from the site. In other cases the artery is sealed closed at the time the catheter is removed.",
"    </p>",
"    <p>",
"     The patient must lie flat and remain still for several hours to reduce the risk of bleeding. During this time, the patient will remain in a recovery area where his or her blood pressure, heart rate, oxygen level, temperature, and puncture site can be monitored frequently. As the sedative medication begins to wear off, pain medication may be given if needed.",
"    </p>",
"    <p>",
"     Most patients will remain in the hospital overnight after angioplasty. A friend or family member must be available to drive the patient home. Most patients are able to walk on the day after the angioplasty and can resume their normal activities, including returning to work, within a week. Driving and heavy lifting and pushing or pulling is not allowed for a few days. Specific activity restrictions should be discussed with a clinician.",
"    </p>",
"    <p>",
"     Questions to ask after angioplasty include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       When do I restart my medications? Do I need any new medications?",
"      </li>",
"      <li>",
"       When should I see the doctor next?",
"      </li>",
"      <li>",
"       Who do I call if I have problems after I go home?",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Antiplatelet medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;One of the most serious complications that can develop after stent placement is the development of a blood clot (thrombosis) inside the stent; this is called stent thrombosis. It is thought that the metal of the stent in contact with components of blood lead to clotting.",
"    </p>",
"    <p>",
"     A stent thrombosis can potentially block blood flow to the heart, causing a heart attack or even death. Stent thrombosis can occur within 24 hours, 30 days, or as late as one year or more after stent placement, although most episodes occur within 30 days.",
"    </p>",
"    <p>",
"     Fortunately, stent thrombosis is rare because aspirin and a second drug which prevents clotting are given before and after stent placement.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;After angioplasty, seek immediate medical assistance if any of the following occur:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Chest pain develops and is not relieved with one dose of sublingual (under the tongue) nitroglycerin",
"      </li>",
"      <li>",
"       The puncture site becomes very painful, swollen, warm, bleeds more than a few drops, or drains pus.",
"      </li>",
"      <li>",
"       A fever higher than 100.4&ordm; F (38&ordm; C) develops",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      OTHER MEASURES TO SLOW OR REVERSE HEART DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     In all patients with coronary artery disease, it is important to follow guidelines to reduce the risk of worsening heart disease. These guidelines, which should be discussed with a healthcare provider, include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Treat high blood pressure (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"        \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Treat high cholesterol (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"        \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Quit smoking (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Lose excess weight (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"        \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Reduce stress",
"      </li>",
"      <li>",
"       Exercise regularly (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"        \"Patient information: Exercise (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Avoid or minimize activities that provoke angina, such as exercising during cold weather or exercising vigorously, particularly after a meal",
"      </li>",
"      <li>",
"       Learn to use nitroglycerin preventively (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?31/1/31766?source=see_link\">",
"        \"Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)\"",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498682716\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112840113\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/27/21940?source=see_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=see_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112840128\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/1/31766?source=see_link\">",
"      Patient information: Angina treatment &mdash; medical therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=see_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=see_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24889?source=see_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42343?source=see_link\">",
"      Management of significant proximal left anterior descending coronary artery disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/25/29081?source=see_link\">",
"      Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20138?source=see_link\">",
"      Role of stress testing after coronary revascularization",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/angioplasty.html\">",
"      www.nlm.nih.gov/medlineplus/angioplasty.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/dci/Diseases/Angioplasty/Angioplasty_WhatIs.html\">",
"      www.nhlbi.nih.gov/health/dci/Diseases/Angioplasty/Angioplasty_WhatIs.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American College of Cardiology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acc.org/\">",
"      www.acc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?17/38/18020/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 11, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?17/38/18020?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18020/abstract/1\">",
"      El-Jack SS, Ruygrok PN, Webster MW, et al. Effectiveness of manual pressure hemostasis following transfemoral coronary angiography in patients on therapeutic warfarin anticoagulation. Am J Cardiol 2006; 97:485.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18020/abstract/3\">",
"      Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18020/abstract/4\">",
"      Kini AS, Lee P, Mitre CA, et al. Postprocedure chest pain after coronary stenting: implications on clinical restenosis. J Am Coll Cardiol 2003; 41:33.",
"     </a>",
"    </li>",
"    <li>",
"     www.circ.ahajournals.org (accessed January 29, 2008) www.circ.ahajournals.org (Accessed on January 29, 2008).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f17_38_18020=[""].join("\n");
var outline_f17_38_18020=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS ANGIOPLASTY?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           THE ANGIOPLASTY PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           OTHER MEASURES TO SLOW OR REVERSE HEART DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/9/3219\" title=\"figure 1\">",
"           Plaque formation PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f17_38_18021="Hyoscyamine, atropine, scopolamine, and phenobarbital: Patient drug information";
var content_f17_38_18021=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hyoscyamine, atropine, scopolamine, and phenobarbital: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/39/39541?source=see_link\">",
"     see \"Hyoscyamine, atropine, scopolamine, and phenobarbital: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/10/25765?source=see_link\">",
"     see \"Hyoscyamine, atropine, scopolamine, and phenobarbital: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Donnatal Extentabs&reg;;",
"     </li>",
"     <li>",
"      Donnatal&reg;;",
"     </li>",
"     <li>",
"      Hyonatol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to slow the speed in the stomach and GI (gastrointestinal) tract.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat irritable bowel syndrome.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat muscle spasms of the GI (gastrointestinal) tract, gallbladder system, or urinary system.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702278",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hyoscyamine, atropine, scopolamine, phenobarbital, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703353",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems, bowel block, glaucoma, myasthenia gravis, porphyria, slow-moving GI (gastrointestinal) tract, trouble passing urine, or ulcerative colitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not sweating during activities or in warm temperatures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for irritable bowel syndrome or spasms of the GI (gastrointestinal) tract, take 30 to 60 minutes before meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (elixir) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10750 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18021=[""].join("\n");
var outline_f17_38_18021=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021129\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021131\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021130\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021135\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021136\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021138\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021133\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021134\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021139\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021140\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/39/39541?source=related_link\">",
"      Hyoscyamine, atropine, scopolamine, and phenobarbital: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/10/25765?source=related_link\">",
"      Hyoscyamine, atropine, scopolamine, and phenobarbital: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_38_18022="Cervical disc herniation";
var content_f17_38_18022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Flexion distraction injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 565px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Lateral radiograph of a patient with flexion distraction injury resulting in acute disc herniation at C5-C6. Note the narrowed disc space and the distruption of the cervical spine alignment. (B) MRI of the same patient demonstrating the cervical disc herniation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles A Reitman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18022=[""].join("\n");
var outline_f17_38_18022=null;
var title_f17_38_18023="Lacunar infarcts MRI";
var content_f17_38_18023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F54402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F54402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Lacunar infarcts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance imaging studies in a 71-year-old woman with a two day history of left-sided ataxic hemiparesis. Left panels: Diffusion weighted images show two acute lesions, one in the cerebellum (top panel) and one in the thalamocapsular region (bottom panel). T2 weighted images (middle panels) and FLAIR (right panels) correctly identify the lesions (arrows) but both cannot be confidently called \"acute.\" A high-risk cardiac source was found on echocardiogram (akinetic left ventricular segment).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jamary Oliveira-Filho, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18023=[""].join("\n");
var outline_f17_38_18023=null;
var title_f17_38_18024="Calcium carbonate: Pediatric drug information";
var content_f17_38_18024=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium carbonate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"    see \"Calcium carbonate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/17/13589?source=see_link\">",
"    see \"Calcium carbonate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alcalak [OTC];",
"     </li>",
"     <li>",
"      Alka-Mints&reg; [OTC];",
"     </li>",
"     <li>",
"      Cal-Gest&reg; [OTC];",
"     </li>",
"     <li>",
"      Cal-Mint [OTC];",
"     </li>",
"     <li>",
"      Calci-Chew&reg; [OTC];",
"     </li>",
"     <li>",
"      Calci-Mix&reg; [OTC];",
"     </li>",
"     <li>",
"      Caltrate&reg; 600 [OTC];",
"     </li>",
"     <li>",
"      Children's Pepto [OTC];",
"     </li>",
"     <li>",
"      Chooz&reg; [OTC];",
"     </li>",
"     <li>",
"      Florical&reg; [OTC];",
"     </li>",
"     <li>",
"      Maalox&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Maalox&reg; Regular Strength [OTC];",
"     </li>",
"     <li>",
"      Nephro-Calci&reg; [OTC];",
"     </li>",
"     <li>",
"      Nutralox&reg; [OTC];",
"     </li>",
"     <li>",
"      Oysco 500 [OTC];",
"     </li>",
"     <li>",
"      Oystercal&trade; 500 [OTC];",
"     </li>",
"     <li>",
"      Rolaids&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Super Calcium 600 [OTC];",
"     </li>",
"     <li>",
"      Titralac&trade; [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; E-X [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Extra Strength Sugar Free [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Quickpak [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Smoothies&trade; [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Ultra [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cal&reg;;",
"     </li>",
"     <li>",
"      Calcite-500;",
"     </li>",
"     <li>",
"      Caltrate&reg;;",
"     </li>",
"     <li>",
"      Caltrate&reg; Select;",
"     </li>",
"     <li>",
"      Os-Cal&reg;;",
"     </li>",
"     <li>",
"      Tums Extra Strength;",
"     </li>",
"     <li>",
"      Tums Smoothies;",
"     </li>",
"     <li>",
"      Tums&reg; Chews Extra Strength;",
"     </li>",
"     <li>",
"      Tums&reg; Regular Strength;",
"     </li>",
"     <li>",
"      Tums&reg; Ultra Strength",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1002776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antacid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     200 mg/day of",
"     <b>",
"      elemental calcium",
"     </b>",
"     ; requirements may vary on prematurity, postnatal age, and other clinical factors; serum calcium concentrations should be monitored closely to determine patient-specific needs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Dose depends on clinical condition and serum calcium concentration: Dose expressed in mg of",
"     <b>",
"      elemental calcium",
"     </b>",
"     : 50-150 mg/kg/day in 4-6 divided doses; not to exceed 1000 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1002801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"      see \"Calcium carbonate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental calcium:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 260 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental calcium;",
"     </b>",
"     during pregnancy and lactation, requirements may change:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 700 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-18 years: 1300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females 19-50 years, males 19-70 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females &ge;51 years, males &ge;71 years: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Antacid:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2-5 years: Children&rsquo;s Pepto: 1 tablet (400 mg calcium carbonate) as symptoms occur; not to exceed 3 tablets/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;5-11 years: Children&rsquo;s Pepto: 2 tablets (800 mg calcium carbonate) as symptoms occur; not to exceed 6 tablets/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;11 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Tums&reg;, Tums&reg; E-X: Chew 2-4 tablets as symptoms occur; not to exceed 15 tablets (Tums&reg;) or 10 tablets (Tums&reg; E-X) per day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Tums&reg; Ultra:  Chew 2-3 tablets as symptoms occur; not to exceed 7 tablets per day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Dose depends on clinical condition and serum calcium concentration: Dose expressed as",
"     <b>",
"      elemental calcium",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 45-65 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 1-2 g or more per day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of hyperphosphatemia in end-stage renal failure:",
"     </b>",
"     Children and Adults: Dose expressed as",
"     <b>",
"      calcium carbonate",
"     </b>",
"     : 1 g with each meal; increase as needed; range: 4-7 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adjunctive prevention and treatment of osteoporosis:",
"     </b>",
"     Adults: 500 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     2-3 times/day; recommended dosage includes dietary intake and should be adjusted depending upon the patient&rsquo;s diet; to improve absorption do not administer more than 500 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hydrofluoric acid (HF) burns (HF concentration &lt;20%):",
"     </b>",
"     Topical: Various topical calcium preparations have been used anecdotally for treatment of dermal exposure to HF solutions; calcium carbonate at concentrations ranging from 2.5% to 33% has been used; a topical calcium carbonate preparation must be compounded; apply topically as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute may require dosage adjustment depending upon serum calcium level",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calci-Mix&reg;: 1250 mg [equivalent to elemental calcium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Florical&reg;: 364 mg [equivalent to elemental calcium 145 mg; contains fluoride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gum, chewing, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chooz&reg;: 500 mg (12s) [sugar free; contains phenylalanine 1.4 mg/tablet; mint flavor; equivalent to elemental calcium 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral:  (480 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Quickpak: 1000 mg/packet (24s) [contains sodium &lt;5 mg/packet; berry fusion flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 1250 mg/5 mL (5 mL, 473 mL, 500 mL) [equivalent to elemental calcium 500 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 648 mg [equivalent to elemental calcium 260 mg], 650 mg [equivalent to elemental calcium 260 mg], 1250 mg [equivalent to elemental calcium 500 mg], 1500 mg [equivalent to elemental calcium 600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caltrate&reg; 600: 1500 mg [scored; equivalent to elemental calcium 600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Florical&reg;: 364 mg [equivalent to elemental calcium 145 mg; contains fluoride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nephro-Calci&reg;: 1500 mg [equivalent to elemental calcium 600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oysco 500: 1250 mg [equivalent to elemental calcium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oystercal&trade; 500: 1250 mg [equivalent to elemental calcium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Super Calcium 600: 1500 mg [gluten free, sugar free; equivalent to elemental calcium 600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Super Calcium 600: 1500 mg [sugar free; equivalent to elemental calcium 600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 420 mg [equivalent to elemental calcium 168 mg], 500 mg [equivalent to elemental calcium 200 mg], 600 mg [DSC] [equivalent to elemental calcium 222 mg], 650 mg [equivalent to elemental calcium 260 mg], 750 mg [equivalent to elemental calcium 300 mg], 1250 mg [equivalent to elemental calcium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alcalak: 420 mg [aluminum free; mint flavor; equivalent to elemental calcium 168 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alka-Mints&reg;: 850 mg [spearmint flavor; equivalent to elemental calcium 340 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-Gest&reg;: 500 mg [equivalent to elemental calcium 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-Mint: 650 mg [aluminum free, dye free, gluten free, sugar free; mint flavor; equivalent to elemental calcium 260 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calci-Chew&reg;: 1250 mg [cherry flavor; equivalent to elemental calcium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children's Pepto: 400 mg [bubblegum flavor; equivalent to elemental calcium 161 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children's Pepto: 400 mg [watermelon flavor; equivalent to elemental calcium 161 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maalox&reg; Children's: 400 mg [contains phenylalanine 0.3 mg/tablet; wildberry flavor; equivalent to elemental calcium 160 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maalox&reg; Regular Strength: 600 mg [contains phenylalanine 0.5 mg/tablet; wildberry flavor; equivalent to elemental calcium 240 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nutralox&reg;: 420 mg [sugar free; mint flavor; equivalent to elemental calcium 168 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Titralac&trade;: 420 mg [sugar free; contains sodium 1.1 mg/tablet; spearmint flavor; equivalent to elemental calcium 168 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg;: 500 mg [contains tartrazine; assorted fruit flavor; equivalent to elemental calcium 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg;: 500 mg [contains tartrazine; peppermint flavor; equivalent to elemental calcium 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [tropical fruit flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [wintergreen flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [contains tartrazine; assorted berries flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [contains tartrazine; assorted fruit flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [contains tartrazine; cool relief mint flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [contains tartrazine; fresh blend flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [contains tartrazine; tropical fruit flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Extra Strength Sugar Free: 750 mg [sugar free; contains phenylalanine &lt;1 mg/tablet; orange cream flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Smoothies&trade;: 750 mg [contains tartrazine; assorted fruit flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Smoothies&trade;: 750 mg [contains tartrazine; peppermint flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Smoothies&trade;: 750 mg [contains tartrazine; tropical assorted fruits flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Ultra: 1000 mg [contains tartrazine; assorted berries flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Ultra: 1000 mg [contains tartrazine; assorted fruit flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Ultra: 1000 mg [contains tartrazine; peppermint flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Ultra: 1000 mg [contains tartrazine; spearmint flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Ultra: 1000 mg [contains tartrazine; tropical assorted fruits flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, softchew, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rolaids&reg; Extra Strength: 1177 mg [contains coconut oil, soya lecithin; vanilla cr&egrave;me flavor; equivalent to elemental calcium 471 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rolaids&reg; Extra Strength: 1177 mg [contains coconut oil, soya lecithin; wild cherry flavor; equivalent to elemental calcium 471 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3429648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with plenty of fluids with or immediately following meals; if using for phosphate-binding, administer with meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Suspension: Shake well before administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chewable tablets: Thoroughly chew tablets before swallowing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Massage calcium carbonate slurry into exposed area for 15 minutes",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1002795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1002777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of hyperacidity associated with peptic ulcer, gastritis, esophagitis, and hiatal hernia; treatment of  hyperphosphatemia in end-stage renal failure; dietary supplement; prevention and treatment of calcium deficiency; topical treatment of hydrofluoric acid burns; adjunctive prevention and treatment of osteoporosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Calcium carbonate may be confused with calcitriol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Florical&reg; may be confused with Fiorinal&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mylanta&reg; may be confused with Mynatal&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nephro-Calci&reg; may be confused with Nephrocaps&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Remegel [Hungary, Great Britain, and Ireland] may be confused with Renagel brand name for sevelamer [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Remegel: Brand name for calcium carbonate [Hungary, Great Britain, and Ireland], but also the brand name for aluminum hydroxide and magnesium carbonate [Netherlands]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F144435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Well tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, acid rebound, anorexia, constipation, flatulence, laxative effect, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Milk-alkali syndrome with very high, chronic dosing and/or renal failure ( or alkalosis, headache, hypercalcemia, irritability, nausea, renal impairment, weakness)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1002779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to calcium formulation; hypercalcemia, renal calculi, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3429082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use cautiously in patients with sarcoidosis, respiratory failure, acidosis, renal or cardiac disease; some chewable tablets contain phenylalanine which must be avoided in patients with phenylketonuria; some products may contain aspartame which is metabolized to phenylalanine and must be avoided in patients with phenylketonuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1002780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing. Some products may contain tartrazine which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1002792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not give orally with bran, foods high in oxalates (spinach, sweet potatoes, rhubarb, beans), or phytic acid ( unleavened bread, raw beans, seeds, nuts, grains, soy isolates) which may decrease calcium absorption; minimize administration with dairy products (when treating deficiency state) as this will reduce absorption",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F144384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium crosses the placenta. Intestinal absorption of calcium increases during pregnancy. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM, 2011). Calcium-based antacids are considered low risk during pregnancy; excessive use should be avoided (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3429083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium (ionized calcium preferred if available), phosphate, magnesium, heart rate, ECG",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1002797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium: Newborns: 7-12 mg/dL; 0-2 years: 8.8-11.2 mg/dL; 2 years to adults: 9-11 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium, ionized, whole blood: 4.4-5.4 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1002796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium moderates nerve and muscle performance via action potential excitation threshold regulation; it is necessary for maintaining the functional integrity of nervous, muscular, and skeletal systems and cell-membrane and capillary permeability. Calcium carbonate combines with dietary phosphate to form insoluble calcium phosphate which is excreted in feces and reduces phosphate absorption.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F3429647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acid neutralizing capacity: Tums&reg; 500 mg: 10 mEq, Tums&reg; E-X 750 mg: 15mEq; Tums&reg; Ultra 1000 mg: 20 mEq",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1002798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 25% to 35%; varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, young adults 25%); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily in the feces as unabsorbed calcium",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1002811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 g calcium carbonate = 400 mg elemental calcium = 20 mEq calcium. Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended. If ionized calcium is unavailable, in low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by this equation (assuming a normal albumin of 4 g/dL); [(4 &ndash; patient's albumin) x 0.8] + patient's measured total calcium",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Calcium Content of Calcium Salts",
"     </caption>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/1 g of salt form)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/g)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate Equivalent Doses",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg of calcium salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium acetate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         354",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium carbonate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         270",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         330",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium citrate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         211",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         425",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium glubionate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         64",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1400",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium lactate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         700",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium phosphate (tribasic)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         390",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         233",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Ross AC, Taylor CL, et al, eds, Washington, DC: National Academies Press (US), 2011. Available at",
"      <a href=\"file://www.nap.edu/catalog.php?record_id=13050\" target=\"_blank\">",
"       file://www.nap.edu/catalog.php?record_id=13050",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/38/18024/abstract-text/21796828/pubmed\" id=\"21796828\" target=\"_blank\">",
"        21796828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/38/18024/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12569 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-D760560F04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18024=[""].join("\n");
var outline_f17_38_18024=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144392\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144393\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002776\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442162\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002801\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144376\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144362\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429648\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002795\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002777\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144437\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144435\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002779\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429082\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002780\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298933\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144371\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002792\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144384\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429083\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002797\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002796\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429647\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002798\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002811\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12569\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12569|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=related_link\">",
"      Calcium carbonate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/17/13589?source=related_link\">",
"      Calcium carbonate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_38_18025="Family and couples therapy for treating depressed adults";
var content_f17_38_18025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Family and couples therapy for treating depressed adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/38/18025/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/38/18025/contributors\">",
"     Gabor Keitner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/38/18025/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/38/18025/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/38/18025/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/38/18025/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/38/18025/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 26, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression occurs in a social context and usually affects the patient's significant others. The way in which family members and significant others respond to the depressed patient, in turn, influences the course and outcome of the depressive episode [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/1\">",
"     1",
"    </a>",
"    ]. While many family members cope well when a member becomes depressed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], others experience significant distress themselves and inadvertently exacerbate the patient's depression, decrease the likelihood of recovery, and increase the probability of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. It therefore makes good clinical sense to include the family as part of evaluating and treating depressed patients.",
"   </p>",
"   <p>",
"    There are psychoeducation, systems, emotion focused, and cognitive-behavioral therapy family therapies. They all share the two-fold aim of modifying negative interactional patterns and promoting supportive aspects of dyadic relationships, to change the interpersonal context linked to depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the use of family assessments and family therapy for treating depression in adult patients. An overview of all options available for treating depression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every depressed patient can benefit from an assessment with their significant others during which the clinician evaluates the:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient's social situation",
"     </li>",
"     <li>",
"      Presence of life changes",
"     </li>",
"     <li>",
"      Nature of the family's relationships",
"     </li>",
"     <li>",
"      Family's understanding of depression",
"     </li>",
"     <li>",
"      Family's awareness of what treatment involves",
"     </li>",
"     <li>",
"      Family's expectations of the patient and the clinician",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A family assessment can facilitate treatment in several ways. The clinician can gain collateral information that patients may be withholding intentionally or not. In addition, some patients resist treatment, and clinicians can recruit family members as allies to help overcome this. Family members themselves may be resistant to certain aspects of treatment and encourage noncompliance on the part of the patient (eg, family members may believe that antidepressant medication is addictive).",
"   </p>",
"   <p>",
"    Family therapy is most appropriate for families who have pronounced difficulty in dealing with depression in their loved one. Family therapy is particularly indicated in families where",
"    <span class=\"nowrap\">",
"     marital/family",
"    </span>",
"    problems predate the onset of the depression, because these families generally have greater difficulties in managing depression in a family member [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/7\">",
"     7",
"    </a>",
"    ]. Family therapy can address both the preceding problems and the difficulties that a family has in dealing with the depression.",
"   </p>",
"   <p>",
"    Family therapy is usually an adjunct to pharmacotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    individual psychotherapy for treating depression. However, family therapy may be indicated as a stand-alone treatment if the depressive syndrome is not severe and occurs in the context of marital or family distress [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no contraindications to a family assessment or family therapy for adult patients with depression. However, family interventions may create problems if the clinician implies that family members and processes caused the patient's depression. Family interventions may also negatively impact well-functioning families if a clinician assumes a causal relationship between normal family problems and the patient's depression, or if a clinician breaches confidentiality by revealing a secret that the depressed patient did not want revealed to other family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THEORETICAL FOUNDATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marital discord are highly prevalent in families with a depressed member [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. One study found that marital distress occurred in 50 to 66 percent of depressed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relationship distress and depression interact such that each exacerbates the other. Both depression and family dysfunction tend to be chronic, creating a vicious cycle lasting for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/12\">",
"     12",
"    </a>",
"    ]. As an example, depressed patients may behave in ways that irritate and alienate family members, eventually leading to rejection of the depressed patient [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, individuals with depression may also selectively seek negative feedback consistent with their poor self-image [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Couple distress can lead to depression through loss of intimacy and emotional connection, combined with tension and interpersonal hostility [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/15\">",
"     15",
"    </a>",
"    ]. One study found that marital distress was associated with a 10-fold increase in depressive symptoms, and another study found that the risk of major depression was 25 times greater in unhappy marriages compared with untroubled marriages [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Conversely, support from a spouse has been shown to decrease the frequency of depression following stressful life events [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family functioning also predicts the course of illness in depressed patients. Interpersonal support, greater intimacy, and help from a partner to improve coping may buffer the effect of depressive symptoms and facilitate recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/19\">",
"     19",
"    </a>",
"    ]. Conversely, family dysfunction may interfere with recovery from depression; in one study, remission occurred in significantly fewer depressed patients with discord in their intimate relationships, compared to depressed patients without discord (34 versus 61 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/20\">",
"     20",
"    </a>",
"    ]. Other studies have found that family dysfunction is associated with a slower rate of recovery from a depressive episode [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], and that excessive criticism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    emotional over-involvement within the family increases the likelihood of recurrence following recovery from depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depression interferes with parenting skills and adversely affects children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Young children of depressed parents have more difficult temperaments, more problems with aggression and mood, more insecure attachments, more difficult interpersonal functioning, poor self esteem, and lower academic performance.",
"     </li>",
"     <li>",
"      Children of parents with depression have higher rates of internalizing (eg, anxiety and depression) and externalizing (eg, substance use) symptoms and disorders.",
"     </li>",
"     <li>",
"      The quality of parenting may not improve significantly despite recovery from the depressive episode.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although many authorities distinguish couples therapy from family therapy because of theoretical and organizational reasons, we maintain that the principles of treatment are similar. Both couples and family therapy focus upon the depressed patient and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    social connections, as opposed to simply focusing upon the individual patient. The clinician may need to make some technical adjustments depending upon whether the clinician meets with two, three, four or more family members, but the principles of treatment are the same. The main determinate for couple or family approaches is the comfort level of the clinician with smaller or larger numbers of significant others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in treating depressed patients with family therapy is to evaluate the patient and the family together.",
"   </p>",
"   <p>",
"    The clinician should assess the nature and quality of the family's relationships to determine whether family therapy is appropriate. Most families do not need family therapy, but all families can benefit from an assessment and opportunity to meet with the treating clinician in order to discuss their concerns, learn more about the illness and available treatments, and to receive support and guidance in how they can help the patient.",
"   </p>",
"   <p>",
"    We suggest that all members of the family should be seen at least for the initial evaluation. \"Family\" means anyone who has a meaningful, emotionally important relationship with the patient. A meaningful relationship is one in which people live together, or see and talk with each other for 10 or more hours per week. After the initial evaluation, decisions can be made about the composition of subsequent meetings for family therapy.",
"   </p>",
"   <p>",
"    This initial meeting should be viewed as an evaluation and not a treatment session. The clinician has to be particularly careful to be open to all participants' perspectives of the presenting problems and not to imply blame.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patient assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should assess the patient's depression, personality, and social life. This part of the interview overlaps with information collected during the initial interview of the patient alone without the family and may thus be truncated. However, family members often reveal new or contrasting information.",
"   </p>",
"   <p>",
"    The patient's specific type of depression should be characterized:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is this the first episode or is it a recurrence?",
"     </li>",
"     <li>",
"      Are there symptoms of psychosis?",
"     </li>",
"     <li>",
"      Is it chronic?",
"     </li>",
"     <li>",
"      Are there any comorbid psychiatric or nonpsychiatric illnesses?",
"     </li>",
"     <li>",
"      Is there a family history of mood disorders?",
"     </li>",
"     <li>",
"      What treatments have been tried?",
"     </li>",
"     <li>",
"      What has been helpful and what has not?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient's personality should be characterized:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What is the person with the depression like?",
"     </li>",
"     <li>",
"      What is his or her temperament?",
"     </li>",
"     <li>",
"      How is the patient coping with the depression?",
"     </li>",
"     <li>",
"      What is the meaning of the depression to the patient?",
"     </li>",
"     <li>",
"      What are the depressed patient's conflicts?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient's social life should be characterized:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What recent changes occurred in the patient's social situation?",
"     </li>",
"     <li>",
"      What is the patient's work situation?",
"     </li>",
"     <li>",
"      Who are the significant people in this person's life?",
"     </li>",
"     <li>",
"      What is the quality of this person's social and family relationships?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of patients with depression is discussed in greater detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Family assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential task in meeting with family members for the first time is to evaluate their functioning. The family assessment determines both the need for family therapy and the specific areas of family life that might need to be addressed.",
"   </p>",
"   <p>",
"    Data from the family assessment are used to develop a biopsychosocial formulation that addresses both the patient's problems and the social context in which they present. All three factors (biological, psychological, and social) should be considered together in developing a formulation and corresponding treatment plan.",
"   </p>",
"   <p>",
"    Assessing and clarifying the family's difficulties can be of significant therapeutic value in and of itself, as it may provide an opportunity for the family to hear each other's concerns in a safe environment in a way that was perhaps not possible up to that point. Families may have been reluctant to express their perspectives to each other for fear of hurting each other's feelings or because of the anger that each may have felt about the burden they have been dealing with.",
"   </p>",
"   <p>",
"    A family assessment does not necessarily lead to family therapy. If the family assessment reveals a well functioning family, then reassurance, support, and education can be offered.",
"   </p>",
"   <p>",
"    The clinician and family members may be most interested in focusing on the depression, its impact on the family, and what the family should do to be helpful. While these issues are central to working with families of a depressed patient, it is also important to do a more comprehensive family assessment in order to better understand the full range of problems and concerns a family may have, because these concerns may influence the depression even if the family is not aware of these issues. As an example, a depressed woman may have a husband and son who often argue with each other and their conflict may contribute heavily to her depression.",
"   </p>",
"   <p>",
"    There are different ways to assess a family and many kinds of information that can be gathered. Some family therapists begin with a long history of the family's life, connections, and evolution as a unit. Other therapists are more interested in a here and now view of how the family functions and current problems with which they are dealing. Still other therapists are focused primarily on the process issues in the family session. All three approaches have merit, are not mutually exclusive, and there is no evidence that one approach is superior to the others.",
"   </p>",
"   <p>",
"    It is important for the clinician to establish a connection with the family when meeting with the family for the first time. The family needs to feel understood, respected, and validated. They should not be blamed for their loved one's problems or judged for their perceived deficiencies. Families are more likely to participate openly in the assessment process if they feel comfortable with it.",
"   </p>",
"   <p>",
"    One effective way of putting a family at ease is to orient them to the evaluation process at the beginning of the meeting. The orientation explains the purpose of the evaluation, establishes goals for the process, and develops consensus about the agenda. It is important to clarify what the family expects will happen and what they would like to get out of the meeting. The clinician explains that the goal of the meeting is to provide an opportunity for all family members to identify what they see as problems and to bring up any areas of concern. The clinician can then outline his or her expectations from the assessment and map out the process ahead.",
"   </p>",
"   <p>",
"    It is most useful to start by asking each family member to identify what they see as the problems in the family. Every person should be given the opportunity to express his or her concerns without being interrupted by others. The challenge for the clinician is to not get sidetracked by beginning therapy to deal with problems before everybody has had an opportunity to present their perspectives. The clinician also has to make sure the problems are not described in such detail as to not leave time for exploration of problems and concerns of other family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Family functioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the concerns of each family member have been delineated, the clinician should evaluate the family's overall functioning. The goal is to understand how the family's specific ways of functioning in different spheres of family life contribute to the patient's depression. The clinician should identify potentially dysfunctional transactional patterns, which are repetitive interactional processes that prevent effective resolution of ongoing interpersonal problems.",
"   </p>",
"   <p>",
"    There is no \"typical\" pattern of family dysfunction. Each family attempts to cope with the reality of its depressed member in ways that are unique to the individuals and circumstances that make up that family constellation.",
"   </p>",
"   <p>",
"    Several models of family functioning have been described, each focusing on different aspects of family life. At the same time, there is considerable overlap between these approaches.",
"   </p>",
"   <p>",
"    One model that provides structure and breadth to the family assessment is the McMaster Model of Family Functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/25\">",
"     25",
"    </a>",
"    ]. In this model, clinicians systematically assess the following dimensions of family functioning:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Problem solving - the family's ability to resolve problems to a level that maintains effective family functioning",
"     </li>",
"     <li>",
"      Communication - the exchange of information within the family.",
"     </li>",
"     <li>",
"      Roles - the repetitive patterns of behavior by which family members fulfill family functions (eg, household chores, child care responsibilities, finances).",
"     </li>",
"     <li>",
"      Affective responsiveness - whether family members are able to respond to the full spectrum of feelings experienced in the emotional life of each member and whether the emotion experienced is consistent or appropriate with the stimulus or situation.",
"     </li>",
"     <li>",
"      Affective involvement - the extent to which the family shows interest in and values the activities of individual family members.",
"     </li>",
"     <li>",
"      Behavior control - the ways in which a family establishes rules about acceptable behavior relating to physically dangerous situations, psychobiological needs and drives, and social behavior between family members and people outside the family.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest using the General Functioning Scale of the Family Assessment Device, a self-report measure, to assess these areas of family functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef54714 \" href=\"UTD.htm?17/22/17771\">",
"     table 1",
"    </a>",
"    ). Families can fill it out prior to the initial family meeting to establish a baseline, and before each treatment session as an outcome measure to track their progress. The results can be shared with the family to augment the clinician's own evaluation of how well the family is doing.",
"   </p>",
"   <p>",
"    Other models of family functioning include the:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beavers Systems Model, which identifies family competence and family style as major constructs of how the family is organized and functions [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Circumflex Model of Marital and Family Systems focuses on family cohesion, flexibility, and communications [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Family focused therapy, which prioritizes problem-solving, family organization, and emotional climate [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Tools for family assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of instruments allow clinicians to evaluate and quantify family functioning systematically in order to track change over time, compare families, and conduct research.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Self-report (internal) instruments include the: Family Assessment Device [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef54714 \" href=\"UTD.htm?17/22/17771\">",
"       table 1",
"      </a>",
"      ), Dyadic Adjustment Scale [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/31\">",
"       31",
"      </a>",
"      ], Self-report Family Inventory [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/32\">",
"       32",
"      </a>",
"      ], Family Environment Scale [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/33\">",
"       33",
"      </a>",
"      ], and Family Adaptability and Cohesion Evaluation Scales III [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Family functioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interviewer-rated (external) instruments include the: McMaster Clinical Rating Scale [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/34\">",
"       34",
"      </a>",
"      ], Global Assessment of Relational Functioning [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/35\">",
"       35",
"      </a>",
"      ], Beavers Interactional Styles Scale [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/31\">",
"       31",
"      </a>",
"      ], and Camberwell Family Interview [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no absolute advantage to either interviewer-rated or self-report perspectives on family functioning because each may be more useful to answer different kinds of questions. Self-report instruments provide information about each family member's view of their family functioning. This can be used to help members see and understand differences in each other's point of view. Interviewer-rated assessments are more comprehensive because the rater can include observed family processes. In addition, interviewer-rated assessments provide information about how the family is seen by others, which the clinician can use when giving feedback to the family and helping them decide which problems to address. Thus, each type of assessment complements the other. Interviewer-rated assessments may yield more valid information, but require time from someone on the treatment team.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General treatment principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family therapy is defined as any psychotherapeutic endeavor that explicitly focuses on altering interactions between family members and seeks to improve the functioning of the family as a unit, or its subsystems, and the functioning of the individual members of the family [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The different types of family therapy include systems, psychoeducation, emotion focused, and cognitive-behavioral therapy. They all aim to modify negative interactional patterns and promote supportive aspects of dyadic relationships, in order to change the interpersonal context linked to depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/6\">",
"     6",
"    </a>",
"    ]. These specific therapies are described below, with greater attention given to a specific form of systems therapy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Systems therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Psychoeducation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Emotion focused therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Cognitive-behavioral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The different types of family therapy have all been shown to be effective in the treatment of families with a depressed member [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/6,38-41\">",
"     6,38-41",
"    </a>",
"    ]. There is no empirical evidence indicating one family therapy is more effective than another. This leads to a dilemma for clinicians trying to determine which family approach to learn and use in particular clinical situations. It makes most sense for a clinician to become competent in one major school of family therapy rather than try to mix ingredients from different models. The selected model of family therapy should be broadly based and well defined so as to allow it to be applied to a wide range of family problems, including families with a depressed patient [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common problems that occur in families of depressed patients and can be treated with family therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor communication",
"     </li>",
"     <li>",
"      Lack of support between family members",
"     </li>",
"     <li>",
"      Not fulfilling parental roles",
"     </li>",
"     <li>",
"      Poor understanding about the nature of depression, the patient's limited capabilities, available treatments, and likely course of illness",
"     </li>",
"     <li>",
"      Blame, criticism, and hostility in response to the depressed patient's social withdrawal, negativity, hopelessness, helplessness, regression, and dependence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A common challenge is to find a balance between encouraging the patient to take on new responsibilities without discounting the patient's incapacity due to the depression. The clinician, patient, and family members should set goals that are realistic in terms of what functions the depressed patient can manage and what family members can do to support the patient. A better understanding of depression can help the patient and family members determine the patient's realistic capabilities.",
"   </p>",
"   <p>",
"    Family therapy meetings generally last from 30 to 60 minutes depending on the stage of treatment. Meetings should initially be held weekly and then with decreasing frequency as the patient and family improve. The number of family meetings range from 1 to more than 20, depending on the type and severity of presenting problems and the specific type of family therapy used.",
"   </p>",
"   <p>",
"    The usual format is for a single clinician to treat a single family. However, family therapy can be delivered within a group format, in which one or two clinicians treat up to five depressed patients and their respective families. Multifamily group therapy is effective for providing psychoeducation and decreasing feelings of isolation and hopelessness by sharing information, support, and coping strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depression is often a chronic and recurring disorder. Thus, patients and other family members need to learn skills to help manage the depressive illness over the patient's lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family therapy can be terminated when the family and clinician agree that the family is dealing with their problems effectively. Family therapy should also be terminated if the patient's and the family's situation is deteriorating or if the family is not committed to the treatment process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common processes and goals in the different effective family therapies are probably more important for treatment outcome than the specific maneuvers of a given school of therapy or of a particular clinician. All of these therapies attempt to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increase knowledge about depression",
"     </li>",
"     <li>",
"      Decrease guilt about the illness",
"     </li>",
"     <li>",
"      Redefine problems between family members",
"     </li>",
"     <li>",
"      Increase use of adaptive coping mechanisms",
"     </li>",
"     <li>",
"      Encourage appropriate emotional expression and responses",
"     </li>",
"     <li>",
"      Improve communication skills",
"     </li>",
"     <li>",
"      Improve problem-solving skills and parenting skills",
"     </li>",
"     <li>",
"      Clarify boundaries between family members",
"     </li>",
"     <li>",
"      Set appropriate boundaries between the familial subsystems and family of origin",
"     </li>",
"     <li>",
"      Promote insight into current transactions and historical factors",
"     </li>",
"     <li>",
"      Decrease conflict",
"     </li>",
"     <li>",
"      Resolve family-of-origin issues",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary challenge for the clinician is to determine the particular needs and goals of any given family and the obstacles that prevent them from achieving those goals. This is most likely to occur by meeting with all available family members to elicit different perspectives of the problem and determine how the family has tried to deal with the problem. Examples of specific goals that the patient and family may desire include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Direct and clear communication of concerns",
"     </li>",
"     <li>",
"      Gradually increasing and fuller involvement in necessary family roles",
"     </li>",
"     <li>",
"      Gradually increasing participation in activities outside of the home",
"     </li>",
"     <li>",
"      Greater levels of physical activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Noncompliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncompliance is common in family therapy, similar to other psychosocial and somatic treatments. Various factors need to be evaluated to deal effectively with lack of follow through in completing homework assignments:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Were the tasks clearly outlined?",
"     </li>",
"     <li>",
"      Were the tasks appropriate to the person's capabilities and schedule?",
"     </li>",
"     <li>",
"      Was there agreement by all family members about their assignments?",
"     </li>",
"     <li>",
"      Did the tasks address identified family problems?",
"     </li>",
"     <li>",
"      Was the family motivated and committed to the treatment process?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The tasks should be renegotiated if noncompliance is related mainly to task assignment and allocation issues. It is this process of negotiating tasks, and evaluating their follow through and the reasons for success and failure, that is the core of the therapeutic work.",
"   </p>",
"   <p>",
"    The family should be given the choice of reengaging in or terminating treatment if noncompliance is related to lack of motivation to change, provided the depressed patient is not at acute risk. Families that terminate treatment should be allowed to return when they are ready to participate more actively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Booster sessions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families should be given the option of \"booster,\" follow-up sessions once they have completed a successful course of treatment. An initial booster session can be scheduled one to three months later and if they report they are doing well, another one six-months after that. The focus should be on reinforcing gains and helping to solve new problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Systems therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systems is a type of family therapy that views the family as a single system or entity. Systemic models view dysfunctional family relationships as causing or reinforcing symptoms. Systems therapists attempt to restructure maladaptive patterns of family interactions.",
"   </p>",
"   <p>",
"    We suggest the Problem Centered Systems Therapy of the Family. This therapy is based upon the McMaster Model of Family Functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/25\">",
"     25",
"    </a>",
"    ]. Treatment emphasizes changing behavior to resolve problems in family functioning identified during the family assessment. The General Functioning Scale from the Family Assessment Device can be used to assess family functioning (",
"    <a class=\"graphic graphic_table graphicRef54714 \" href=\"UTD.htm?17/22/17771\">",
"     table 1",
"    </a>",
"    ) and (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Family functioning'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The clinician focuses upon stages of treatment rather than on specific intervention skills:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assessment of the patient and family functioning",
"     </li>",
"     <li>",
"      Contracting and setting goals for treatment",
"     </li>",
"     <li>",
"      Treatment",
"     </li>",
"     <li>",
"      Termination of treatment and closure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient, family, and clinician determine the goals of treatment by discussing which problems in family functioning should be addressed. These problems are identified in the family assessment, which includes use of the General Functioning Scale from the Family Assessment Device (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Family functioning'",
"    </a>",
"    above)&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef54714 \" href=\"UTD.htm?17/22/17771\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The basic principles of treatment are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Including as many family members as possible",
"     </li>",
"     <li>",
"      Treating current problems and developing the family's problem-solving skills",
"     </li>",
"     <li>",
"      Active collaboration between the clinician and family",
"     </li>",
"     <li>",
"      Modeling of open and direct communication by the clinician",
"     </li>",
"     <li>",
"      Focusing on the family's strengths",
"     </li>",
"     <li>",
"      Family's responsibility for changing their behavior",
"     </li>",
"     <li>",
"      Emphasizing behavioral change and concrete tasks that are easily evaluated",
"     </li>",
"     <li>",
"      Emphasizing positive feelings for emotionally-oriented tasks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Improving the family's problem-solving skills starts by eliciting how the family identifies and resolves problems that occur, the difficulties and dissatisfactions that arise during this process, and what changes the family wants to make so that problems are resolved in a reasonable manner that is satisfactory to all. As an example, the family may need to reduce its expenses because the depressed patient is no longer providing an income. Treatment involves examining how the family identifies, discusses, and negotiates this problem; who decides what expenses will be reduced or how new income will be generated; who is responsible for carrying out the necessary steps; and who is responsible for ensuring the necessary steps have been taken. The family decides which aspects of this process to change in order to better its skills at addressing issues as they arise, and practices its skills with other problems.",
"   </p>",
"   <p>",
"    Improvements in family functioning should focus upon specific behaviors that are easily verified. As an example, if the family identifies a dirty kitchen as a problem and decides who is responsible for keeping it clean, the next step is to determine what concrete changes need to be made. Do the dishes need to be washed? How frequently? Does the floor need to be swept or washed? How frequently? Does the trash need to be removed? How frequently?",
"   </p>",
"   <p>",
"    Emotionally-oriented tasks may involve changing how family members respond to each others' feelings. As an example, family members may need to consciously work to respond with empathy to the patient's depressed feelings, rather than impatience or frustration.",
"   </p>",
"   <p>",
"    Problem Centered Systems Therapy of the Family is a short-term, time-limited treatment. A typical course of treatment is 6 to 12 weekly sessions, each lasting one hour. A practical guide for",
"    <span class=\"nowrap\">",
"     couples/family",
"    </span>",
"    therapy for depression is shown (",
"    <a class=\"graphic graphic_table graphicRef78200 \" href=\"UTD.htm?31/34/32300\">",
"     table 2",
"    </a>",
"    ). In addition, a manual is available for problem centered systems therapy, which permits easier learning and consistent application [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Psychoeducation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychoeducational family therapy focuses upon altering negative attributions about the patient's depression, teaching coping skills, providing support, and teaching the family about the signs and symptoms of depression, available treatments, and course of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Emotion focused therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emotion focused therapy is the integration of a family systems approach, an affective and experiential approach, and attachment theory. It delineates conflicts between partners, identifies negative interactional cycles, accesses unacknowledged feelings, reframes problems in terms of underlying feelings, promotes identification with disowned needs and aspects of self, promotes acceptance by each partner of the other partner's experience, facilitates the expression of needs and wants, and establishes the emergence of new solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral marital therapy is a time-limited and structured treatment which emphasizes changes in attitude, behavior, and affect [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/46\">",
"     46",
"    </a>",
"    ]. Treatment initially focuses on outlining problems, modifying negative expectations about individual and relationship change, and changing explanatory style. Treatment emphasizes restoring pleasant interactions and shared activities for the couple, and improving communication and problem-solving skills [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CONTINUING CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Through a course of family therapy it is important to continue to monitor the patient's depression and also the possibility of the emergence or presence of mood disorders in other family members.",
"   </p>",
"   <p>",
"    There is some controversy about who should provide family interventions and how to integrate family therapy with individual psychotherapy and pharmacotherapy for the depressed patient. Many psychiatrists choose to meet with family members solely for gathering historical information, and delegate family interventions to social workers or family therapists.",
"   </p>",
"   <p>",
"    Integration of care refers to the coordination of different therapies such as pharmacotherapy and family therapy provided by different clinicians. This is the model that is most frequently used. It has the advantage of being less time-consuming for the clinician and allows for greater specialization of skills. Its disadvantages are that it requires ongoing communication between the different clinicians and requires that they have a synergistic or complementary approach that suits the patient.",
"   </p>",
"   <p>",
"    Integrated treatment refers to the provision of the necessary components of treatment, biological, psychological,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    social by one clinician. The benefits include better understanding of the illness and its context, more consistent and better coordinated care, and lower cost. Its shortcomings are the difficulty in acquiring the different skills, it is more time-consuming for the clinician, it has a greater potential for breaching confidentiality, and it is more difficult for the clinician to maintain neutrality. In order for the psychiatrist to deliver integrated treatment, he or she has to be comfortable with multiple roles, accepted by the patient and the family, and able to pay special attention to boundaries and confidentiality.",
"   </p>",
"   <p>",
"    There are currently no studies to compare the effectiveness of the integration of care model with the integrated treatment model. Choosing a model is thus based upon the available resources and patient and family preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EVIDENCE OF EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research studies indicate that family therapy effectively treats depression in adults.",
"   </p>",
"   <p>",
"    Psychotherapy trials, like pharmacotherapy trials, are methodologically variable. Some psychotherapy trials are rigorous and specify a priori hypotheses and analytic tests, use active psychotherapy comparators that control for the nonspecific aspects of psychotherapy, use standardized diagnostic criteria and outcome measures, carefully blind outcome ratings, develop manuals for the psychotherapies that are studied and measure adherence, and stratify patients on predetermined risk variables. Less meticulous studies use open-label designs, less rigorous comparators (eg, treatment as usual or waiting lists), or fail to adequately blind outcome ratings. Although it is commonly believed that blinding of patients in psychotherapy is less successful compared with pharmacotherapy trials, this has never been studied.",
"   </p>",
"   <p>",
"    Family therapy and couples therapy appear to be efficacious in treating depression in adults, based upon a meta-analysis of randomized trials, a systematic review of randomized trials, and other randomized trials not included in the meta-analysis or review.",
"   </p>",
"   <p>",
"    A meta-analysis of eight randomized trials found couples therapy was efficacious for treating middle-aged adults with mild to moderate depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/6\">",
"     6",
"    </a>",
"    ]. There were a total of 567 couples. Most studies did not permit use of antidepressant medication. Specifically, the meta-analysis showed that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scores on depression rating scales were significantly lower in patients who received couples therapy compared to those who received no treatment (waiting list control), and the clinical effect was large (standardized mean difference -1.3, 95% CI -1.9 to -0.7). In addition, patients who received couples therapy were half as likely to meet diagnostic criteria for a depressive syndrome after treatment (relative risk 0.5, 95% CI 0.3 to 0.8).",
"     </li>",
"     <li>",
"      Couples therapy was equally efficacious with individual psychotherapy (either cognitive-behavioral or interpersonal therapy) in reducing scores on depression rating scales and the proportion of patients meeting diagnostic criteria for a depressive syndrome.",
"     </li>",
"     <li>",
"      Relationship distress was significantly reduced in the couples therapy group.",
"     </li>",
"     <li>",
"      Confidence in the results was limited due to small sample sizes, short follow-up periods, unclear sample representativeness, and heterogeneity among studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Too few data were available for adequately testing whether successful treatment of depression is mediated by improvement in the quality of couple relationships.",
"   </p>",
"   <p>",
"    A systematic review of six randomized trials found generally consistent evidence that family therapy was more efficacious than no treatment (waiting list) for treating depression and for improving family functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials not included in the meta-analysis or systematic review also support using family therapy to treat depression. These trials have found that family therapy provides additional benefits beyond those provided by pharmacotherapy alone and that the benefits of family therapy are comparable to individual therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial assigned 121 patients with moderate to severe major depression to pharmacotherapy alone, pharmacotherapy plus family therapy (Problem Centered Systems Therapy of the Family), pharmacotherapy plus individual cognitive therapy, or pharmacotherapy plus family therapy plus individual cognitive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/38\">",
"       38",
"      </a>",
"      ]. Improvement in depression occurred in significantly more patients who received a family therapy component compared to patients who did not (45 versus 10 percent). In addition, patients treated with family therapy had significantly less suicidal ideation.",
"     </li>",
"     <li>",
"      A trial assigned 60 outpatients with major depression to couples therapy, individual cognitive-behavioral therapy, or individual interpersonal psychotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/40\">",
"       40",
"      </a>",
"      ]. Depressive symptoms improved significantly and to a similar degree in all three groups.",
"     </li>",
"     <li>",
"      A trial assigned 83 depressed patients and their partners to treatment as usual, treatment as usual combined with single family therapy, or treatment as usual combined with multifamily group therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/49\">",
"       49",
"      </a>",
"      ]. Significantly more patients who received either multifamily group or single family therapy improved compared with patients who received treatment as usual (49 versus 24 versus 9 percent).",
"     </li>",
"     <li>",
"      A trial compared family psychoeducation plus treatment as usual with treatment as usual alone in 54 patients partially or fully remitted from a major depressive episode [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/50\">",
"       50",
"      </a>",
"      ]. Only family members participated in the four family psychoeducation group sessions, which consisted of didactic lectures and group problem-solving. Relapse during the nine-month follow-up occurred in significantly fewer patients in the psychoeducation group, compared to the control group (8 versus 50 percent).",
"     </li>",
"     <li>",
"      A trial assigned 20 outpatients with a recurrent major depressive episode despite maintenance pharmacotherapy to treatment with the same antidepressant at an increased dose or to treatment with the same antidepressant at the same dose plus the addition of family therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/39\">",
"       39",
"      </a>",
"      ]. Seven patients in both groups responded to treatment and were evaluated one year after treatment. Recurrence of depression occurred in significantly fewer patients who received family therapy compared to those who did not (14 versus 86 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of family therapy for treatment-resistant depression has not been well studied. One open-label study included family members in a depression management program that taught patients to cope more effectively with their depressive illness in spite of its persistence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/51\">",
"     51",
"    </a>",
"    ]. The program consisted of nine sessions (five individual and four family), each lasting 50 minutes, conducted over 16 weeks, that focused upon improving quality of life and psychosocial and family functioning, rather than decreasing depressive symptoms. Nineteen patients enrolled in the study. Psychosocial and family functioning improved significantly in the 14 patients who completed the program. Depressive symptoms also improved significantly, although this was not a primary outcome.",
"   </p>",
"   <p>",
"    Meta-analyses appear to overestimate the clinical effect for nearly all types of psychotherapy in treating depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. These inflated clinical effects seem to be the result of publication bias and study quality. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Durability of improvements",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no long-term studies of family therapy that have evaluated whether treatment gains persist for years. Outcome studies of other psychotherapies suggest that patients who have learned to identify and manage their problems are in a better position to maintain treatment gains and avoid a recurrent depressive episode, or can deal more effectively with a recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18025/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depressed patients can benefit from a meeting with their clinician and significant others in order to evaluate the patient's social situation, the presence of life changes, nature of the family's relationships, the family's understanding of depression, their awareness of what treatment involves, and the family's expectations of the patient and the clinician. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Family therapy is indicated for families who have pronounced difficulty in dealing with depression in their loved one, particularly when",
"      <span class=\"nowrap\">",
"       marital/family",
"      </span>",
"      problems predate the onset of the depression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Family therapy is usually combined with individual therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pharmacotherapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no contraindications to a family evaluation or therapy, but family interventions can create difficulties if the clinician implies that family members caused the patient's depression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The essential tasks in meeting with family members for the first time are to establish a connection, evaluate their functioning, and determine whether there are any problems that require family therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Family assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The General Functioning Scale of the Family Assessment Device can be used to assess the following areas of functioning: problem solving, communication, roles, affective responsiveness, affective involvement, and behavior control. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Family functioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many types of family therapy have been found to be effective for helping families with a depressed member. Common features of these therapies include: changing maladaptive patterns of family interactions, promoting supportive aspects of relationships, rebuilding pleasant interactions, educating families about depression and ways of coping with it, improving communication and problem-solving skills, and reducing blame and criticism within the family. The Problem Centered Systems Therapy of the Family is described in more detail. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment goals'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Systems therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A common challenge for the clinician and family is to encourage the patient to take on new responsibilities and at the same time, accept the patient's incapacity due to depression. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'General treatment principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Family therapy is terminated when the clinician, patient, and other family members agree that the family is managing their problems effectively. Family therapy should also be terminated if the patient or the family's functioning deteriorates, or if the family is not seriously involved in treatment. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'General treatment principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/1\">",
"      Keitner GI, Miller IW. Family functioning and major depression: an overview. Am J Psychiatry 1990; 147:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/2\">",
"      Keitner GI, Miller IW, Epstein NB, et al. Family functioning and the course of major depression. Compr Psychiatry 1987; 28:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/3\">",
"      Keitner GI, Ryan CE, Miller IW, et al. Role of the family in recovery and major depression. Am J Psychiatry 1995; 152:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/4\">",
"      Hooley JM, Teasdale JD. Predictors of relapse in unipolar depressives: expressed emotion, marital distress, and perceived criticism. J Abnorm Psychol 1989; 98:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/5\">",
"      Leskel&auml; U, Ryts&auml;l&auml; H, Komulainen E, et al. The influence of adversity and perceived social support on the outcome of major depressive disorder in subjects with different levels of depressive symptoms. Psychol Med 2006; 36:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/6\">",
"      Barbato A, D'Avanzo B. Marital therapy for depression. Cochrane Database Syst Rev 2006; :CD004188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/7\">",
"      Mead DE. Marital distress, co-occurring depression, and marital therapy: a review. J Marital Fam Ther 2002; 28:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/8\">",
"      Denton, WH, Golden, RN, Walsh, SR. Depression, marital discord, and couple therapy. Curr Opin Psychiatry 2003; 16:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/9\">",
"      Miller IW, Keitner GI, Whisman MA, et al. Depressed patients with dysfunctional families: description and course of illness. J Abnorm Psychol 1992; 101:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/10\">",
"      Rounsaville BJ, Prusoff BA, Weissman MM. The course of marital disputes in depressed women: a 48-month follow-up study. Compr Psychiatry 1980; 21:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/11\">",
"      Coyne JC, Thompson R, Palmer SC. Marital quality, coping with conflict, marital complaints, and affection in couples with a depressed wife. J Fam Psychol 2002; 16:26.",
"     </a>",
"    </li>",
"    <li>",
"     Coyne, JC, Benazon, RC. Not Agent Blue: Effects of marital functioning on depression and implications for treatment. In: Martial and Family Processes in Depression: A Scientific Foundation for Clinical Practice, Beach, S (Eds), American Psychiatric Association, Washington, DC 2001. p.25.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/13\">",
"      Coyne JC. Depression and the response of others. J Abnorm Psychol 1976; 85:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/14\">",
"      Swann WB Jr, Wenzlaff RM, Krull DS, Pelham BW. Allure of negative feedback: self-verification strivings among depressed persons. J Abnorm Psychol 1992; 101:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/15\">",
"      Beach, SRH, O'Leary, KD. Dysphoria and marital discord: Are dysphoria individuals at risk for marital maladjustment? J Marital and Family Therapy 1993; 19:4:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/16\">",
"      O'Leary, KD, Christian, JL, Mendell, NR. A closer look at the link between marital discord and depressive symptomatology. J Soc Clin Psychol 1994; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/17\">",
"      Weissman MM. Advances in psychiatric epidemiology: rates and risks for major depression. Am J Public Health 1987; 77:445.",
"     </a>",
"    </li>",
"    <li>",
"     Brown, GW, Harris, TO. Social Origins of Depression: A Study of Psychiatric Disorders in Women, Free Press, New York 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/19\">",
"      Goering PN, Lancee WJ, Freeman SJ. Marital support and recovery from depression. Br J Psychiatry 1992; 160:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/20\">",
"      Denton WH, Carmody TJ, Rush AJ, et al. Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression. Psychol Med 2010; 40:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/21\">",
"      Keitner GI, Ryan CE, Miller IW, Norman WH. Recovery and major depression: factors associated with twelve-month outcome. Am J Psychiatry 1992; 149:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/22\">",
"      Keitner GI, Ryan CE, Miller IW, Zlotnick C. Psychosocial factors and the long-term course of major depression. J Affect Disord 1997; 44:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/23\">",
"      Hooley JM, Orley J, Teasdale JD. Levels of expressed emotion and relapse in depressed patients. Br J Psychiatry 1986; 148:642.",
"     </a>",
"    </li>",
"    <li>",
"     Depression in Parents, Parenting, and Children: Opportunities to Improve Identification, Treatment and Prevention by Committee on Depression, Parenting Practices, and the Healthy Development of Children, National Research Council and Institute of Medicine, England, MJ, Sim, LJ (Eds), The National Academies Press, Washington, DC 2009.",
"    </li>",
"    <li>",
"     Ryan, CE, Epstein, N, Keitner, GI, et, al. Evaluating and Treating Families: The McMaster Approach, Routledge Taylor &amp; Francis Group, New York 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/26\">",
"      Epstein, NB, Baldwin, LM, Bishop, DS. The McMaster Family Assessment Device. J Marital Fam Ther 1983; 9(2):171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/27\">",
"      Miller, IW, Epstein, NB, Bishop, DS, Keitner, GI. The McMaster Family Assessment Device: reliability and validity. J Marital Fam Ther 1985; 11:345.",
"     </a>",
"    </li>",
"    <li>",
"     Beavers, WR, Hampson, RB. Measuring family competence: The beavers systems model. In: Normal Family Processes Growing Diversity and Complexity, 3rd, Walsh, F (Eds), The Guilford Press, New York 2003. p.549.",
"    </li>",
"    <li>",
"     Olson, DH, Russell, CS, Sprenkle, DH. Circumplex Model: Systemic Assessment and Treatment of Families, Haworth Press, New York 1989.",
"    </li>",
"    <li>",
"     Miklowitz, DJ, Clarkin, JF. Diagnosis of family relational disorders. In: Textbook of Family and Couples Therapy, Sholevar, GP, Schwoeri, LD (Eds), American Psychiatric Publishing, Inc., Washington, DC 2003. p.341.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/31\">",
"      Spanier, GB. Measuring dyadic adjustment: new scales for assessing the quality of marriage and similar dyads. J Marital Fam 1976; 38:15.",
"     </a>",
"    </li>",
"    <li>",
"     Beavers, R, Hampson, RB. Successful families: Assessment and Intervention, Norton, New York 1990.",
"    </li>",
"    <li>",
"     Moos, R, Moos, B. Family Environment Scale Manual, Consulting Psychologists Press, Palo Alto, California 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/34\">",
"      Miller IW, Kabacoff RI, Epstein NB, et al. The development of a clinical rating scale for the McMaster model of family functioning. Fam Process 1994; 33:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/35\">",
"      Rosen, KH, Mccollum, EE, Middletown, K, et al. Interrater reliability and validity of the global assessment of relational functioning (GARF) scale in a clinical setting: a preliminary study. Am J Fam Ther 1997; December 25:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/36\">",
"      Brown, GW, Rutter, M. The measurement of family activities and relationships: A methodological study. Human Relations 1966; 19:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/37\">",
"      Cottrell, D. Outcome studies of family therapy in child and adolescent depression. J Fam Therapy 2003; 25:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/38\">",
"      Miller IW, Keitner GI, Ryan CE, et al. Treatment matching in the posthospital care of depressed patients. Am J Psychiatry 2005; 162:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/39\">",
"      Fabbri S, Fava GA, Rafanelli C, Tomba E. Family intervention approach to loss of clinical effect during long-term antidepressant treatment: a pilot study. J Clin Psychiatry 2007; 68:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/40\">",
"      Bodenmann G, Plancherel B, Beach SR, et al. Effects of coping-oriented couples therapy on depression: a randomized clinical trial. J Consult Clin Psychol 2008; 76:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/41\">",
"      Hughes S, Cohen D. A systematic review of long-term studies of drug treated and non-drug treated depression. J Affect Disord 2009; 118:9.",
"     </a>",
"    </li>",
"    <li>",
"     McDermut, W, Alves, JW, Miller, IW. treatment of depression and the McMaster model of family functioning. In: Family Therapy and Mental Health: Innovations in Therapy and Practice, MacFarlane, MM (Eds), Haworth Clinical Practice Press, New York 2001. p.83.",
"    </li>",
"    <li>",
"     Keitner, GI, Drury, LM, Ryan, CE, et, al. Multifamily group treatment for major depressive disorder. In: Multifamily Groups in the Treatment of Severe Psychiatric Disorders, McFarlane, WR (Eds), The Guilford Press, New York 2002. p.244.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/44\">",
"      Diamond G, Siqueland L. Current status of family intervention science. Child Adolesc Psychiatr Clin N Am 2001; 10:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/45\">",
"      Dessaulles, A, Johnson, SM. Emotion-focused therapy for couples in the treatment of depression: A pilot study. Am J Fam Therapy 2003; 31:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/46\">",
"      Baucom DH, Sayers SL, Sher TG. Supplementing behavioral marital therapy with cognitive restructuring and emotional expressiveness training: an outcome investigation. J Consult Clin Psychol 1990; 58:636.",
"     </a>",
"    </li>",
"    <li>",
"     Beach, SRH, Sandeen, EE, O'Leary, KD. Depression in Marriage: A Model for Etiology and Treatment, Guilford Press, New York 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/48\">",
"      Henken, T, Huibers, MJ, Churchill, R, et al. Family therapy for depression. Cochtane Database Syst Rev 2007; :CD006728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/49\">",
"      Lemmens GM, Eisler I, Buysse A, et al. The effects on mood of adjunctive single-family and multi-family group therapy in the treatment of hospitalized patients with major depression. A 15-month follow-up study. Psychother Psychosom 2009; 78:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/50\">",
"      Shimazu K, Shimodera S, Mino Y, et al. Family psychoeducation for major depression: randomised controlled trial. Br J Psychiatry 2011; 198:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/51\">",
"      Ryan, CE, Keitner, GI, Bishop, S. An adjunctive Management of Depression Program for difficult-to-treat depressed patients and their families. Depress Anxiety 2009; 27:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/52\">",
"      Cuijpers P, van Straten A, Bohlmeijer E, et al. The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychol Med 2010; 40:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/53\">",
"      Cuijpers P, Smit F, Bohlmeijer E, et al. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias. Br J Psychiatry 2010; 196:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/54\">",
"      Imel ZE, Malterer MB, McKay KM, Wampold BE. A meta-analysis of psychotherapy and medication in unipolar depression and dysthymia. J Affect Disord 2008; 110:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18025/abstract/55\">",
"      Bockting CL, Spinhoven P, Wouters LF, et al. Long-term effects of preventive cognitive therapy in recurrent depression: a 5.5-year follow-up study. J Clin Psychiatry 2009; 70:1621.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1710 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18025=[""].join("\n");
var outline_f17_38_18025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THEORETICAL FOUNDATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patient assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Family assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Family functioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Tools for family assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General treatment principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment goals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Noncompliance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Booster sessions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Systems therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Psychoeducation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Emotion focused therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cognitive-behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CONTINUING CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EVIDENCE OF EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Durability of improvements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1710\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1710|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/22/17771\" title=\"table 1\">",
"      General functioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/34/32300\" title=\"table 2\">",
"      Guidelines for family and couple therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_38_18026="Treatment of hepatitis C virus infection in the HIV-infected patient";
var content_f17_38_18026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hepatitis C virus infection in the HIV-infected patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/38/18026/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/38/18026/contributors\">",
"     Barbara H McGovern, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/38/18026/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/38/18026/contributors\">",
"     David Thomas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/38/18026/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/38/18026/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/38/18026/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of hepatitis C virus (HCV) infection in HIV-infected patients are significant and include accelerated liver disease progression, high rates of end-stage liver disease, and shortened lifespan after hepatic decompensation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/1\">",
"     1",
"    </a>",
"    ]. In the era of potent antiretroviral therapy, end-stage liver disease is the second leading cause of death among HIV-infected patients who are coinfected with HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are six different HCV genotypes worldwide; most information on the treatment of the HIV-infected patient is related to genotypes 1, 2 and 3. Dual therapy with pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    is mainly applied to the treatment of genotypes 2 and 3. The same approach has been applied to genotype 1 with much lower success rates; however, preliminary data suggest that the addition of an HCV protease inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    ) to dual therapy significantly increases the rates of viral clearance in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients with genotype 1 infection, as discussed below.",
"   </p>",
"   <p>",
"    This topic will address the management of the",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patient. The epidemiology, natural history, diagnosis, and evaluation of this patient population are discussed elsewhere. Detailed clinical data from pivotal randomized controlled trials are also available for review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38536?source=see_link\">",
"     \"Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of therapy is to achieve a sustained virologic response (SVR), which is defined as an undetectable hepatitis C virus (HCV) RNA 24 weeks after the end of treatment (ie, SVR-24). The SVR-24 benchmark represents treatment-induced viral eradication and is used as the primary endpoint in most treatment trials of HCV therapy in patients with and without HIV infection. Studies of earlier time points among patients with HCV alone, such as SVR-12, demonstrate that few patients have rebound viremia between weeks 12 and 24; some have suggested that SVR-12 should be used as the primary endpoint in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Through viral eradication, the following secondary goals may be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/5-15\">",
"     5-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improvement of fibrosis and necroinflammation",
"     </li>",
"     <li>",
"      Reduction of morbidity and mortality secondary to liver disease",
"     </li>",
"     <li>",
"      Reduced incidence of hepatocellular carcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One observational study of 711 HIV-infected patients who had been treated for HCV infection demonstrated that an SVR was associated with a reduced risk of liver-related death (3.7 percent versus 0.5 percent) and liver decompensation (9.1 percent versus 0.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/13\">",
"     13",
"    </a>",
"    ]. Another potential benefit of sustained HCV clearance may be a reduced risk of drug-induced liver injury associated with antiretroviral therapy (ART) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22811476\">",
"    <span class=\"h1\">",
"     PREDICTORS OF TREATMENT RESPONSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H820050\">",
"    <span class=\"h2\">",
"     Pretreatment predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predictors of treatment response in HIV-infected patients receiving pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    are similar to those reported in patients with hepatitis C virus (HCV) alone and include HCV genotype, lower baseline levels of viremia, race, insulin resistance and host genetic background (ie, IL-28B gene polymorphism) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/1,16-19\">",
"     1,16-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40870?source=see_link\">",
"     \"Predictors of response to hepatitis C treatment in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For example, patients with genotype 2 or 3 infections have higher rates of viral eradication than those with other genotypes, particularly genotype 1. In addition, patients with low levels of viremia (eg, &lt;400,000",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    at baseline have higher rates of sustained virologic response (SVR) than those with high viral loads [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/7\">",
"     7",
"    </a>",
"    ]. This observation also applies to HIV-infected patients with genotype 1 infection where SVR rates with dual therapy vary from 61 percent in patients with low-level viremia to 18 percent with high-level viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of the HCV protease inhibitors to dual therapy has significantly improved overall SVR rates among HIV-seronegative patients with HCV genotype 1 infection. The negative impact of high-level viremia on overall SVR rates was still evident in the randomized controlled trial evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    -containing triple therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/20\">",
"     20",
"    </a>",
"    ], while baseline viremia had no impact on SVR rates in two randomized controlled trials evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    -containing triple therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Although the addition of HCV protease inhibitors to dual therapy is also associated with significantly higher SVR rates compared with dual therapy among",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients, the effect of baseline viremia as a predictor of response is not yet clear due to the small numbers of patients studied to date [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the above factors, treatment response rates are also higher in patients with early fibrosis compared with advanced fibrosis, regardless of genotype. Staging of liver disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=see_link&amp;anchor=H21#H21\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\", section on 'Staging of liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H820064\">",
"    <span class=\"h2\">",
"     On-treatment predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important on-treatment predictor is the rapidity of viral suppression, as assessed after four weeks of therapy. Patients who achieve a rapid virologic response have generally high rates of sustained viral suppression, despite the presence of poor pre-treatment prognosticators [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40870?source=see_link\">",
"     \"Predictors of response to hepatitis C treatment in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819027\">",
"    <span class=\"h2\">",
"     Overall HCV treatment responses in HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no treatment trials directly comparing treatment responses to pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    in patients with and without HIV infection, historical data seem to suggest that rates of SVR appear to be lower in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients than in patients with HCV alone. This discordance is particularly notable in patients with genotype 1 infection taking dual therapy with pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin;",
"    </span>",
"    in patients with",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfection, overall SVR rates range from approximately 17 to 29 percent compared with 42 to 46 percent in patients with HCV alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/6,7,26-29\">",
"     6,7,26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, however, preliminary data from phase 2b trials among",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients demonstrate that the addition of HCV protease inhibitors to dual therapy significantly increases SVR rates (eg, 61 to 74 percent) compared with dual therapy plus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. These early data suggest that",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients may be able to achieve comparable response rates to patients with HCV alone with the availability of specifically-targeted HCV agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR HCV TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H821658\">",
"    <span class=\"h2\">",
"     Clinical decision making",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat an HIV-infected patient for hepatitis C virus (HCV) infection will depend on the stage of liver disease (eg, portal fibrosis or higher stage), patient readiness, or presence of comorbidities, which may prohibit treatment with interferon.",
"   </p>",
"   <p>",
"    The timing of treatment is more urgent in patients with bridging fibrosis or cirrhosis compared with patients with mild to moderate disease. However, treatment for mild disease (ie, portal fibrosis) can also be justified since patients with HIV have faster fibrosis progression rates than patients with HCV alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients with minimal liver disease do not require treatment, but should be monitored over time to assess for progression of liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=see_link&amp;anchor=H21#H21\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\", section on 'Staging of liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Contraindications to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following patients are NOT candidates for",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy: history of decompensated cirrhosis, pregnancy or inability to prevent pregnancy, uncontrolled depression, and unstable cardiac and pulmonary conditions. In addition, coinfected patients with uncontrolled HIV disease and advanced immunosuppression are not optimal candidates for HCV therapy. Patients with decompensated liver disease (eg, ascites) should be referred to a transplant center with expertise in",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfection. A detailed discussion of these issues is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5443630\">",
"    <span class=\"h2\">",
"     Order of HIV and HCV treatment initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment-naive",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients should be initiated on antiretroviral therapy (ART) for their HIV disease, regardless of their CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally recommend ART for approximately four to six weeks before starting pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy to determine adverse events on ART alone. Potential drug-drug interactions with HCV antiviral medications must also be considered when selecting antiretroviral medications. (See",
"    <a class=\"local\" href=\"#H819606\">",
"     'Potential drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of drug-drug interactions, pill burden, and regimen complexity, some clinicians may prefer to delay the initiation of ART in the treatment-naive patient with a CD4 cell count &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    until completion of HCV therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of HIV restores immunologic function, which may theoretically translate into better HCV outcomes. In the APRICOT treatment trial, no differences in SVR rates were noted based on the pretreatment CD4 cell count or between those taking or not taking ART [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/32\">",
"     32",
"    </a>",
"    ]. However, an analysis of whether HIV suppression per se was associated with higher treatment response rates was not performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40870?source=see_link&amp;anchor=H20766312#H20766312\">",
"     \"Predictors of response to hepatitis C treatment in HIV-infected patients\", section on 'Immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     AVAILABLE THERAPEUTIC REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    dual therapy is the treatment of choice for all non-genotype 1 infections, regardless of HIV status.",
"   </p>",
"   <p>",
"    In HIV-uninfected patients with hepatitis C virus (HCV) genotype 1 infection, the standard of care is triple therapy with pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    plus an HCV-specific protease inhibitor (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    ). Preliminary data regarding the use of triple therapy in HIV-infected patients with genotype 1 infection suggest that the addition of an HCV protease inhibitor is efficacious with a similar safety profile. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link&amp;anchor=H148834010#H148834010\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Treatment regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following brief discussion highlights major advances in the treatment of HCV infection, including data regarding",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients. An in-depth discussion of the various major clinical trials is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38536?source=see_link\">",
"     \"Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Standard interferon and ribavirin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no longer used, clinical data on standard interferon and the later addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    are instructive. When interferon was used as monotherapy for HCV infection, relapse rates after the discontinuation of treatment were high, even among those who did achieve viral suppression during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/26,33\">",
"     26,33",
"    </a>",
"    ]. Clinical trials definitively demonstrated that the addition of ribavirin to interferon significantly decreased relapse rates after treatment discontinuation compared with interferon alone. The importance of ribavirin in preventing relapse continues to be observed in trials of directly-acting antiviral medications in HIV-uninfected patients with genotype 1 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pegylated interferon and ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next major advance in the treatment of hepatitis C was the development of pegylated interferon. \"Pegylation\" refers to the addition of a polyethylene molecule to the native protein, which decreases excretion of interferon and thereby increases its half-life.",
"   </p>",
"   <p>",
"    A meta-analysis of seven clinical treatment trials in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients determined that pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy led to significantly improved sustained virologic response rates compared with standard",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    therapy for patients with genotype",
"    <span class=\"nowrap\">",
"     1/4",
"    </span>",
"    infection (26 versus 8 percent) and genotype",
"    <span class=\"nowrap\">",
"     2/3",
"    </span>",
"    infection (57 versus 33 percent). Information regarding details of individual trials can be found elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/7,35-37\">",
"     7,35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38536?source=see_link\">",
"     \"Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two formulations of pegylated interferon are available. Dosing recommendations for both pegylated interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    vary depending on the formulation used and are discussed below. (See",
"    <a class=\"local\" href=\"#H747986\">",
"     'Dosing of antiviral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1659199\">",
"    <span class=\"h2\">",
"     HCV-specific protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two HCV-specific protease inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    , were approved in 2011 by US and European agencies for use in combination with pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    among HIV-seronegative patients with HCV genotype 1 infection only [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. This approval was based on phase 3 trials demonstrating significantly greater efficacy of triple therapy compared with standard dual therapy in achieving viral eradication in HCV-infected patients who were treatment-naive and among prior",
"    <span class=\"nowrap\">",
"     non-responders/relapsers",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary data are available regarding the efficacy and safety of these HCV protease inhibitors in combination with pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    among",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients compared with dual therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. These data are encouraging because a greater proportion of patients achieved rapid virologic suppression at four weeks with triple therapy than with dual therapy. In addition, 12 weeks after completion of therapy (ie, sustained virologic response [SVR]-12), significantly more patients in the triple therapy arms remain virologically suppressed than in the dual therapy arm. &nbsp;Furthermore, adverse events on treatment appear similar to those seen in patients with HCV alone. The SVR-24 data for both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    trials will be available in late 2012 or early 2013.",
"   </p>",
"   <p>",
"    Data from the individual trials are discussed briefly below and in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38536?source=see_link&amp;anchor=H16230082#H16230082\">",
"     \"Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients\", section on 'Trials of triple therapy including HCV protease inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of the",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patient is addressed below. Prior to starting these medications, the clinician needs to be aware that there are drug-drug interactions between HCV protease inhibitors and certain antiretroviral medications, which can negatively impact management of both HIV and HCV infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38536?source=see_link&amp;anchor=H16230082#H16230082\">",
"     \"Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients\", section on 'Trials of triple therapy including HCV protease inhibitors'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H820159\">",
"     'Management of the HIV-infected patient with HCV infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22811556\">",
"    <span class=\"h3\">",
"     Telaprevir-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a controlled trial, 60 HIV-infected patients with HCV genotype 1 infection were randomly assigned to 12 weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (400 mg twice daily) plus either placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/23,40\">",
"     23,40",
"    </a>",
"    ]. Patients in both arms received an additional 36 weeks of peginterferon with ribavirin. Approximately 83 percent of these patients had high-level viremia (ie, &gt;800,000",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    and 10 percent had advanced liver disease.",
"   </p>",
"   <p>",
"    After four weeks of therapy, 68 percent of patients assigned to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    arm achieved viral suppression consistent with a rapid virologic response; in contrast, none of the patients taking dual therapy achieved this benchmark. At 12 weeks after completion of therapy (SVR-12), viral suppression was maintained in a higher proportion of patients on the triple therapy arm (74 versus 45 percent); final 24-week results off treatment are expected in late 2012 or early 2013.",
"   </p>",
"   <p>",
"    These preliminary data strongly suggest that triple therapy is more effective than dual therapy in the",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patient. Safety data also suggest a similar toxicity profile as demonstrated in large registration trials among HCV-monoinfected patients. Specifically, pruritis, rash, nausea, vomiting, anorexia, and dizziness were more common in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    -containing arm. There were three patients in this small trial who discontinued treatment and all were in the telaprevir arm; however, none of the patients discontinued therapy because of severe rash. Grade 3 anemia (7 to 8.9 hemoglobin), erythropoietin use, and blood transfusions occurred in a higher number of patients in the telaprevir arm than the placebo arm. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38536?source=see_link&amp;anchor=H16230082#H16230082\">",
"     \"Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients\", section on 'Trials of triple therapy including HCV protease inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Larger clinical trials to assess efficacy and safety are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22811563\">",
"    <span class=\"h3\">",
"     Boceprevir-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase 2 clinical trial, 98",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients with genotype 1 infection received four weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/36/24137?source=see_link\">",
"     pegylated interferon alfa-2b",
"    </a>",
"    plus weight-based",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (13",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    and then were randomly assigned (2:1) to either pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    (800 mg every seven to nine hours) or pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    plus placebo for an additional 44 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/24,41\">",
"     24,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of patients who achieved viral suppression at week 8 was higher in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    -containing arm (42 versus 15 percent, respectively). At 12 weeks following discontinuation of therapy (ie, SVR-12), significantly more patients maintained viral suppression in the boceprevir arm compared with the placebo arm (61 versus 27 percent).",
"   </p>",
"   <p>",
"    These data strongly suggest that triple therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    is more effective than dual therapy alone. No new adverse events were reported in this trial among coinfected patients compared with the large registration trials among patients with HCV alone. Treatment discontinuation due to an adverse event occurred in 20 percent of patients assigned to the boceprevir arm compared with 9 percent of those assigned to the placebo arm. Compared with the control group, patients in the boceprevir arm were more likely to have decreased appetite, pyrexia, dysgeusia, vomiting, and asthenia. Boceprevir was associated with a significant increase in overall anemia (41 versus 26 percent). The rates of blood transfusion were equivalent in both arms (6 percent), although the use of erythropoietin was more common in the boceprevir arm (38 versus 21 percent).",
"   </p>",
"   <p>",
"    Larger clinical trials to assess efficacy and safety are planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H820159\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE HIV-INFECTED PATIENT WITH HCV INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H821577\">",
"    <span class=\"h2\">",
"     Treatment of HCV non-genotype 1 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among HIV-infected patients with hepatitis C virus (HCV) infection related to non-1 genotypes, pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    combination therapy remains the treatment of choice.",
"   </p>",
"   <p>",
"    Motivated patients with genotype 2 or 3 infection may be considered candidates for pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy, regardless of their stage of disease, since treatment eradication rates are high (eg, greater than 60 percent) and the risk of disease progression in the HIV-infected host is significant [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of treatment is generally 48 weeks for",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients, although some experts suggest that a shorter duration of treatment may be considered for some HCV genotype 2 or 3 patients with rapid viral suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36345?source=see_link&amp;anchor=H20764681#H20764681\">",
"     \"Monitoring the HIV-infected patient taking hepatitis C therapy\", section on 'Hepatitis C virus viral load monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H820402\">",
"    <span class=\"h2\">",
"     Treatment of HCV genotype 1 infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In recognition of the preliminary sustained virologic rate (SVR)-12 results from two small trials, which demonstrate the greater efficacy of triple therapy versus dual therapy, an expert panel on the Department of Health and Human Services (DHHS) HIV treatment guidelines recommends the use of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    in combination with pegylated interferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for the treatment of HIV-infected patients with genotype 1 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/23,24,42\">",
"     23,24,42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1659199\">",
"     'HCV-specific protease inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In clinical decision-making, we weigh the staging of liver disease to determine whether to initiate treatment or to follow expectantly over time. (See",
"    <a class=\"local\" href=\"#H821658\">",
"     'Clinical decision making'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28616266\">",
"    <span class=\"h3\">",
"     Minimal or no liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with minimal or no liver disease (as determined on liver biopsy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    noninvasive markers) may be followed expectantly over time, particularly in light of new HCV agents that are currently being evaluated for the treatment of HCV genotype 1. In addition, larger treatment trials using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    are planned, which may further elucidate the efficacy and safety of these agents in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link\">",
"     \"Investigational therapies for hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344584\">",
"    <span class=\"h3\">",
"     All other patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild or moderate fibrosis should be counseled regarding the potential benefits and possible side effects of treatment. Motivated patients without significant comorbidities may be offered treatment, since treatment response rates are generally higher in patients with mild to moderate liver disease than advanced fibrosis. Those who are concerned about adverse events have the option to await additional data from larger phase 3 clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or trials of other investigational agents.",
"   </p>",
"   <p>",
"    Patients with bridging fibrosis and compensated cirrhosis should be considered for HCV therapy as soon as possible to avert liver decompensation or the development of hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to initiation of therapy, drug-drug interactions must be carefully assessed, including antiretroviral medications. The choice of HCV protease inhibitor will influence the selection of antiretroviral therapy (ART) in the treatment-naive patient or the modification of ART in the treatment-experienced patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      , we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (300 mg once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      (200 mg once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      (400 mg twice daily)",
"     </li>",
"     <li>",
"      In patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      , we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (300 mg once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      (200 mg once daily) plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      (600 mg daily) or ritonavir-boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      does not have any known interactions with telaprevir and may also be considered in combination with tenofovir and emtricitabine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with cirrhosis also need evaluation for varices and screening for hepatocellular carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\", section on 'Patients with suspected cirrhosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H747986\">",
"    <span class=\"h1\">",
"     DOSING OF ANTIVIRAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H748035\">",
"    <span class=\"h2\">",
"     Pegylated interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;For",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/36/24137?source=see_link\">",
"     pegylated interferon alfa-2b",
"    </a>",
"    , weight-based dosing (1.5",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    is employed. For",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    , a standard dose of 180 mcg is used, regardless of weight. Both are administered once weekly via a subcutaneous route. Pegylated interferon alfa-2a is approved by the Food and Drug Administration (FDA) for use in HIV-infected patients with hepatitis C virus (HCV) infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H748042\">",
"    <span class=\"h2\">",
"     Ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HCV alone, randomized trials have established that fixed-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (ie, 400 mg twice daily) is sufficient for patients with genotype 2 and 3 infection, while weight-based ribavirin (13",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    divided into two daily doses) is optimal in those with genotype 1 and 4 infections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/29,44-46\">",
"     29,44-46",
"    </a>",
"    ]. We use a similar approach in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients, although data on the use of weight-based ribavirin in HCV genotype 1-infected patients are limited.",
"   </p>",
"   <p>",
"    The optimal dosing for",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients with genotype 1 infection has not been established because some of the early clinical trials used only fixed dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (400 mg twice daily) due to toxicity concerns; later studies, which utilized weight-based dosing, did not have comparator arms with fixed dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/6,7,27,47-49\">",
"     6,7,27,47-49",
"    </a>",
"    ]. The PARADIGM trial, which was specifically designed to answer this question, did not demonstrate an advantage of weight-based ribavirin compared with fixed-dose ribavirin for the treatment of genotype 1 infection in coinfected patients; however, the trial results were limited by loss to follow-up (ie, greater than 50 percent in each treatment arm) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38536?source=see_link\">",
"     \"Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until additional published data are available, we suggest the use of pegylated interferon plus weight-based",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for HIV-infected patients with HCV genotype 1 or 4 infection who are receiving dual therapy alone. We recommend fixed-dose ribavirin for patients with HCV genotype 2 or 3. Ribavirin is given on a twice-daily basis with food for greater absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H820140\">",
"    <span class=\"h2\">",
"     Telaprevir",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, only preliminary data are available on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (400 mg twice daily) for the treatment of HIV-infected patients with HCV genotype 1 infection. In the ongoing phase 2 clinical trial, patients are being treated with pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    plus telaprevir for 12 weeks. Telaprevir is then stopped and pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    is continued for an additional 36 weeks of therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    is dosed every seven to nine hours at 750 mg, except when administered with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ; among these patients, telaprevir is dosed as 1125 mg every seven to nine hours because of known drug-drug interactions that result in lower telaprevir blood levels; this increased dosing of telaprevir significantly increases the cost of therapy. Telaprevir is administered with food containing 20 or more grams of fat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H820148\">",
"    <span class=\"h2\">",
"     Boceprevir",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, only preliminary data are available on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    with pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    for the treatment of HIV-infected patients with HCV genotype 1 infection. Patients with genotype 1 infection are treated with four weeks of pegylated",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    dual therapy. Boceprevir is then initiated at week five after this lead-in phase of dual therapy; triple therapy continues for an additional 44 weeks.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     Boceprevir",
"    </a>",
"    is dosed as 800 mg every seven to nine hours in patients with HCV genotype 1 infection.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    is administered with food, although there is no strict requirement for fat content.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H748049\">",
"    <span class=\"h2\">",
"     Summary of dosing schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with genotype 1 and 4 infection, the doses of peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (given daily in two divided doses) differ between the two preparations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For peginterferon alfa-2a, the dose is 180 micrograms subcutaneously per week with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      given orally at a dose of 1000 mg for patients who weigh 75 kg or less, or 1200 mg for those who weigh more than 75 kg.",
"     </li>",
"     <li>",
"      For peginterferon alfa-2b, the dose is 1.5",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      subcutaneously per week with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      given orally at a dose of 800 mg for patients weighing &lt;65 kg, 1000 mg for 65 to 85 kg, 1200 mg for &gt;85 to 105 kg, and 1400 mg for &gt;105 kg.",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      is also being used, this medication should be given in addition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/27/27064?source=see_link\">",
"       pegylated interferon alfa-2a",
"      </a>",
"      plus fixed-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for the first 12 weeks of triple therapy; telaprevir should be dosed as 750 mg orally every seven to nine hours with a fat-containing snack. If combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      , telaprevir dosing is 1125 mg three times daily.",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      is also being used, this medication should be given after a full month of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/36/24137?source=see_link\">",
"       pegylated interferon alfa-2b",
"      </a>",
"      plus weight-based",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      therapy has been given; then boceprevir can be added at a dose of 800 mg every seven to nine hours with a snack. Triple therapy continues for an additional 44 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to initiation of HCV protease inhibitor therapy, drug-drug interactions must be carefully assessed, including antiretroviral medications. As noted above, the choice of HCV protease inhibitor will influence the selection of antiretroviral therapy (ART) in the treatment-naive patient or the modification of ART in the treatment-experienced patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      , we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (300 mg once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      (200 mg once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      (400 mg twice daily)",
"     </li>",
"     <li>",
"      In patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      , we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (300 mg once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      (200 mg once daily) plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      (600 mg daily) or ritonavir-boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      . If the patient is taking an efavirenz-based regimen, the dose of telaprevir must be increased to 1125 mg every seven to nine hours [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/41\">",
"       41",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      does not have any known interactions with telaprevir and may also be considered in combination with tenofovir and emtricitabine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with genotype 2 or 3 infection, the dosing schedule is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For peginterferon alfa-2a, the dose is 180 micrograms subcutaneously per week with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      given orally at a dose of 400 mg twice daily",
"     </li>",
"     <li>",
"      For peginterferon alfa-2b, the dose is 1.5",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      subcutaneously per week with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      given orally at a dose of 400 mg twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients should be counseled to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    with food for maximal absorption. Clinicians must check for drug-drug interactions when using HCV protease inhibitors. (See",
"    <a class=\"local\" href=\"#H819606\">",
"     'Potential drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H820201\">",
"    <span class=\"h1\">",
"     STANDARD DURATION OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the larger clinical trials of hepatitis C virus therapy in HIV-infected patients have used 48 weeks of treatment, regardless of genotype. A detailed discussion is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36345?source=see_link\">",
"     \"Monitoring the HIV-infected patient taking hepatitis C therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20767646\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be monitored for viral load responses on therapy, adherence, and side effects, which include depression, irritability, weight loss, fatigue, and other symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36345?source=see_link\">",
"     \"Monitoring the HIV-infected patient taking hepatitis C therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819606\">",
"    <span class=\"h1\">",
"     POTENTIAL DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians need to be aware of several potential drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H819678\">",
"    <span class=\"h2\">",
"     ART and HCV protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant drug-drug interactions exist between hepatitis C virus (HCV) protease inhibitors (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    ) and certain antiretroviral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Until further data are available,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"        boceprevir",
"       </a>",
"       /pegylated",
"      </span>",
"      <span class=\"nowrap\">",
"       interferon/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      should only be used with the specific antiretroviral therapy (ART) regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/31,52\">",
"       31,52",
"      </a>",
"      ]. The coadministration of boceprevir and ritonavir-boosted protease inhibitors (ie, lopinavir,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      ) should be avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/53\">",
"       53",
"      </a>",
"      ]. Boceprevir should also not be coadministered with nonnucleoside reverse transcriptase inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      ). Dosing recommendations are found above. (See",
"      <a class=\"local\" href=\"#H820148\">",
"       'Boceprevir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Until further data are available,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"        telaprevir",
"       </a>",
"       /pegylated",
"      </span>",
"      <span class=\"nowrap\">",
"       interferon/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      should only be administered to patients taking the following ART combinations:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      or ritonavir-boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/31,54\">",
"       31,54",
"      </a>",
"      ]. The coadministration of telaprevir and other ritonavir-boosted protease inhibitors (ie, lopinavir,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      ) should be avoided. Dosing recommendations are found above. (See",
"      <a class=\"local\" href=\"#H820140\">",
"       'Telaprevir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preliminary data in healthy volunteers also suggest that the nonnucleoside reverse transcriptase inhibitors (NNRTI)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"       etravirine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"       rilpivirine",
"      </a>",
"      do not have significant drug-drug interactions with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/55\">",
"       55",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H821797\">",
"    <span class=\"h2\">",
"     HCV protease inhibitors and other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple other drug-drug interactions that clinicians must know if they are prescribing HCV protease inhibitors. A detailed discussion is found elsewhere (",
"    <a class=\"graphic graphic_table graphicRef78070 \" href=\"UTD.htm?11/30/11744\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66181 \" href=\"UTD.htm?7/31/7664\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link&amp;anchor=H148834094#H148834094\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Drug interactions with protease inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H821817\">",
"    <span class=\"h2\">",
"     ART and ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    -containing ART may develop jaundice due to an increase in total serum bilirubin levels following initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/56\">",
"     56",
"    </a>",
"    ]. The mechanism leading to this observation may be related to increased ribavirin-associated hemolysis in combination with decreased physiologic clearance of bilirubin due to atazanavir use. Clinicians should discuss this potential side effect with patients who are taking atazanavir. Patients who develop jaundice should have assays for indirect hyperbilirubinemia to be certain that the total increase in serum bilirubin is consistent with the drug effect of atazanavir. An increase in direct bilirubin, which suggests hepatic disease rather than drug effect, would be of much greater concern.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    should NOT be used with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    because of the increased risk of mitochondrial toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Ribavirin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    increases the risk of anemia. Didanosine is no longer recommended for the treatment of HIV infection due to these intrinsic mitochondrial toxicity concerns; zidovudine is no longer considered a first-line agent for the treatment of HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link&amp;anchor=H40#H40\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'Antiretroviral combinations to avoid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are conflicting retrospective data as to whether or not the inclusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    within ART regimens may decrease rates of sustained virologic response (SVR) in",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients taking pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    dual therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     BARRIERS TO CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;One significant problem has been the difficulty of identifying candidates for treatment, given the number of comorbidities and underlying psychiatric and substance abuse issues that can complicate delivery of care for this complex patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. However, dedicated programs with case management and stabilization of psychiatric and addiction care can increase the proportion of patients eligible for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3690389\">",
"    <span class=\"h1\">",
"     DURABILITY OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The durability of a sustained virologic response following treatment for hepatitis C virus was examined in 1343 patients participating in nine randomized clinical trials, including 100 patients who were coinfected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?17/38/18026/abstract/67\">",
"     67",
"    </a>",
"    ]. Over a mean of 3.9 years of follow-up, 99 percent of patients who achieved a sustained virologic response maintained virologic suppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h1\">",
"     TREATMENT-EXPERIENCED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a patient for retreatment of hepatitis C virus (HCV) with pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    should include close examination of his or her prior treatment response and treatment regimen.",
"   </p>",
"   <p>",
"    Patients who do not \"respond\" to treatment fall into various categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Virologic relapsers: Patients who relapse after treatment is discontinued",
"     </li>",
"     <li>",
"      Virologic non-responders or &ldquo;null&rdquo; responders: Patients who did not have a 2-log drop in viremia by week 12 of treatment",
"     </li>",
"     <li>",
"      Partial responders: Patients who have a 2-log drop of viremia at week 12 but who never reach a non-detectable viral load",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, some patients may have virologic breakthrough during pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy. This is often due to lack of adherence.",
"   </p>",
"   <p>",
"    If the prior therapeutic regimen included either standard thrice-weekly interferon, with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , or monotherapy with pegylated interferon, the patient should be considered for retreatment, particularly if he or she has advanced liver disease and has a history of a partial response or a treatment relapse. Retreatment for such patients who have genotype 1 infection should include triple therapy with an HCV protease inhibitor.",
"   </p>",
"   <p>",
"    HCV genotype 1-infected patients with a history of null response on pegylated",
"    <span class=\"nowrap\">",
"     interferon/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    therapy are at high risk of developing HCV protease inhibitor drug resistance on triple therapy. We prefer to enroll",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients with this profile into a clinical trial. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary goal of therapy is to achieve a sustained virologic response (SVR), which is defined as an undetectable hepatitis C virus (HCV) RNA six months after the end of treatment. Viral eradication may lead to reduction of morbidity and mortality secondary to liver disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pretreatment predictors of treatment response include low-level HCV viremia (&lt;400,000",
"      <span class=\"nowrap\">",
"       IU/ml)",
"      </span>",
"      and HCV genotype 2 or 3 infection. (See",
"      <a class=\"local\" href=\"#H22811476\">",
"       'Predictors of treatment response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to treat an HIV-infected patient for HCV infection will depend on the stage of liver disease (eg, portal fibrosis or higher stage), patient readiness, and presence of comorbidities, which may prohibit treatment with interferon. The timing of treatment is more urgent in patients with bridging fibrosis or cirrhosis compared with patients with mild to moderate disease. However, treatment for mild disease (ie, portal fibrosis) can also be justified since patients with HIV have faster fibrosis progression rates than patients with HCV alone. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Candidates for HCV treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with minimal liver disease do not require treatment, but should be monitored over time to assess for progression of liver disease. Motivated patients with genotype 2 or 3 infection may be considered candidates for pegylated",
"      <span class=\"nowrap\">",
"       interferon/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      therapy, even with minimal disease, since treatment eradication rates are high and the risk of disease progression in the HIV-infected host is significant. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Candidates for HCV treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients should be initiated on antiretroviral medications for HIV disease, regardless of CD4 cell count. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"       \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is preferable to begin HIV treatment before HCV therapy to determine adverse events on antiretroviral medications alone. Because of drug-drug interactions, pill burden, and regimen complexity, some clinicians prefer to delay the initiation of ART in the treatment-naive patient with a CD4 cell count &gt;500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      until completion of HCV therapy. (See",
"      <a class=\"local\" href=\"#H5443630\">",
"       'Order of HIV and HCV treatment initiation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"       \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among HIV-infected patients with non-genotype 1 HCV infection who are candidates for antiviral treatment, we recommend pegylated interferon plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      dual therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H821577\">",
"       'Treatment of HCV non-genotype 1 infection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H747986\">",
"       'Dosing of antiviral therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Specific dosing regimens are provided above. (See",
"      <a class=\"local\" href=\"#H748049\">",
"       'Summary of dosing schedules'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      In HIV-uninfected patients with HCV genotype 1 infection, the addition of an HCV protease inhibitor to pegylated",
"      <span class=\"nowrap\">",
"       interferon/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      therapy significantly increases the proportion of patients who achieve viral eradication. Early data demonstrate that similar benefits are seen in",
"      <span class=\"nowrap\">",
"       HIV/HCV-coinfected",
"      </span>",
"      patients with similar toxicity profiles. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link&amp;anchor=H148834010#H148834010\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Treatment regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend triple therapy with pegylated",
"      <span class=\"nowrap\">",
"       interferon/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      plus an HCV protease inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"       telaprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"       boceprevir",
"      </a>",
"      ) for HIV-infected patients with liver disease related to HCV genotype 1 infection compared with dual therapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, the decision to use triple therapy should balance the potential risk (ie, toxicity and drug-drug interactions) versus potential benefit (ie, greater efficacy) pending the results of larger clinical trials. (See",
"      <a class=\"local\" href=\"#H820402\">",
"       'Treatment of HCV genotype 1 infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to initiation of therapy, drug-drug interactions must be carefully assessed, including antiretroviral medications. The choice of HCV protease inhibitor will influence the choice of antiretroviral therapy. (See",
"      <a class=\"local\" href=\"#H819606\">",
"       'Potential drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be monitored for viral load responses on therapy, adherence, and side effects, which include depression, irritability, weight loss, fatigue, and other symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36345?source=see_link\">",
"       \"Monitoring the HIV-infected patient taking hepatitis C therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/1\">",
"      McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 2007; 45 Suppl 2:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/2\">",
"      Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/3\">",
"      Weber R, Sabin CA, Friis-M&oslash;ller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/4\">",
"      Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/5\">",
"      Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/6\">",
"      Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/7\">",
"      Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/8\">",
"      Soriano V, Labarga P, Ruiz-Sancho A, et al. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. AIDS 2006; 20:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/9\">",
"      Lissen E, Clumeck N, Sola R, et al. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006; 20:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/10\">",
"      Rodr&iacute;guez-Torres M, Rodr&iacute;guez-Orengo JF, R&iacute;os-Bedoya CF, et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol 2007; 46:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/11\">",
"      Barreiro P, Labarga P, Mart&iacute;n-Carbonero L, et al. Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Antivir Ther 2006; 11:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/12\">",
"      Soriano V, Maida I, N&uacute;&ntilde;ez M, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther 2004; 9:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/13\">",
"      Berenguer J, Alvarez-Pellicer J, Mart&iacute;n PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/14\">",
"      Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/15\">",
"      Cooper CL. De-\"Liver\"-ing HIV/hepatitis C virus-coinfected patients from antiretroviral hepatotoxicity. J Infect Dis 2007; 196:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/16\">",
"      Rall&oacute;n NI, Soriano V, Naggie S, et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011; 25:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/17\">",
"      Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 2007; 14:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/18\">",
"      Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/19\">",
"      Neukam K, Camacho A, Caruz A, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol 2012; 56:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/20\">",
"      Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/21\">",
"      Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/22\">",
"      Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2011/Abstracts/42467.htm (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     Sulkowski M, Pol S, Cooper C, et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV coinfected pateints: interim on-treatment results [Abstract LB-37]. In: Programs and abstracts of the 49th Annual Meeting of the Infectious Diseases Society of America. Boston, MA. (Accessed on February 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/25\">",
"      Van den Eynde E, Crespo M, Esteban JI, et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis 2009; 48:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/26\">",
"      McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/27\">",
"      Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/28\">",
"      Bode JG, Ludwig S, Ehrhardt C, et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003; 17:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/29\">",
"      Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958.",
"     </a>",
"    </li>",
"    <li>",
"     Sulkowksi M, Mehta S, Torbenson M, et al. Presented at the 12th annual Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 2005; abstract #121.",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     Opravil M, Sasadeusz J, Cooper D, et al. Effect of baseline CD4 count on efficacy and safety of pegylated interferon plus ribavirin in HIV/HCV coinfected patients. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, February 22-25, 2005, Boston, MA [Abstract # 926].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/33\">",
"      Soriano V, Garc&iacute;a-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/34\">",
"      H&eacute;zode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/35\">",
"      Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003; 38:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/36\">",
"      Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/37\">",
"      Crespo M, Esteban JI, Ribera E, et al. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients. AIDS 2007; 21:477.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm (Accessed on June 09, 2011).",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm (Accessed on June 09, 2011).",
"    </li>",
"    <li>",
"     D Dieterich, V Soriano, K Sherman, et al. Telaprevir in Combination with Pegylated Interferon-alfa-2a + Ribavirin in HCV/HIV-coinfected Patients: A 24-Week Treatment Interim Analysis. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012). Seattle, WA. March 5-8, 2012. Abstract 46. (Accessed on April 20, 2012).",
"    </li>",
"    <li>",
"     M Sulkowski, S Pol, C Cooper, et al. Boceprevir + Pegylated Interferon + Ribavirin for the Treatment of HCV/HIV-coinfected Patients: End of Treatment (Week 48) Interim Results. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012). Seattle, WA. March 5-8, 2012. Abstract 47. (Accessed on April 20, 2012).",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/ (Accessed on April 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/43\">",
"      Mart&iacute;n-Carbonero L, Tuma P, Vispo E, et al. Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. J Viral Hepat 2011; 18:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/44\">",
"      Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/45\">",
"      Jacobson IM, Brown RS Jr, McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007; 46:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/46\">",
"      Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/47\">",
"      N&uacute;&ntilde;ez M, Mari&ntilde;o A, Mari&ntilde;o A, et al. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007; 45:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/48\">",
"      Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/49\">",
"      Tural C, Galeras JA, Planas R, et al. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients. Antivir Ther 2008; 13:1047.",
"     </a>",
"    </li>",
"    <li>",
"     Rodriguez-Torres M, Slim J, Bhatti L, et al. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: final results of the PARADIGM study. Program and abstracts of the 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30 - November 3, 2009; Boston, Massachusetts. Abstract 1561.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/51\">",
"      Thomas DL, Bartlett JG, Peters MG, et al. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis 2012; 54:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/52\">",
"      de Kanter CT, Blonk MI, Colbers AP, et al. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis 2013; 56:300.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm291144.htm (Accessed on February 10, 2012).",
"    </li>",
"    <li>",
"     Sherman KE, Rockstroh JK, Dieterich DT, et al. Telaprevir in combination wth peginterferon alfa-2a/ribavirin in HCV/HIV coinfected patients: a 24-week treatement interim analysis [abstraact LB-8]. Annual Meeting of the American Association for the Study of Liver Disease San Francisco, CA 2011.",
"    </li>",
"    <li>",
"     Preliminary data in healthy volunteers also suggest that the nonnucleoside reverse transcriptase inhibitors (NNRTI) do not have significant drug-drug interactions with telaprevir.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/56\">",
"      Rodr&iacute;guez-N&oacute;voa S, Morello J, Gonz&aacute;lez M, et al. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008; 22:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/57\">",
"      Balzarini J, Lee CK, Herdewijn P, De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus. J Biol Chem 1991; 266:21509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/58\">",
"      Mauss S. Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management. J Hepatol 2006; 44:S114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/59\">",
"      McGovern B, Bica I. Risk of HAART therapy in hepatitis C. Hepatology 2002; 35:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/60\">",
"      Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/61\">",
"      Mira JA, L&oacute;pez-Cort&eacute;s LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; 62:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/62\">",
"      Laufer N, Laguno M, Perez I, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008; 13:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/63\">",
"      Fleming CA, Craven DE, Thornton D, et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/64\">",
"      Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/65\">",
"      Butt AA, Khan UA, Shaikh OS, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 2009; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/66\">",
"      Taylor LE, Schwartzapfel B, Allen S, et al. Extending treatment for HCV infection to HIV-HCV coinfected individuals with psychiatric illness and drug dependence. Clin Infect Dis 2003; 36:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/38/18026/abstract/67\">",
"      Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3701 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18026=[""].join("\n");
var outline_f17_38_18026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H60\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22811476\">",
"      PREDICTORS OF TREATMENT RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H820050\">",
"      Pretreatment predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H820064\">",
"      On-treatment predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H819027\">",
"      Overall HCV treatment responses in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CANDIDATES FOR HCV TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H821658\">",
"      Clinical decision making",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Contraindications to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5443630\">",
"      Order of HIV and HCV treatment initiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      AVAILABLE THERAPEUTIC REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Standard interferon and ribavirin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pegylated interferon and ribavirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1659199\">",
"      HCV-specific protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22811556\">",
"      - Telaprevir-based therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22811563\">",
"      - Boceprevir-based therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H820159\">",
"      MANAGEMENT OF THE HIV-INFECTED PATIENT WITH HCV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H821577\">",
"      Treatment of HCV non-genotype 1 infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H820402\">",
"      Treatment of HCV genotype 1 infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28616266\">",
"      - Minimal or no liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344584\">",
"      - All other patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H747986\">",
"      DOSING OF ANTIVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H748035\">",
"      Pegylated interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H748042\">",
"      Ribavirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H820140\">",
"      Telaprevir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H820148\">",
"      Boceprevir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H748049\">",
"      Summary of dosing schedules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H820201\">",
"      STANDARD DURATION OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20767646\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H819606\">",
"      POTENTIAL DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H819678\">",
"      ART and HCV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H821797\">",
"      HCV protease inhibitors and other medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H821817\">",
"      ART and ribavirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      BARRIERS TO CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3690389\">",
"      DURABILITY OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      TREATMENT-EXPERIENCED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3701\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3701|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/30/11744\" title=\"table 1\">",
"      Telaprevir drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/31/7664\" title=\"table 2\">",
"      Boceprevir drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38536?source=related_link\">",
"      Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=related_link\">",
"      Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=related_link\">",
"      Investigational therapies for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36345?source=related_link\">",
"      Monitoring the HIV-infected patient taking hepatitis C therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40870?source=related_link\">",
"      Predictors of response to hepatitis C treatment in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_38_18027="Resource use disabled children";
var content_f17_38_18027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    1999-2000 use of health care services by disabled and nondisabled children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Health service",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disabled children",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nondisabled children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hospital discharges per 1000",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hospital days per 1000",
"       </td>",
"       <td>",
"        464",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Average number of doctor visits per child",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Average number of non-MD visits",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Average number prescribed meds",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: 1999 and 2000 Medical Expenditure Panel Survey. In: Newacheck PW, Inkelas M, Kim SE. Health services use and health care expenditures for children with disabilities. Pediatrics 2004; 114:79.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18027=[""].join("\n");
var outline_f17_38_18027=null;
var title_f17_38_18028="Fast track protocol for adult colorectal surgical procedures";
var content_f17_38_18028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fast-track protocol for adult colorectal surgical procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preoperative period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Counseling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Optimization of medical co-morbidities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoidance of menchanical bowel preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fasting from fried or fatty foods or meat for eight hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fasting from light meals and unclear liquids (eg, tea and toast, juice with pulp, milk) for six hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fasting from clear liquids (excludes alcoholic beverages, beverages with milk, juice with pulp) for two hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No premedication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbohydrate drink two hours prior to the procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intra-operative period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thromboprophylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antibiotic prophylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High concentration inspired oxygenation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic epidural analgesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normothermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluid optimazation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimally invasive surgical approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No nasogastric tubes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No intra-abdominal or perineal drains (except in settings such as colonic spillage or purulent drainage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Postoperative period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteral nutrition beginning on day one",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High calorie supplements twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opioid sparing analgesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multimodal antiemetic regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Removal of urinary catheter, typically on postoperative day one",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mobilization using a structured program, typically on the evening of the procedure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This fast-track protocol is an example of a protocol that is used for colorectal surgical patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18028=[""].join("\n");
var outline_f17_38_18028=null;
var title_f17_38_18029="Factors RAI ablation";
var content_f17_38_18029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major factors impacting decision making in radioiodine remnant ablation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Factors",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Expected benefit",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        RAI ablation usually recommended",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Strength of evidence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Decreased risk of death",
"       </td>",
"       <td class=\"subtitle2\">",
"        Decreased risk of recurrence",
"       </td>",
"       <td class=\"subtitle2\">",
"        May facilitate initial staging and follow-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         T1",
"        </strong>",
"       </td>",
"       <td>",
"        1 cm or less, intrathyroidal or microscopic multifocal",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        E",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 2 cm, intrathyroidal",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Conflicting data*",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Selective use*",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         T2",
"        </strong>",
"       </td>",
"       <td>",
"        &gt;2 to 4 cm, intrathyroidal",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Conflicting data*",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Selective use*",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        <strong>",
"         T3",
"        </strong>",
"       </td>",
"       <td colspan=\"6\">",
"        &gt;4 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;45 years old",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Conflicting data*",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;45 years old",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any size, any age, minimal extrathyroidal extension",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Inadequate data*",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Selective use*",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         T4",
"        </strong>",
"       </td>",
"       <td>",
"        Any size with gross extrathyroidal extension",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Nx, N0",
"        </strong>",
"       </td>",
"       <td>",
"        No metastatic nodes documented",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         N1",
"        </strong>",
"       </td>",
"       <td>",
"        &lt;45 years old",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Conflicting data*",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Selective use*",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;45 years old",
"       </td>",
"       <td>",
"        Conflicting data",
"       </td>",
"       <td>",
"        Conflicting data*",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Selective use*",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         M1",
"        </strong>",
"       </td>",
"       <td>",
"        Distant metastasis present",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        A",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Because of either conflicting or inadequate data, the ATA cannot recommend either for or against RAI ablation for this entire subgroup. However, selected patients within this subgroup with higher risk features may benefit from RAI ablation.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper, DS, Doherty, GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167. Copyright &copy; 2009 Mary Ann Liebert, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18029=[""].join("\n");
var outline_f17_38_18029=null;
var title_f17_38_18030="Fluorochrome stain of sputum";
var content_f17_38_18030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fluorochrome stain of sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluorochrome staining of sputum for AFB: Increases sensitivity, decreases examination time versus Ziehl-Neelsen method.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Bernardo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18030=[""].join("\n");
var outline_f17_38_18030=null;
var title_f17_38_18031="P wave before QRS I";
var content_f17_38_18031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    P wave before each QRS complex with constant PR relationship",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 446px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_38_18031=[""].join("\n");
var outline_f17_38_18031=null;
